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Abstract 
Background: Musculoskeletal manifestations are common in Systemic lupus erythematosus.  
Most patients with inflammatory pain have no objective abnormality detectable by current 
clinical tools. Also, these tools may be poorly responsive. This is important because physicians 
need to decide when to start, increase or decrease immunosuppression for arthralgia.  
Imaging modalities such as ultrasound and magnetic resonance imaging have a promising 
role to solve these issues. 
Objectives: (1)define and quantify inflammatory musculoskeletal phenotypes in SLE; (2) to 
evaluate the accuracy and responsiveness of existing outcome measures; (3)determine 
whether patients with ultrasound-only synovitis are more responsive to therapy; (4) determine 
whether ultrasound is a more responsive outcome measure than the other tools; (5) to validate 
Ultrasound against MRI. 
Methods: (1) Consecutive SLE patients were evaluated clinically and by ultrasound synovitis; 
(2) a pilot longitudinal study was performed in 20 patients receiving glucocorticoids; (3) a 
definitive study (USEFUL) was performed in 133 patients to determine the responsiveness of 
ultrasound and other musculoskeletal variables, and predictive value of baseline ultrasound; 
(4) MRI scans were performed in 36 patients with varying degrees of clinical and US-synovitis. 
Results: (1) most patients with active musculoskeletal symptoms did not have clinical 
synovitis on examination and a large group of patients with subclinical synovitis found only 
using ultrasound was associated with worse symptoms and serology; (2) clinical instruments 
underestimated ultrasound-confirmed response to therapy; (3) the USEFUL study showed that 
patients with baseline ultrasound synovitis had better responses to therapy as long as 
fibromyalgia was excluded. Ultrasound remained highly responsive, with varying degrees of 
responses in clinical instruments, but this did not correlate with patient-reported improvement; 
(4) MRI synovitis was confirmed in patients with ultrasound-only synovitis. 
Conclusion: Ultrasound provides an accurate objective measure of synovitis in lupus patients 
and could be used to improve patient care and clinical trials 
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Chapter 1: Introduction  
Systemic lupus erythematosus (SLE) is a multisystem autoimmune condition that causes 
significant morbidity and mortality [1].  Musculoskeletal manifestations are among the most 
common features of systemic lupus erythematosus (SLE) both in initial diagnosis and in 
long-term management. They are crucial to the overall patient outcome as well as the 
development of new therapeutics. Musculoskeletal manifestations of SLE are the first 
symptom in up to 50% of SLE patients and affect up to 95% during the clinical course.  My 
thesis dissects musculoskeletal presentations in SLE looking at the best way to assess then 
aiming to incorporate imaging in assessment and validating outcome measures in SLE. 
Accurate assessment of disease activity (e.g. synovitis) and joint damage (e.g. bone 
erosion) are imperative in rheumatology.  Finding a tool that provides a sensitive and 
accurate measurement of inflammation and damage with the ability to discriminate between 
diseases and offer prediction and evaluation of outcome is a consistent demand in 
rheumatology to guide treatment decisions. 
Recent clinical trials in SLE have cast doubt on the existing outcome measures. Rituximab 
was not proven to be effective in randomised controlled trials, but is widely believed to be 
effective.  Belimumab(Anti CD20), epratuzumab(Anti CD22) and anifrolumab(Anti type I 
interferon) all demonstrated different outcomes in phase II and phase III trials, and data 
suggested outcome measures were partially responsible for this. Since approximately 90% 
of patients in non-renal trials had musculoskeletal disease activity this organ system is an 
important factor. 
In SLE there is a lower frequency of clinical synovitis than in rheumatoid arthritis( RA), which 
is a challenge in the identification of patients amenable to immunosuppressive therapy, as 
well as in the assessment of response in clinical trials and routine practice [2].  In the various 
forms of the systemic lupus erythematosus disease activity index (SLEDAI) this is accounted 
for by the inclusion of tender, erythema or warmth to define synovitis, as well as just joint 
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swelling.  In total, 4 points are scored for two or more joints with these signs (SLEDAI-2K) or 
more than two joints (SELENA–SLEDAI), and no points for lesser degrees of inflammation.  
However, these signs are more subjective than joint swelling and partial response cannot be 
captured. In clinical trials of belimumab an endpoint primarily based on the SLEDAI called 
the SLE responder index (SRI) was developed and has been used in trials of other agents 
[3].  The key criterion to meet this endpoint is a 4-point reduction in SLEDAI (qualified by no 
worsening in BILAG or Physician’s Global Assessment).  Hence, this criterion may be met by 
improvement in arthritis.  The BILAG-2004 index is semiquantitative for each organ system 
assessed. For the musculoskeletal domain, BILAG A (the highest score) requires observed 
active synovitis in more than two joints with marked loss of functional range of movements. 
BILAG B is scored for tendonitis/tenosynovitis or active synovitis in more than one joint 
(observed or through history) with some loss of functional range of movement (or improving 
BILAG A disease).  BILAG C is scored for inflammatory pain (e.g. with morning stiffness) 
without synovitis (or improving BILAG B disease).  Pain without inflammatory symptoms (e.g. 
pain that clinically appears to be because of osteoarthritis) is scored as BILAG D, as are 
patients with no current symptoms. Analogous to the SRI from the SLEDAI, the based 
combined lupus assessment (BICLA) is a clinical trials endpoint derived principally from the 
BILAG. BICLA requires reduction of BILAG A or B scores by at least one grade (qualified by 
no worsening in other BILAG domains, SLEDAI, physician global VAS or treatment failure). 
Overall in the scoring of arthritis, all indices are strongly weighted by the detection of swollen 
joints. 
Therefore, while clinical examination and laboratory markers are traditionally used to assess 
diseases their lack of specificity and sensitivity to change over time may limit their use in 
SLE.  Histopathology, which is considered to be the diagnostic gold standard investigation 
for the presence of synovitis, does not play a large role here due to the invasive nature of 
obtaining tissue for analysis.  Conventional radiography (CR) has been used for assessment 
of joint disease, but because it can only measure damage and not inflammation (as limited 
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soft tissue visualisation), it is becoming less beneficial as an outcome measure in the last 
few years.  Magnetic resonance imaging (MRI), especially the gadolinium enhanced MRI, is 
widely considered to be one of the best imaging modalities for providing information about 
the synovium [4-6].  However, MRI is relatively expensive with limited access in many 
centres.  In contrast, Ultrasound offers a feasible and inexpensive alternative for assessing 
synovial inflammation. 
One of the most important, of recent insights, has been the observation from ultrasound 
studies that a large number of lupus patients with arthralgia had subclinical synovitis, despite 
the lower rates of clinical synovitis compared to other inflammatory arthritides.  This is crucial 
for clinical practice and trials because existing clinical disease activity instruments are all 
heavily weighted by the presence of synovitis. Our group recently published a systematic 
review of these studies [7, 8]. 
The overall aim of my thesis is to improve the care of patients with musculoskeletal 
manifestations of Systemic lupus erythematosus. 
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Chapter 2: Literature Review 
 Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune condition with 
heterogeneity of laboratory and clinical manifestations ranging from mild musculoskeletal or 
cutaneous disease to potentially life-threatening renal, cardiac or central nervous system 
involvement.   It is a lifetime disease with a relapsing and remitting course with variable 
severity [1, 9-11].  SLE predominantly affects women of childbearing age (female: male ratio 
of 9:1) with a peak incidence between the ages of 15 and 40.  Nevertheless, SLE can affect 
all age groups [10, 12, 13].   
2.1.1 Epidemiology 
In Europe, the prevalence ranges between 20 to 50 cases per 100000 population, while 
much higher rates have been reported in Afro-Caribbean and Asian population [14].  In the 
UK, the prevalence of SLE had increased from 65 per 100 000 in 1999 to 97 per 100 000 in 
2012 [15]. 
2.1.2 Clinical features 
SLE is a multisystem disease with a heterogeneous spectrum of presentation and disease 
severity.  The most common presentations are polyarthritis (joint pain and swelling), 
photosensitive skin rash, scaring or non-scaring alopecia, malar rash, and mucocutaneous 
lesions.  In more severe cases, SLE can manifest with solid organ involvement such as 
nephritis, serositis (pleural and pericardial effusion), cardiac vasculitis, cerebritis and 
interstitial lung disease [16]. 
Classification criteria for SLE have been developed for the purpose of research and 
surveillance rather than clinical diagnosis.  In 1971 the American College of Rheumatology 
(ACR) published classification criteria made of 11 criteria that occur in SLE, in order to be 
classified as SLE, at least four of them must be present serially or simultaneously during any 
interval of observation.  These were revised in 1982 and 1997 [17, 18] (Table 2-1).  There 
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are several issues with the ACR classification such as omitting hypocomplementemia, one of 
the most important characteristics for SLE.  The criteria duplicated highly correlated 
cutaneous features such as photosensitivity and malar rash whilst excluding other common 
features as maculopapular rash.  In 2012, the Systemic Lupus International Collaborating 
Clinics (SLICC) group revised ACR criteria to diagnose SLE, to require 4 of 17 criteria, with 
at least 1 of 11 clinical criteria and 1 of 6 immunological criteria being present; or biopsy-
proven SLE nephritis in the presence of ANA or anti-dsDNA antibodies [19].  SLICC criteria 
(Table 2-1) demonstrate greater sensitivity (97% vs 83%, p<0.0001) but less specificity (84% 
vs 96%, p<0.0001) compared to the ACR criteria within validation cohort [20].
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Table 2-1. ACR-97 and SLICC criteria 
Criteria 1997 Revised ACR Criteria  SLICC 2012 Criteria 
 Four out of 11 criteria are required for the classification of 
SLE 
Four out of 17 criteria are needed, including 11 clinical and one of 6 
immunological criteria. 
OR Biopsy-proven SLE nephritis in the presence of ANA or Anti-dsDNA 
antibodies are required to diagnose SLE 
Mucocutaneous 1- Malar rash: Fixed erythema, flat or raised, sparing the 
nasolabial folds 
2- Discoid rash: Erythematous raised patches with 
adherent keratotic scaling and follicular plugging; atrophic 
scaring may occur in older lesions 
3-Photosensitivity: Skin rash resulted from unusual 
reaction to sunlight , by patients history or physician 
observation 
4-Oral or nasal ulcer ulceration: usually painless 
 
1- Acute cutaneous lupus (ACLE) [lupus malar rash( do not count if 
malar discoid), bullous lupus, Toxic epidermal necrolysis variant of SLE, 
maculopapular lupus rash and photosensitive lupus rash in the absence of 
dermatomyositis OR subacute cutaneous lupus (SCLE) [non-indurated 
psoriasiform and/or annular polycyclic lesions that resolve without 
scarring]  
2- Chronic cutaneous lupus (CCLE) [classic discoid rash: localised 
above the neck or generalised above and below the neck, hypertrophic 
verrucous lupus, lupus panniculitis (prefunds), mucosal lupus, lupus 
erythematosus tumidus, chilblains lupus, discoid lupus/lichen planus 
overlap]  
3-  Non-scarring alopecia  Diffuse thinning or hair fragility with visible 
broken hairs in the absence of other causes  
4. Oral or nasal ulcers :in the absence of other causes 
Arthritis 5- Non-erosive arthritis involving 2 or more peripheral 
joints, charactarised by tenderness, swelling or effusion. 
5- Inflammatory synovitis 
 Involving  ≥2 joints:  characterised by swelling or effusion, OR Tenderness 
in 2 or more joints and ≥30 minutes of morning stiffness 
Serositis 6-  Any of:  
a. Pleuritis: convincing history of pleuritic pain or rub heard 
by a physician or evidence of pleural effusion  
b. Pericarditis: documented by electrocardiogram or rub or 
evidence of pericardial effusion  
 
6- Any of 
a. Typical pleurisy lasting >1 day, or pleural effusions or pleural rub 
b. Typical pericardial pain (pain with recumbency, improved by sitting 
forward) for >1 day, or pericardial effusion, or pericardial rub or pericarditis 
by electrocardiography in the absence of the other causes such as 
infection or uraemia 
Renal 7-  Any of:  
a. Persistent proteinuria >0.5 grams/day or >3+ on urine 
dipstick if quantitation not performed  
b. Cellular casts(maybe  red cell, haemoglobin or granular 
tubular or mixed) 
7-  Any of:  
a. Urine protein- to- creatinine ratio (or 24 -h urine protein) representing 
≥500 mg of protein/24 hour, or  
b. Red blood cell casts 
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Criteria 1997 Revised ACR Criteria  SLICC 2012 Criteria 
Haematological 8- Any of:  
a. Haemolytic anaemia with reticulocytosis  
b. Lymphopenia: <1500/mm3 
c.Thrombocytopenia: <100 000/mm3 in the absence of 
offending drugs  
 
8-  Haemolytic anaemia  
9-Leucopoenia (<4000/mm3), OR lymphopenia (<1000/mm3) of at 
least once in the absence of other known causes  
10-Thrombocytopenia (<100 000/mm3) of at least once in the absence 
of other known causes. 
 
Neurological 9- Any of:  
Seizures: in the absence of offending drugs or known 
metabolic derangements  
b. Psychosis: in the absence of offending drugs or known 
metabolic derangements 
11- Any of:  
a. Seizures b. Psychosis c. Mononeuritis multiplex( in the absence of 
other known causes as primary vasculitis)   
d. Myelitis  
e. Peripheral or cranial neuropathy ( in the absence of other known 
causes as diabetes, primary vasculitis or infection) 
f. Cerebritis (acute confessional state) in the absence of other known 
causes as toxic, metabolic or drugs 
Immunological 10-  Any of:  
a. Anti-DNA: antibody to native DNA in abnormal titre  
b. Anti-Sm: presence of antibody to Sm nuclear antigen  
c. Positive finding of anti-phospholipid antibodies 
based on: (i) an abnormal serum concentration of IgG or 
IgM anti-cardiolipin antibodies, (ii) a positive test result 
for SLE anti-coagulant or (iii) a false-positive serological 
test for syphilis known to be positive for ≥6 months and 
confirmed by Treponema pallidum immobilisation or 
fluorescent Treponemal antibody absorption test 
12- Anti-dsDNA above laboratory reference range 
 (or 2-fold the reference range if tested by enzyme –linked 
immunosorbent assay ELISA)  
13-  Anti-Sm presence of antibody to Sm nuclear antigen 
14- Anti-phospholipid antibody  SLE anti-coagulant, false-positive test 
for syphilis  
15- Anti-cardiolipin (at least twice normal or medium–high titre), or anti-
β2 glycoprotein 1  
16. Low complement: low C3, or low C4, or low CH50  
17- Direct Coombs test in the absence of haemolytic anaemia 
Antinuclear 
antibody(ANA) 
11- Abnormal titre of ANA by immunofluorescence or 
an equivalent assay at any time and in the absence of 
drugs which my induce lupus 
18- ANA above laboratory reference range 
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2.1.3 Pathogenesis of SLE 
No single entity can be identified as the dominant factor in the pathogenesis of SLE.  This 
condition is a multifactorial disease with genetic susceptibility and environmental factors 
resulting in innate and adaptive immune system imbalance.  In addition to the inadequate 
clearance of apoptotic cells, increased cytokine production, and aberrant B- cell immunity 
and T-cell signalling also play a role here [21]. 
The central pathogenic feature is the production of autoantibodies in particular against 
nuclear antigen, resulting in immune complex deposition inflammation and end organ 
damage [10, 13, 22].  The characteristic feature of SLE is the deposition of immune 
complexes within the tissue, results in activation of the complement system with the 
recruitment of inflammatory cells, and consequent vasculopathy [13, 16].   
Aberrant immune response has a significant role in the development of SLE, this happens 
through both tissue injury via release of inflammatory cytokines and through aberrant 
activation of autoreactive T and B cells.  Consequently, production of autoantibody and end-
organ injury [23].  
The first step in the development of SLE is the breakdown of self-tolerance.  Deficiency in 
the clearance of apoptotic cells leads to abundance of nucleic acid remnants.  These 
activate the TLR7 and TLR9, expressed by plasmacytoid dendritic cells (pDCs) leading to 
excessive production of inflammatory cytokines including IFN-alpha (IFN-α).  IFN-α activates 
several components of the immune system including myeloid dendritic cells (mDCs).  Once 
activated, mDCs present self-antigens and other proteins to T- and B-cells leading to cell 
proliferation, maturation, differentiation and survival, and excess autoantibody and cytokine 
production.   
The second step in the development of SLE pathology is the production of autoantibodies.  
Initiated by ANA presentation on Dendritic cells (DC), antigen specific T cells. 
T-cell receptor interacts with MHC on antigen presenting cells and triggers the T-cell 
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response  These stimulate T cell in addition to co-stimulatory molecules such as CD28:B7 
and CD40:CD40 ligands, these help activate B-cells.  Thus, autoreactive T-cells provide help 
to B-cells which subsequently produce a large amount of autoantibodies.   
In healthy individuals, immune complexes are cleared by Fc and complement receptors [24] 
However in SLE, genetic variations in FcR genes and the C3bi receptor gene (ITGAM) [25, 
26] may impair the clearing of immune complexes, which then deposit and cause tissue 
injury at sites such as the skin and kidney. Immune complex-associated inflammation can 
also occur activation of macrophages and neutrophils via surface Fc-receptors which bind 
IgG.  Finally, the production of pro-inflammatory and pro-fibrotic cytokines including IL-4 and 
tissue growth factor-beta (TGF-β) lead to irreversible tissue damage or scarring.  Eventually, 
as these immune elements remain dysregulated in SLE, these lead to more tissue damage 
and cell death, perpetuating the cycle of inflammation [25]. 
 Pathogenesis of SLE arthritis 
Genetic susceptibility plays a central role in this process.  Many studies have attempted to 
identify candidate susceptibility genes, which could be responsible for the development of SLE 
arthritis.  However, despite the identification of several possible genes, to date, no clear 
explanation of the mechanisms of these associations has been developed.  A study conducted 
by Warchol et al. demonstrated a significant correlation between the development of arthritis 
and the ITGAM (Integrin alpha M) gene [27].  De Azevedo Silva et al. showed a relationship 
between arthritis and polymorphism within the Vitamin D Receptor (VDR).  They demonstrated 
that Vitamin D affects the differentiation of dendritic cells, and in turn inhibits B cell 
proliferation, inhibiting Th1 immune response and upregulation of regulatory T cells [28].  Low 
Vitamin D level is a common finding within SLE cohorts [29].  Correlation between C4 and the 
ACP5 (Acid Phosphatase 5) variant has also been associated with the development of SLE 
arthritis [30, 31].  Low FCGR3A (Fc fragment of IgG receptor III-a) and FCGR2B (Low affinity 
immunoglobulin gamma Fc region receptor II-b) genes were highly associated with the 
development of arthritis in Taiwanese SLE patients [32, 33].   
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In several studies, the presence of high serum IFN alpha level is associated with the 
development of SLE and correlates with increased severity and activity.  The gene expression 
pattern of IFN is called IFN signature [34].  MIR146a (MicroRNA 146a) has some regulatory 
effects on the IFN pathway and the under-expression of this microRNA has been 
demonstrated in SLE patients with arthritis [34].  SNPrs15866 of STK17A gene has also 
demonstrated a relationship with SLE arthritis.  The STK17A gene encodes a nuclear protein 
known as DRAK1 (DAP protein kinase related apoptosis-inducing kinase 1).  DRAK1 plays a 
major role in the regulation of nuclear and apoptotic cellular processes, including DNA damage 
repair.  UV-light exposure and certain medications can activate the STK17A polymorphism 
which explains its possible role in the initiation of SLE arthritis [35]. 
Eilersten et al in a cross-sectional study comparing the level of pro-inflammatory cytokines 
between SLE, RA patients and a group of healthy controls.  They found high levels of IL-6, IL-
8, IL-1 beta and TNF expression in the SLE and RA patients.  Notably, patients with SLE with 
ongoing inflammatory arthritis had substantially higher levels of IL-6 [36].  Ball et al. confirmed 
this in 2014.  They showed  correlations between  IL-6 levels and ultrasound findings of active 
arthritis(Grey scale and Power Doppler ) in SLE patients with JA [37]. 
At a molecular level, synovial mediator expression studies in SLE patients demonstrate a 
distinct appearance compared to osteoarthritis and RA.  SLE synovium has marked 
upregulation of type I IFN-stimulated genes and downregulation of extracellular matrix 
homeostasis [38].  The stratification of SLE according to type I IFN status is increasingly 
important as this may predict response to a range of therapies.  However, the role of type I 
interferons in arthritis is complex.  Interferon (IFN)-alpha  expression, primarily produced by 
circulating plasmacytoid dendritic cells and monocytes is generally associated with more 
severe disease in SLE [39].   Interestingly, although interferon expression is related to overall 
disease activity and individual organ involvement such as mucocutaneous disease, it has not 
clearly been associated with arthritis  [40].  Synoviocytes and fibroblasts produce IFN-b and 
this has been shown in laboratory models to have regulatory roles in terms of down-regulatory 
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effects on Tumour Necrotizing Factor and up regulatory effect on Tumour Growth Factor- b, 
Interleukin (IL)-10, and IL1ra [41-44].  Meanwhile, an interferon regulatory factor 5 risk 
haplotype for SLE has been associated with non-erosive rheumatoid factor-negative RA 
suggesting an overlapping role for  interferon-mediated pathogenesis [45].  Understanding the 
role of type I interferons in SLE is of renewed interest as therapies that target this pathway 
have demonstrated efficacy for arthritis-specific outcomes in phase III trials when targeting 
either (IFN)-alpha alone or the interferon receptor that is shared by IFN-a and IFN-b [46, 47]. 
 Aetiology: 
The exact cause of SLE remains vague.  This condition results from interaction between 
different factors among various genetic, epigenetic, hormonal and environmental factors is 
probably involved [48]. 
2.2.1.1 Genetic factors 
Genetic susceptibility plays a key role in the development of SLE.   This can be seen in the 
concordance of SLE in identical twins, the large number of SLE among first degree relatives 
and the increased risk of developing the disease in siblings of SLE patients reflects a 
polygenic inheritance of the disease Homozygous deficiency in the early complements 
system has been associated with a high risk of developing SLE.  In addition, the 
concordance rate in monozygotic twins is up to 57% [49, 50].  The first degree relatives of 
SLE patients have a 17-fold increased risk of developing the disease when compared 
with general population [51, 52].  Of the genetic elements, the genes of the major 
histocompatibility (MHC) have been extensively studies for their role to SLE 
development.  Studies revealed that the susceptibility to SLE involves human leucocyte 
antigen (HLA) class II gene polymorphism.  An association was found between HLA DR2 
and DR3 with a relative risk for the development of the disease of approximately two to five.  
The HLA class II genes have been associated with the high level of anti-dsDNA, anti-nRNP, 
anti-Ro, anti-La and anti-Sm antibodies.  Genetic alterations in Mannose Binding Protein, 
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TNFα, the T-cell receptor, IL-6, Complement Receptor 1, immunoglobulin Gm and Km 
allotypes, FcγRIIA and FcγRIIIA (both IgG Fc receptors), and heat shock protein 70 are also 
known risk factors [13].  
Most single-nucleotide polymorphisms (SNPs) linked to SLE are components of non-coding 
DNA regions of immune response-related genes [53, 54].  Some genes are specific to SLE. 
Certain SNPs associated with SLE have been identified to contribute to aberrant dendritic 
cell function and interferon (IFN) signalling (TREX1 and STAT4); whilst others are linked to 
dysfunction of immune-complex processing and innate immunity such as impaired 
interleukin (IL) expression (C1QA, ITGAM); T cell function and signalling (STAT4 and 
PTPN22); cell cycle, apoptosis and cellular metabolism (CASP10); and transcriptional 
regulation (MECP2) in SLE [55]. 
SLE is associated with the inherited deficiency of complement components C1q, C1r/s, C2, 
and C4.  This decrease in complement activity could promote the susceptibility to the 
disease by impairing the neutralisation and clearance of self and foreign antigens.  This 
accumulation of antigen overwhelms the clearance capacity of the immune system [13]. 
2.2.1.2 Epigenetic effects  
Epigenetic effects such as DNA methylation, post-translational histone modifications and 
micro ribonucleic acids (miRNAs), either genetically determined or environmentally induced 
may influence the risk of SLE [56].  The role of epigenetics is supported by the discordance 
seen in identical twins who are discordant for SLE [57].  The most well-understood type of 
epigenetic factor is DNA methylation, which affects specific genes and variation in 
acetylation of histones, therefore, effects transcription into protein.  DNA methylation plays a 
key role in a variety of human processes.  Abnormal methylation has been associated with 
development of SLE [58] miRNAs are important in both adaptive and innate immunity by 
controlling the differentiation of different immune cell subsets such as B-cells, T-cells and 
their immunological functions [59, 60].  Aberrantly expressed miRNAs have been observed 
in different cell types, tissues and play an important role in the progression of SLE [61]. 
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2.2.1.3 Nuclear antibody spectrum and SLE 
The presence of Anti-nuclear antibody (ANA) is one of the immunological criteria present in 
both SLE classifications (Table 2-1).  Negative ANA test (titer less than 1/160) makes the 
diagnosis of SLE unlikely.  Hence it represents an essential screening tool for the disease.  
On the other hand, positive ANA even with a high titer is not specific for SLE as it is also 
found in a variety of other conditions including other connective tissue diseases (CTDs), 
virus infections, hepatic and haematological diseases.  In addition, up to 5% of healthy 
individuals in the western word are ANA positive with the majority of them never having any 
symptoms of CTD.  Various types of SLE-specific ANA anti-bodies are summarized in (Table 
2-2) [55]. 
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Table 2-2. ANA antibodies associated with SLE 
ANA Prevalence  Sensitivity Specificity Clinical features 
Anti-dsDNA 43-92% 5-54% 89-99% Related to disease activity 
Anti-nucleosome 60-62% 52-61% 88-96% Related to disease activity 
Anti-Sm 15-56% 10-55% 98-100% Highly specific for SLE 
AntiC1q 4-60% 28% 92% Associated with lupus nephritis 
Anti-Ribosomal P 12-60% 36% 97-100% Neuropsychiatric Lupus 
Anti-Ro/SSa 36-64% - - Congenital heart block-Cutaneous 
SLE 
Anti-La/SSb 8-34% 26% 98% Same as Anti-Ro, less frequent 
Anti-RNP 23-49% 8-69% 25-82% Mixed CTD 
Anti-histone 50-80% >90% in 
drug induce SLE. 
- - Drug induce lupus 
 
2.2.1.4 Hormonal factors: 
The prototypical patient with SLE  is a female of childbearing age [62] suggesting a pathogenic 
role of oestrogen hormone [13].  This is supported by evidence that SLE patients have 
abnormal oestrogen metabolism with high level of expression of 16α-hydroxyestrone (16α –
OH-E1) and low level of expression of testosterone, dihydrotestosterone, 
dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate [63-65].  In contrast, 
high serum androgens levels are associated with low SLE disease activity [63].  Oestrogen 
stimulates thymocytes, CD8+ and CD4+ T-cells, B-cells, macrophages leading to the 
release of some types of cytokines such as (IL-1) [66].  Oestrogen also reduces apoptotic 
activity in self-reactive B-cells, thus promoting the maturation of autoreactive B-cells with 
high affinity for anti-dsDNA [67].  It has been reported that women who had early 
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menarche or those receiving oestrogen-containing treatment such as oral contraceptives 
or postmenopausal hormone replacement therapy had a significantly increased risk for 
SLE (HR of 1.5 to 2.1) [68].  In contrast, male patients with SLE have lower testosterone 
levels compared to those without the disease [69]. 
2.2.1.5 Environmental factors 
Environmental factors are known to trigger SLE and disease activity.  Ultraviolet (UV) light and 
smoking increase the risk of SLE development through unknown mechanisms.  Exposure to 
UV light can exacerbate cutaneous SLE erythematosus and increase the risk of a flare. This 
causes aberrant apoptosis of keratinocytes and contributes to the accumulation of 
apoptotic cells in the skin of patients with SLE [70].  Apoptotic cells that fail to be cleared 
by phagocytes undergo secondary necrosis and subsequently releasing inflammatory 
mediators including IL-1, IL-3, IL-6, granulocyte macrophage colony-stimulating factor 
(GM-CSF), IFNs and TNF, thereby stimulating B-cells to make more antibodies [71].  Other 
factors include exposure to silica dust, petroleum and organic solvents [21].  Infectious agents, 
drugs and dietary factors have the ability to modulate the immune response and potentiate 
progression to SLE in individual who considered to be ‘at risk’ [13].  It is known that viral 
infections, such as Epstein-Barr virus (EBV) are linked to the initiation and exacerbation of 
SLE. Studies on EBV in SLE patients found high antibody titers of anti-EBV antibodies and 
increased viral load.  These individuals also make antibodies to protein regions of retroviruses 
which are homologous to nuclear antigens [72]. 
There are many reports about drug-induced lupus (DIL).  The implicated drugs are mainly 
those that are metabolized by acetylation such as procainamide and hydralazine, 
especially in people who are genetically slow acetylator phenotype [73]. 
2.2.2 Management of SLE 
Although considerable progress in SLE prognosis and management has been made in the 
last century, successful treatment of moderate to severe SLE remains unsatisfactory when 
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compared with rheumatoid arthritis management.  Potential reasons for this include paucity of 
randomized controlled trials of SLE treatment and the lack of the uniformity in SLE research 
inclusion criteria.  The heterogeneity and complexity of SLE are major factors that cause 
difficulty in identifying the best treatment for it [74, 75].  The goals of successful SLE 
management care are: low disease activity, avoidance of organ damage and minimising 
systemic corticosteroid exposure [75]. 
2.2.3 Non-Steroidal Anti Inflammatory Drugs 
Nonsteroidal anti-inflammatory drugs (NSAID) have analgesic, antipyretic and anti-
inflammatory properties through their inhibitory effect on cyclo-oxygenase1 (COX-1) and 
(COX-2).  NSAIDs are commonly used for symptomatic relief of arthralgia, mild arthritis, 
myalgia and fever in patients with SLE.  However, there is a lack of strong evidence to support 
the safety or efficacy of NSAIDs in clinical trials.  They can be used for short periods of time 
to minimise their side effect profiles.  This includes interstitial nephritis, renal impairment, fluid 
retention, peptic ulceration and increased risk of ischemic heart disease [16, 76]. 
2.2.4 Glucocorticoids 
Glucocorticoids are potent immunosuppressant drugs that induce the formation of anti-
inflammatory cytokines (IL10, IL1Ra) and reduce the formation of adhesion molecules and 
inflammatory cytokines (IL2, IL6 and tumour necrosis factor).  There are additional 
immunosuppressant effects which include the inhibition of antigen presentation and the 
synthesis of COX-2 and nitric oxide synthase.  Despite their toxic side effects (including 
osteoporosis, diabetes mellitus, increased infection risk and cardiovascular disease), 
glucocorticoids tend to produce a significant improvement in severe autoimmune disease.  
Glucocorticoids are the mainstay of SLE treatment in the acute phase of the disease due to 
the rapid onset of its anti-inflammatory effects [77, 78].  The preference is for glucocorticoids 
to be prescribed at the lowest possible dose for the shortest period of time  as the cumulative 
exposure is directly linked with their side effect profile [16].  They can be given in topical form 
for inflammatory cutaneous systemic lupus, as an intra articular preparation in active localised 
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synovitis, or alternatively as intramuscular and intravenous preparations [76]. 
2.2.5 Hydroxychloroquine and other antimalarial medications 
Hydroxychloroquine has immunomodulatory properties without immunosuppressive effects. It 
is recommended and licensed for use in SLE patients unless there are contraindications [74].  
The pharmacodynamics properties of the drug are based on alteration of lysosomal pH which 
leads to decreased cytokine and reduced prostaglandin production. Hydroxychloroquine 
blocks toll-like receptors on PDCs, by decreasing TLR signaling, this reduces the activation of 
DC and the inflammatory process. TLR 9 recognizes DNA-containing immune complexes and 
leads to the production of IFN and causes the DC to mature and present antigen to T cells, 
therefore reducing anti-DNA auto-inflammatory process.  The starting dose is 200-400mg 
daily. Its use in SLE has been supported by a randomized control trial conducted by Williams 
et al. where significant improvement was noticed in the patients with hydroxychloroquine 
compared to placebo [78].  For many years hydroxychloroquine was the primary treatment for 
CLE and serological abnormalities.  A phase III double blinded-clinical trial conducted in Japan 
for 103 patients with CLE were randomised to receive hydroxychloroquine or placebo.  They 
reported that the investigator’s global assessment showed a large number of patients who 
received hydroxychloroquine either  “improved” or “remarkably improved” in terms of their 
disease activity  (51.4% versus 8.7% in the placebo group [P=0.0002 between groups]) [79].  
Evidence also exists that hydroxychloroquine has additional benefits in improving overall 
survival in SLE [80].   Recently, it has been shown to have cardio protective effects by reducing 
the level of total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG) 
and increasing high-density lipoprotein (HDL) cholesterol levels.  Patients on 
hydroxychloroquine require annual ophthalmology follow up to screen for retinal toxicity 
(known as plaquenil maculopathy or Bulls eye maculopathy) which can lead to irreversible 
loss of central vision [76, 81, 82]. 
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2.2.6 Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) 
In the event that SLE patients require glucocorticoids at a dose of  5-7.5 mg/day or equivalent, 
which cannot be reduced or discontinued, the EULAR recommendations are to add in steroid-
sparing agents [83].  These agents are typically used for induction of remission when 
glucocorticoids are contraindicated or in more severe cases of arthritis [78]. 
2.2.6.1 Methotrexate 
Methotrexate is an anti-folate drug with anti-inflammatory and immunosuppressive properties.  
It inhibits DNA synthesis and is the most commonly prescribed agents for rheumatoid and 
psoriatic arthritis treatment [84].  Several clinical trials support its use as a potentially effective 
agent in the management of SLE arthritis and this is supported by positive outcomes in many 
clinical trials [84-86].  It can be considered as the leading steroid-sparing agent in SLE patients 
with articular presentation [84].  
2.2.6.2 Azathioprine 
Azathioprine is metabolized to 6 mercaptopurine and has immunosuppressant effects through 
suppression of xanthylic and adenylic acids synthesis.  It is one of the steroid-sparing agents 
which has shown its effectiveness in SLE patients who have central nervous system or renal 
involvement.  It is effective and safe to be prescribed during pregnancy [81, 87].  The main 
adverse effects are gastrointestinal manifestations which include nausea, vomiting, diarrhoea 
and elevation of liver enzymes.  It can also cause reversible bone marrow suppression.  Prior 
to commencing azathioprine, Thiopurine Methyl Transferase (TPMT) enzyme levels are 
checked.  Patients with a low level of the TPMT enzyme are prone to leukopenia due to drug 
toxicity as they lack sufficient levels to be able to adequately clear azathioprine from their 
bodies [76]. 
2.2.6.3 Mycophenolate Mofetil 
Mycophenolate Mofetil (MMF) mainly acts on inosine monophosphate dehydrogenase which 
inhibits B-and T-lymphocyte proliferation.  It has been used in SLE arthritis with positive 
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outcomes [88, 89].  The ALMS (Aspreva Lupus Management Study) showed that MMF was 
successful in the induction and maintenance of remission as well as prevention of flares in 
SLE nephritis.  The study concluded that the combination of MMF with corticosteroid is 
comparable to cyclophosphamide with corticosteroid in the induction and maintenance of 
remission in SLE nephritis [90]. 
2.2.6.4 Cyclophosphamide 
Cyclophosphamide prevents the division of cells by cross-linking DNA and suppressing DNA 
synthesis.  It can be given intravenously or orally, and clinical trials suggested that intermittent 
IV pulse therapy is less toxic and more efficacious.  It has become the treatment of choice for 
the induction of remission of severe SLE nephritis with the added benefit of preventing 
progression to end-stage renal failure [91].  Additionally, it can induce remission in severe 
neurological manifestations such as SLE cerebritis or neuropathy.  The side effects of 
cyclophosphamide include bone marrow suppression, gastrointestinal upset and premature 
ovarian failure.  There is also an increased risk of opportunistic infections, haematological 
malignancies and bladder cancer.  It is not safe to be given in pregnancy and should be 
discontinued at least three months before conception [76]. 
2.2.7 B cell depleting agents 
B-cells have a central role in the pathogenesis of several autoimmune diseases such as RA 
and SLE through their maturation into antibody secreting plasma cells, production of pro-
inflammatory cytokines, antigen presentation and supporting T-cells[92].  Inhibiting B-cells 
using antibodies against CD19 and CD20 can potentially modulate this process. Anti-CD20 
mAbs can be subdivided into type I or type 2 according to their ability to induce the 
reorganisation of CD20 molecules into lipid rafts upon binding.  Type1 mAbs induce 
translocation of CD20 into lipid rafts and efficiently activate the classical pathway of the 
complement system.  Examples include rituximab, ofatumumab and ocrelizumab. Conversely, 
type 2 mAb such as obinutuzumab poorly activates complement but directly induces cell death 
upon binding to CD20 without cross-linking by with secondary antibodies.  Both types of mAbs 
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are capable of inducing antibody dependent cell-mediated cytotoxicity (ADCC) in the presence 
of effector cells [93]. 
2.2.7.1 Rituximab 
Rituximab is an anti-CD20 chimeric mAbs that has been used successfully in many 
autoimmune diseases in which B-cells are implicated [94-97].  Rituximab kills B-cells by 
different mechanisms: 1- ADCC in the presence of effector cells, 2-complement activation 
resulting in complement-dependent cytotoxicity (CDC) and, 3-cross-linking of multiple CD20 
molecules, leading to cell death via induction of  apoptosis [93]. 
It was approved for the treatment of B-cell lymphoma in 1997.  Several recent double-blind 
placebo controlled trials of rituximab in RA have shown its effectiveness and safety [98, 99].   
However, the pivotal trials of rituximab in SLE have failed to reach their end points[81].  The 
problems with these trials is discussed in more detail in 2.15. 
Nevertheless, the drug is commonly used based on open label data. Rituximab was first used 
in an open uncontrolled study by Isenberg et al. It was shown to improve both clinical and 
laboratory manifestations in patients with refractory SLE [100, 101].  
2.2.7.2 Belimumab 
Belimumab is the only licenced biological therapy for SLE. It is a fully humanised mAb that 
specifically binds to and neutralises B-cell Activating Factor (BAFF).  This decreases the life 
span of CD20+ B-cells, reducing expression of both B-lymphocyte stimulator (BLyS)/BAFF 
and positive feedback for B-cell survival and anti-dsDNA expression.  There are two cytokines 
responsible for B-cell survival, maturation and differentiation BAFF and its homologue: A 
PRoliferation-Inducing Ligand (APRIL).  They bind to three receptors that are expressed on 
B-cells at different stages, thereby activating their own signalling pathways: i-BAFF receptor 
(BAFF-R) binds BAFF strongly; ii- B-cell maturation antigen (BCMA) binds APRIL and iii-TNF 
receptor superfamily member 13b (TACI) binds both BAFF and APRIL.  Approved for the 
treatment of SLE in 2012 on the indication of severe disease despite having maximum 
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treatment or the requirement for very high glucocorticoid dose  
Two Randomised control trial BLISS 52 and BLISS 76 assessed the efficacy of belimumab 
over placebo in active SLE patients.  Both studies reached their primary endpoints.  The 
endpoints were (a) improvement in the Systemic Lupus Erythematosus Responder Index 
(SRI) at week 52 (which is defined as reduction ≥4 points in SELENA-SLEDAI score (b) no 
new British Isles Lupus Assessment Group [BILAG A] organ domain score and no worsening 
in Physician's Global Assessment [PGA] score comparing to baseline [67, 97, 98, 102, 103]. 
These outcome measures and potential trial design issues are also discussed further below. 
2.2.7.3 Epratuzumab 
Epratuzumab is a fully humanised mAb targeting CD22.  It induces complete depletion of 
activated B-cells without influence on T-cells or serum levels immunoglobulins [76].  Many 
studies have shown that epratuzumab reduces total BILAG score and glucocorticoid 
requirements [104, 105].  
2.2.7.4 Ofatumumab 
Ofatumumamb is a fully human anti-CD20 mAb which binds to a membrane-proximal epitope 
of the CD20 molecules (targets a different epitope than rituximab). It is used for resistant 
chronic lymphoblastic leukaemia and with evidence for efficacy in RA, but no study has 
been done in SLE [106]. 
2.2.7.5 Ocrelizumab 
Ocrelizumab is a humanized monoclonal antibody that targets CD20+ B-cells. In-vitro 
ocrelizumab has demonstrated enhanced ADCC and reduced complement‐dependent 
cytotoxicity when compared with rituximab [107]. It met their endpoints; American College of 
Rheumatology 20% improvement criteria (ACR 20%) in RA clinical trials[107, 108].   But this 
development and its use was stopped due to some safety issues such as increasing the risk 
of opportunistic infections[109]. 
2.2.8 Interferon blockade 
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Interferon (IFN) is a family of cytokines that are typically secreted by cells in response to 
exposure to a pathogen (viruses) or nucleic acids from increased apoptosis.  There are three 
types of the INFs: Type I, Type II and Type III IFN that differ according to molecular subtype 
and IFN receptor binding.  Type I IFNs (IFN-I) is the largest family and consists of the IFN-α 
and IFN-β molecular subtypes which bind to the IFN-α receptor (IFNAR).  Dysregulation in the 
IFN pathway is considered to play an essential role in the development and activity of 
SLE[110].  Many studies have shown that high IFN-α expression correlated with both 
increased activity and severity of SLE [111, 112].  The increased expression levels of  IFN 
regulated genes (called the IFN signature), correlates closely with the presence of auto-
antibodies and  SLE disease activity [113].  Supersession of this pathway is the target of many 
therapeutic agents for SLE.   
Sifalimumab is a fully human IgG1k monoclonal antibody that inhibits Type I IFN-α.  
Promising results were found in a phase IIb randomized, double-blind, placebo-controlled 
study in subjects with moderate to severe SLE.  Patients who received sifalumumab met the 
primary end points in comparison with the placebo group [114].  The details of this study are 
discussed in 2.23.1. 
Rontalizumab is a humanized IgG1 monoclonal antibody against IFN-α.  There were 
acceptable results from a phase I dose-escalating study [115].  A Phase II study of the efficacy 
and safety of rontalizumab showed a failure to meet the primary and secondary endpoints. 
However, it reported an improvement in disease control based on a reduction in flares and 
steroid use [116].  
Anifrolumab is a fully human IgG1κ monoclonal antibody directed against subunit 1 of the 
type I IFN Receptor (IFNAR1).  It has been studied in a phase II, open-label, dose-escalation 
study in Japanese SLE patients [117]. The results of a phase II efficacy and safety study in 
adults with moderate to severe active chronic SLE with inadequate response to standard 
treatment illustrated reduced disease activity in anifrolumab recipient compared with placebo 
[118].  The details are discussed in 2.23.2. 
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 Criteria for biologic therapy for SLE in the UK 
The current criteria for the use of belimumab and rituximab in SLE are shown in (Figure 2-1).  
For patients with predominant musculoskeletalinvolvement these will require at least BILAG B 
or SLEDAI MSK points more than four, therefore they will need clinical synovitis.  For 
belimumab, to achieve 10 points on the SLEDAI the patient will need four points for clinical 
synovitis, four points for the required dsDNA antibodies and complement, and two points 
elsewhere in the score (e.g., mouth ulcers or alopecia).  For rituximab, patients require either 
BILAG B (moderate synovitis) as well as one other BILAG B in another domain, or BILAG A 
(severe synovitis) alone. Hence, it is not possible for patients to receive biologic therapy for 
musculoskeletal SLE unless they have at least moderate synovitis.   
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Figure 2-1. Criteria for Biological therapy in the UK [119, 120] 
 
ACR: American College of Rheumatology, BILAG: British Isles Lupus Assessment Group, CNS: 
Central Nervous System SLEDAI: Systemic Lupus Erythematosus Activity Index, SLICC: Systemic 
Lupus International Collaborating Clinics. 
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 Musculoskeletal SLE 
Musculoskeletal manifestations are among the most common features of SLE both in initial 
diagnosis and in long-term management.  The control of musculoskeletal SLE symptoms is 
critical as they are crucial to the overall patient outcome as well as the influential in the 
development of new therapies [7].  Articular involvement is mainly characterised by transient, 
migratory arthralgia and arthritis.  The spectrum of musculoskeletal conditions also includes: 
myositis, tenosynovitis, tendon rupture, tendinitis or non-inflammatory presentations such as 
avascular necrosis of the bone and fibromyalgia [121].  In a minority of cases deforming and/or 
erosive arthropathy, respectively named Jaccoud’s arthropathy(JA) and Rhupus syndrome 
can be found [122].  Musculoskeletal SLE is the theme of this thesis. 
 Importance of Musculoskeletal SLE 
Musculoskeletal manifestations of SLE are the first presenting symptom in up to 50% of 
patients with SLE and affect up to 95% of patients during the clinical course of the disease 
[123, 124] .  Although other manifestations may be more critical in terms of risk of organ failure 
and early mortality, musculoskeletal manifestations are the key determinant of disease impact 
in this group of patients.  Apart from fatigue, the most frequently reported difficult symptom of 
SLE is pain (50%) and musculoskeletal (46%) and these symptoms were most strongly related 
to reduced health-related quality of life [125].  In a systematic review, only 47% of SLE patients 
reported to be engaged in full-time employment and 34% reported work disability[126].  
Arthralgia was individually the only symptoms to be significantly associated with work 
disability, with odds ratio (OR)  of 2.41 [95% confidence interval (CI)1.53–3.79] [127].  By 
comparison, overall disease activity as measured by the systemic lupus erythematosus 
disease activity index (SLEDAI) showed no association with work disability, and when 
measured by Systemic Lupus Activity Measure (SLAM) had only a modest association (OR 
1.12, 95% CI 1.03–1.21).  Age, household income, and fibromyalgia were most strongly 
associated with work disability. In a longitudinal follow-up, 34 % of patients with 
musculoskeletal manifestations discontinued their involvement in the workforce after a median 
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of four years [128].  Arthralgia is, therefore demonstrated to be one of the most important 
modifiable factors in disability in SLE patients.  Musculoskeletal manifestations of SLE are 
frequently treated with glucocorticoids and NSAIDs, and both have an association with an 
increasing rate of long-term cardiovascular complications.  A recent French study found that 
cardiovascular disease is the greatest cause of mortality in SLE [129], and in a 2016 
systematic review cardiovascular diseases were most strongly associated with increased 
standardized mortality ratios in SLE after renal disease and infection[130]. 
Interestingly, cluster analysis of Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage Index domains found low level damage, musculoskeletal 
damage, and cardiovascular damage,  to be associated with death rates of 3.7,10.8, and 
20.5%, respectively[131].  Regarding therapeutics: the majority of non-renal SLE patients 
qualify for clinical trials and biologic therapy because of activity in skin and musculoskeletal 
systems.  For example, in the ILLUMINATE-1 phase III trial of tabalumab (anti BAFF), 78.8–
83.5% of patients had activity in the musculoskeletal system in each arm.  Only Skin 
involvement was more common than musculoskeletal activity: and the proportions of 
patients with activity in other organs was far smaller: the next largest clinical manifestation 
was haematological – approximately 11% of patients [132].  In the UK BILAG registry data, 
31% of all renal and non-renal SLE patients treated with a biologic in the UK received it for 
musculoskeletal disease [133].  
 Subtypes of SLE Arthritis 
2.6.1 Jaccoud’s Arthropathy 
Jaccoud’s arthropathy (JA) was first described as a non-erosive arthropathy with reversible 
deformities in association with rheumatic fever.  An identical phenotype was noted in patients 
with SLE in 1975 [134].  JA may also occur in other connective tissue diseases, although, this 
appearance is frequently cited as being pathognomonic for SLE in the textbooks. It is in fact, 
quite an uncommon characteristic of SLE.  The prevalence of JA in  SLE range from 2.8 to 
3.5% in the registry database of the last decade [135, 136]. 
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2.6.2 Rhupus 
Approximately 5% of SLE patients are estimated to present with a combined RA/SLE clinical 
syndrome referred to as ‘Rhupus’.  These patients meet classification criteria for both RA and 
SLE, which presents as erosive arthritis with identical radiographic appearance to RA, and 
often in association with rheumatoid factor and anticitrullinated peptide antibodies.  The 
pathogenesis of rhupus is thought to be more typical of RA [137, 138].  A recent study 
compared features of SLE arthritis among children and adults.  Although chronic polyarthritis 
tended to be more common and severe in children, rates of JA and rhupus did not differ 
between the two groups [139]. 
2.6.3 Non-deforming Non-erosive Arthritis 
The vast majority of patients with SLE arthritis are described as non-deforming non-erosive 
(NDNE) arthritis.  Although these patients have similar inflammatory features to other 
inflammatory arthritidis , such as symmetrical small joint distribution and morning stiffness, 
clinically detectable synovitis is present in only a small number of patients [7]. Non 
Inflammatory musculoskeletal symptoms in SLE 
A great majority of SLE patients present with nonspecific, non-inflammatory clinical features 
which are difficult to distinguish from the inflammatory manifestations [121]. 
2.6.4 Fibromyalgia 
Fibromyalgia (FM) is a widespread chronic musculoskeletal pain disorder affecting 2-3% of 
general population.  It is widely defined according to ACR criteria as tenderness on palpation 
of at least 11/18 bodily points for a minimum three month period [140-142].  It is associated 
with fatigue and somatic symptoms such as poor sleep, mood and neurological 
disturbances[143].  There are no objective or laboratory features to evaluate FM.  It is difficult 
to differentiate FM from SLE, and their concomitant prevalence is approximately 20%, which 
means FM is more common in SLE patients than in the general population [144].  There are 
many shared symptoms between SLE and Fibromyalgia and this may lead to 
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misinterpretation, misdiagnosis and over treatment[145].  Di Franco et al. studied patients with 
different rheumatological inflammatory diseases and fibromyalgia and they detected a 
substantial proportion of patients with  FM had been misdiagnosed as having connective tissue 
disease, including SLE [142].  Wallace and colleagues studied 44 female patients who had 
been referred to the rheumatology clinic because of positive ANA and found after six months 
that 19/44(43%) met the ACR criteria for SLE  while 14/44 (32%) fulfilled the ACR criteria for 
FM [146].  Gladman et al. studied 119 patients with SLE.  They reported that the prevalence 
of fibromyalgia was 21% and there was no relation to either the overall scores or any of the 
components of SLEDAI or Damage Index but there was a strong negative correlation with all 
eight domains of the Short Form 36(SF-36) [147]. 
2.6.5 Avascular Necrosis 
Systemic lupus erythematosus itself and the drugs used to treat it interfere with the blood 
supply to the bone and initiate the process of necrosis.  Osteonecrosis is a painful condition 
that interferes with the quality of life of patients in terms of pain and impaired mobility[148].  
There are many factors beyond those mentioned that may cause osteonecrosis; long duration 
and large doses of steroid use, Raynaud phenomenon, vasculitis, and antiphospholipid 
syndrome [149].  The prevalence of osteonecrosis varies between 4.6% and 40% [150]. 
2.6.6 Osteoporosis 
Low bone density, osteoporosis and fragility fractures are common in SLE.  Osteopenia is 
found in 4% to 74% and Osteoporosis in approximately 3% to 48% of patients with SLE. Risk 
factors include immobility, chronic inflammation, and vitamin D deficiency often due to lack of 
sun exposure and steroid treatment leads to decrease bone formation [151]. 
 Treatment of musculoskeletal SLE 
Although arthritis is a common feature in research populations, many clinical trials have 
neglected to report response in individual organ domains. In clinical practice, conventional 
therapy for SLE, i.e. (azathioprine, MMF, or cyclophosphamide) is frequently selected 
 29 
because of their established efficacy in the treatment of other organ domains. However, in RA 
and other inflammatory arthritis, these agents have been shown to be less effective for arthritis 
than methotrexate.  For this reason, methotrexate is often selected in SLE as a first-line 
immunosuppressive as a reflection of RA data [2].  Evidence for the overall efficacy of 
methotrexate for the treatment of non-renal SLE is mixed. Steroid-sparing, but not global 
disease activity reduction (Systemic Lupus Activity measure and SLEDAI) was concluded to 
be the effect of methotrexate in SLE patients found in one randomized control trial[84].  
However, two smaller randomized trials did demonstrate some efficacy in arthritis-specific 
outcome measures [152, 153].  Similarly, in trials of biologic therapies, a few have reported 
organ-specific outcomes including arthritis and differences in efficacy between individual 
domains, especially comparing skin and arthritis domains.  Musculoskeletal domain is 
frequently one of the most responsive organ systems.   Belimumab is the only biologic therapy 
licensed for SLE.  Musculoskeletal domain was reported to be one of the most common 
manifestations at baseline in two phase III studies on belimumab [154, 155].  BILAG domain 
responses in arthritis following belimumab suggest it is one of the most responsive organ 
systems [156].  Pooled post hoc analysis showed 60.7% of the patients in the musculoskeletal 
domain with active disease at baseline improved by at least one BILAG grade, compared to 
50% of those on placebo.  The Musculoskeletal domain outcomes were somewhat better than 
the results in the mucocutaneous domain (the next most common manifestation) which had 
improvement rates of 47.8 and 39.1% for the combined active and placebo groups.  No 
substantive difference was observed between groups for the less common manifestations of 
renal and haematological domains.  Further, rates of worsening reduced in the 
musculoskeletal domain from 5.0 to 3.9/3.8% for the 1 and 10-mg/kg active groups in 
musculoskeletal disease.  By comparison, rates of worsening in the mucocutaneous domain 
were 4.5, 4.3, and 5.4% in the placebo, 1 and 10-mg/kg arms.  Similarly, improvements were 
seen in the quality of life domains of the Short Form Survey 36, such as physical function and 
bodily pain[157].  A study of abatacept in patients with lupus arthritis, discoid lupus and lupus 
pleuritis showed a reduction in BILAG-defined flare rate for arthritis with abatacept but not 
 30 
discoid lesions [158].  Our own group’s open-label data suggests a similar pattern of efficacy 
with rituximab in SLE, with consistent efficacy in musculoskeletal disease but variable efficacy 
in mucocutaneous manifestations, and non-response in discoid lupus [159, 160].  Although 
phase III trials for the B-cell-targeted biologic epratuzumab were negative, earlier phase II data 
reported efficacy for epratuzumab in the musculoskeletal BILAG domain [161].  Phase II data 
on type I IFN-targeted biologics, sifalimumab, and anifrolumab included joint counts as 
secondary endpoints, demonstrating greater reductions in treatment groups compared to 
placebo [46]. Overall, arthritis often appears to be more responsive to immunosuppressive 
therapy than mucocutaneous disease using existing validated outcome measures.  Further, 
the literature suggests that arthritis has a greater breadth of responsivity to a wide range of 
conventional and targeted therapies. 
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Figure 2-2. Treatment of musculoskeletal SLE 
 
ACPA: -citrulillinated protein antibodies. INF-I: Interferon-I, US: ultrasound, MRI: magnetic resonance 
imaging. BILAG index: British Isles Lupus Assessment Group .SLEDAI: Systemic Lupus 
Erythematosus Disease Activity Index. RA33: heterogeneous nuclear ribonucleoprotein A2/B1 
Figure 2-2 summarises treatment of musculoskeletal manifestation of SLE.  Current 
knowledge (solid arrows and boxes) and knowledge gaps (dotted arrows and boxes) in the 
treatment of inflammatory musculoskeletal SLE. The main gaps in the knowledge are: (i) the 
value of immunosuppressive treatment for subclinical synovitis is not proven, nor the outcome 
of symptomatic treatment only in patients with normal imaging; (ii) erosions are more 
widespread than radiographic studies indicated but their long-term significance and any benefit 
of immunosuppression, are unknown; (iii) although SLE is heterogeneous for serology and 
interferon status, these subgroups of SLE  have not been investigated with respect to their 
response to therapy.  
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 Clinical Outcome Measures for SLE 
Measuring SLE disease activity in clinical research is very important for several reasons 
including patient outcomes and disease prognosis, differentiating between patient groups 
and differences between therapeutic responses.  The British Society of Rheumatology (BSR) 
2017 Guidance recommends that all patients should be monitored on a regular basis for 
disease manifestations, clinical activity, drug toxicity and co-morbidities [162].  Assessment 
of patients with SLE is notoriously challenging because of the complexity of the disease, its 
multisystem nature in the same patient, its fluctuating course and the absence of a gold 
standard tool that measures the activity of the disease[163].   
There are several outcome measures used in SLE.  Probably the most commonly used tools 
are the British Isles Lupus Assessment Group (BILAG), Systemic Lupus Activity Measure 
(SLAM), European Community Lupus Activity Measure (ECLAM), SLE Disease Activity 
Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/ American College of 
Rheumatology (SLICC/ACR) [164].  While BILAG, SLAM, ECLAM and SLEDAI are disease 
activity indices, SLICC/ACR is a damage index.  As SLE is a multisystem disease, all these 
outcome measures represent an assessment of all potential systems affected in order to 
produce a composite score.  For this reason, the outcome measures are limited in their 
ability to provide a sensitive index of individual systems, such as the musculoskeletal 
system.  The validated outcome measures such as BILAG and SLEDAI are based on the 
detection of clinical swelling and in cases of active arthritis without clear detectable swelling, 
may fail to capture true disease activity.  Many other additional tools are used to measure 
the quality of life in SLE.  Medical Outcomes Survey Short Form 36(F-36), for example, 
assesses the physical function, the social function, mental health impact, role impact from 
physical problems, role impact from emotional problems, energy level, pain levels and 
general health perception [121, 165].  Other functional measures include the Health 
Assessment Questionnaire (HAQ)[166], General Health Questionnaire [167], and Quality of 
Life Questionnaire [168] which have the applicability for use in other rheumatic diseases 
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aside from SLE. 
2.8.1 British Isles Lupus Assessment Group (BILAG) 
The BILAG score was developed in 1988 and modified in 2000.  It is used to evaluate SLE 
disease activity in individual organ systems and was developed based on the physician’s 
intention to treat.  The revised BILAG Index (version 2004) measures disease activity 
(scored from grade A to E) in 9 body or organ systems affected by SLE based on clinical 
assessments and laboratory results [11, 169].  The BILAG-2004 index covers 97 items as 
opposed to 86 items in the classic BILAG and records disease activity occurring over the 
past four weeks. The BILAG items are scored as 0 = not present, 1 = improving, 2 = same, 3 
= worse, or 4 = new based on the trajectory of activity in the proceeding four weeks, so not 
just present or absent.  The numerical global BILAG-2004 score has also been introduced to 
facilitate comparison with other disease activity indices[170].  Each grade is weighted as 
follows: grade A = 12 points, grade B = 8 points, grade C = 1 point and grades D/E = 0. The 
global BILAG-2004 score is then calculated by adding the total points from the nine BILAG 
grades. 
The BILAG 2004 has been designed and validated with the focus on the physician's intention 
to treat in SLE and is a modern version of the Classic BILAG assessment tool [11].  Although 
there are many similarities, the Classic BILAG included tendon contractures and avascular 
necrosis.  These items were removed in BILAG 2004 because they were felt to represent 
disease damage and not disease activity. Classic BILAG was a commonly used tool in earlier 
SLE studies of the past century.  At each patient's visit, the BILAG (classical and 2004) 
instrument assesses (general, renal, haematological, neuropsychiatric, respiratory, 
mucocutaneous and musculoskeletal systems).  In this instrument, disease activity is graded 
on a 5-grade scale. Grade A represents a very active disease, for which a change in therapy 
is required.  Grade B represents a moderately active disease and implies that the patient 
needs an increase in treatment. Grade C indicates mild stable disease and requires 
symptomatic therapy.  Grade D represents no current disease activity.  Grade E represents 
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no current or previous activity [171].  The validity of BILAG has been assessed in several 
studies.  In 2010 Siavash Nasiri et al. studied the correlation between different laboratory 
investigations (ESR, C3, C4, anti-DNA) and SLE activity.  The group also studied the construct 
and criterion validity of the BILAG index as a tool for assessing the activity of systemic lupus 
erythematosus.  They demonstrated that the validity of the BILAG index as a measure of SLE 
disease activity, based on its construct validity.  Construct validity was confirmed by the 
expected association between high BILAG score and high level of ESR and anti-dsDNA (OR 
= 2.6 (1.2 - 4.3) for ESR> 60  mm/h, OR = 2.5 (1.4 – 3.6) for anti-dsDNA greater than 5 times 
the normal value ) and low level of C4 and C3 (OR = 4.8 (1.4 - 15.1) for C3 below half the 
normal limit, OR = 4.1 (2.3 - 5.8) for C4 below half the normal value) and high SLEDAI-2K 
score(OR = 215.6 (99.8 - 387.6) for a value of SLEDAI above 6).  Criterion validity was 
confirmed by the increasing strength of the association between BILAG scores and raised 
disease activity[172].  Chee-Seng Yee and colleagues through a prospective multicenter 
longitudinal study assessed BILAG sensitivity.  The group studied the relationship between 
changes in BILAG score and treatment alterations over two consecutive visits.  The conclusion 
was that increases in BILAG scores was correlated with increasing treatment (coefficient 
multinomial logistic regression: 1.35; 95% CI: 1.01-1.70).  This association was also found in 
the opposite direction [173].  The strong points of the BILAG include highlighting the 
importance of assessing patients' individual bodily systems rather than a global or overall 
score, it includes the important element of change in disease state with time, is sensitive to 
small changes [173] and seems to distinguish between disease activity and disease severity. 
There are several problems however that linked with the BILAG.  BILAG fails to capture minor 
improvement, is time-consuming, requires assessment by a trained person and it does not 
consider immunologic serology in its final score.  Further, it omits some important clinical 
manifestations such as Raynaud phenomenon and antiphospholipid syndrome.   
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2.8.2 SLE Disease Activity Index (SLEDAI) 
The SLEDAI was developed in 1985 as a clinical tool to classify SLE disease activity in the 
ten days preceding assessment. It is a scale of 24 clinical and laboratory parameters that 
assess nine organ systems. The score can range from 0 to 105 and is based on the absence 
or presence of various manifestations in the preceding 10 days.  However, there are some 
weakness in SLEDAI score. SLEDAI does not score life-threatening manifestations such as 
pulmonary haemorrhage and haemolytic anaemia [174].  It was modified in 2002 to (SLEDAI-
2K) the period of the assessment was extended from 10 days to 30 days.  Another modified 
version of SLEDAI was developed for use in the Safety of Oestrogens in Lupus National 
Assessment (SELENA) study; SELENA-SLEDAI. A glossary was added and the modification 
allowed for documentation of persistently active disease in some descriptors, which previously 
were not scored unless they were new or recurrent such as rash, mucosal ulcers, and 
alopecia.  Additionally, the SELENA-SLEDAI also accepts the presence of either the objective 
or subjective findings for the descriptor to be scored as present [175].  SLEDAI and its versions 
have the advantage of easy documentation and low administrative burden and that explains 
why it is one of the most commonly used tools in the clinical trials and longitudinal 
observational studies.  However, there are some problems with it. It does not have the ability 
to detect the improvement or deterioration in the patient’s symptoms, but instead only identifies 
the presence or absence of the symptom.  For these reasons the SLEDAI responder index 
50(SLEDAI-RI 50) was developed as a way of detecting improvement or deterioration.  It 
records a ≥ 50% worsening or improvement in disease activity between visits[176].  The 
SLEDAI-RA 50 composite score cannot discriminate between different symptoms in the 
presence of the same disease activity score.  In addition, the tool is less detailed in its capture 
of SLE disease severity and range of manifestations.  For example, joint involvement is 
defined as having inflammation in two or more joints but cannot discriminate if the arthritis is 
mild or severe; also it does not include a myositis index. Finally, not all SLE-related 
manifestations are included in the SLEDAI-2K [176].   None of the versions has the ability in 
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capturing the partial response or progression of an existing feature because the score only 
reduced when the item is completely recovered. 
2.8.3 European Community Lupus Activity Measure (ECLAM) 
The European Consensus Lupus Activity Measure (ECLAM) was developed in 1992 to index 
disease manifestations in the last 30 days prior to patient assessment [176]. 
The ECLAM uses a list of disease activity items which a physician judges as present or absent.  
Each item has a different weighting and a maximum score of ten.  For musculoskeletal 
disease, one point is awarded for either non-erosive arthritis or evolving arthralgia.  ECLAM 
showed correlation greater than 0.72 with SLAM, BILAG and SLEDAI, and correlated with 
Physician global assessment(PGA) as the gold standard, both on a quantitative scale (0-10) 
and a qualitative scale (inactive to active) [177].  
2.8.4 Systemic Lupus Activity Measure (SLAM) 
The SLAM was released 1986 and revised two years later and renamed SLAM-R. The SLAM 
grades 31 items into 0-2 or 0-3 and provides a summated score.  For musculoskeletal disease 
the scores are: 0 = absent; 1 = arthralgia only; 2 = objective synovitis; 3 = limits function.   Bae 
et al. presented a study of 30 patients to evaluate the feasibility and construct validity of this 
new version. Reliability was estimated by analysis of variance, with 0.78 inter-observer 
reliability and 0.61 intra-observer reliability.  Regarding construct validity, Pearson correlations 
were calculated for SLAM-R with PGA (0.87), levels of anti-dsDNA (0.51), C3 (-0.60) and C4 
(-0.29) [178].  The SLAM is used to assess and capture disease activity in the last month.  It 
includes 30 items that cover nine organs/systems and seven laboratory parameters.  The 
score ranges from 0 to 84.  The limitations are that the SLAM does not consider the severity 
of the disease. It also has many subjective items such as fatigue and joint pain that depend 
mainly on the report of the patient to rather than objective manifestations [11].  Similar to other 
activity indices, both the ECLAM and SLAM lack sensitivity in detecting change. 
2.8.5 SLE Responder Index (SRI) 
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The SRI-4 is a composite tool that includes the BILAG, modification of the Safety of 
Estragon in Lupus Erythematosus National Assessment/SLE activity index (SELENA-
SLEDAI) score and the 3-cm Physician Global Assessment (PGA).  The SRI-4 has the ability 
to assess for improvement in disease activity in each organ alone and the overall condition 
[77].  A responder is defined as one who has (1) no new BILAG A or  not more than one new 
BILAG B organ domain score ;(2) at least a 4 point reduction in SLENA-SLEDAI score 
and;(3) no deterioration from baseline in the physician global assessment  by at least 0.3 
points [22].  The SRI was derived following post-hoc analysis of a phase II belimumab study 
in SLE in order to identify subjects with a significant  clinical improvement in disease activity 
and response to treatment [179].  They defined response as if fulfilling all of the following: (i) 
≥ 4-point reduction in SELENA-SLEDAI score; (ii) no new BILAG A or two new BILAG B 
scores and (iii) no deterioration from baseline in the PGA by at least 0.3 points (or 10 % of 3-
point VAS). 
The advantages of SRI include: it minimises the limitations of each of the individual index 
that constitute this composite measure.  However, the SRI has some significant differences 
in outcome from the scores from which it was derived. For instance, the BILAG component is 
only defined by no new worsening. Thus, a patient can qualify as a responder using SRI-4 
when a feature of SLEDAI resolves, while other features (if present at baseline) remained 
the same or worsened to some extent (one BILAG B score).  The applicability of this index 
for clinical practice is therefore currently less clear. 
2.8.6 British Isles Lupus Assessment Group-based Combined Lupus Assessment 
(BICLA): 
The BILAG-Based Composite Lupus Assessment (BICLA) is a composite index that was 
developed by expert’s consensus of disease activity indices.  BICLA was first used as the 
primary endpoint in the phase II randomised controlled trial (RCT) of epratuzumab in 
patients with autoantibody positive SLE [180].  Requirements for response were: (i) BILAG-
2004 improvement (all A scores improved to B/C or D and all B scores improved to C or D); 
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(ii) no worsening in disease activity (no new BILAG A or no more than one new BILAG B 
score); (iii) no worsening of entire SLEDAI-2K score from baseline; (iv) no significant 
deterioration (<10% worsening relative to baseline) in physician’s global assessment and (v) 
no treatment failure(defined as new or increased use of oral corticosteroids or other 
immunosuppressant above baseline).  
The strong point of the BICLA index is that it requires a stringent response in all body 
systems that are involved at baseline and requires that there are no new flares in the other 
body systems.  In addition, BICLA includes treatment failure which is clinically meaningful 
particularly in terms of disease burden and comorbidity perspectives, whether this may be 
termination of therapy, increment in daily oral prednisolone dose or adding of alternative 
immunosuppressant. 
BICLA is disadvantaged by the administrative burden that requires formal training and it also 
requires further validation in clinical practice and clinical trials.  
2.8.7 Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and 
the revised version (RCLASI) 
Skin involvement is one of the most common features of SLE.   It is measured by an organ-
specific tool (CLASI).  CLASI is a comprehensive tool that comprises assessment for disease 
activity and damage in cutaneous lupus erythematosus (CLE).  It aims to measure the level of 
active inflammation in the skin, scalp, and oral mucosa.  For instance, lesions with greater 
visual intensity (dark purple is worse than faint erythema) and scaling are considered to be 
more active and would be scored appropriately higher than those without.  The damage is 
defined as depigmentation, scarring or atrophy and scarring alopecia.  It is reported that CLASI 
is valid, reliable and sensitive to changes [181, 182].  A four-point or 20% decrease in CLASI 
activity score has been shown to be the most specific criterion in classifying patients as 
responders or non-responders and also represents the minimal clinically important changes 
[183].  D Bein et al. reported that CLASI as an overall useful instrument to analyse disease 
activity and damage in Cutaneous Lupus Erythematosus.  Nevertheless, the CLASI does not 
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reflect an accurate assessment of all disease subtypes; therefore, a revision of the CLASI 
(RCLASI) was derived by adding oedema or infiltration and subcutaneous nodules or plaques 
as descriptors for disease activity[184].  RCLASI has been used in clinical trials; however the 
limitations include high administrative burden and lack of use in clinical practice. 
2.8.8 Damage Indices 
As a direct result of the improvement in SLE therapies, the survival rate of individuals with 
SLE has increased.  The downside is that the cumulative effect of chronic disease due to end-
organ damage and cardiovascular or infectious complications.  Different from the previously 
mentioned outcome measure, The Systemic Lupus International Collaborative Clinics damage 
index (SLICC) is used to record irreversible damage that may happen in SLE patients either 
due to disease, medications or any undercurrent illness that presents for at least six months, 
any other illnesses that has developed after the diagnosis of SLE [185].  The musculoskeletal 
damage items are muscle atrophy or weakness, deformity or erosive arthritis, osteoporosis 
with fracture or vertebral collapse, avascular necrosis and osteomyelitis.  Although this tool is 
not useful in assessing the response to therapy, it can be used to evaluate the general health 
and SLE control over time. 
2.8.9 Blood investigations 
There are multiple autoantibodies that can be detected in SLE patients.  Of these the most 
commonly detected is anti-double strand DNA(ds DNA) [186].  Rising anti-double strand DNA 
is sometimes associated with flare but cannot be used as a marker of a flare because the 
pattern is inconsistent for all patients with SLE and this is thought to be due to the deposition 
of the antibodies in the tissues at the peak of the disease [12, 187].  Anti-C1q antibodies are 
present in 20%–44% of SLE patients.  Anti C1q antibody titres correlate strongly with global 
SLE disease activity scores, and so are predictive of the development of renal involvement or 
flares in SLE patients [12].  Anti-chromatin antibodies can be detected in around 69% of 
patients with SLE, and mainly in patients with lupus nephritis, but can also be found in patients 
with Sjögren’s syndrome, and systemic sclerosis [22].  Anti-Sm and anti-Ro antibodies can be 
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found in patients with SLE.  However, these antibodies are neither specific nor sensitive in the 
function of monitoring for disease activity.      
Traditionally, both C3 and C4 levels have been used as one of the most reliable biomarkers 
of SLE disease activity.  Individual patients however show variation in complement levels, and 
other weaknesses of complement as a biomarker is that they are acute phase response items, 
they may be low due to genetic deficiency, and can be found in low levels in non-SLE 
conditions [174].  A decrease in complement (C1q, C3 or C4) level is associated with an 
increased risk of renal and haematological activity in SLE [176].  The measurement of 
complement breakdown products (i.e. C3d or C4d) may also be useful as these tend to 
increase following SLE flare but can indicate impending disease activity [188].  They have the 
same limitations as C3, C4 and C1q levels.  
 Quality of life 
As a result of its variable course, complications, and the side effects of the medications, SLE 
is a debilitating disease with a negative impact on quality of life.  In particular, patients have a 
higher mortality rate, decreased productivity at work, and many psychological issues. Patients 
with SLE have a large disease burden.  There are many quality of life domains of importance 
to SLE patients such as social and family life, pain, fatigue, work, and independence [189, 
190].  In comparison with other chronic diseases and healthy controls, SLE patients have the 
lower health related quality of life [191].  
SLE has a comparable effects on patients to that of AIDS, RA, and Sjogren’s syndrome[192, 
193].  However, the physical function and pain domains were more affected in RA patients 
than patients with SLE, which could be explained by the nature of RA as it affects joints 
predominantly.  Objective assessments of disease activity and damage are judged only by 
doctors and do not consider the patient’s perspective of their health [194].  Therefore, 
assessment of health-related quality of life (HRQoL) in conjunction with clinical measures of 
disease activity and damage indices provides a more comprehensive impression of the patient 
and their condition. 
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2.9.1 Health-related quality of life 
Health related quality of life (HRQoL) refers to various aspects of life that are affected by health 
such as functional status but excludes income, job security and living conditions which are the 
other determinants of QoL [195].  Various measures have been described for health related 
quality of life, which are not specific to SLE, but have been reported in SLE trials.  These are 
summarised in Table 2-3. 
  
 42 
Table 2-3: Measures of quality of life used in SLE 
Measure Contents 
Medical Health Assessment 
Questionnaire  
1-Degree of difficulty 
2-Satisfuction with function 
3-Need for help in daily activities 
Quality of Life  scale Material goods, health, interpersonal relationship, self, 
recreational activities and independence. 
Arthritis Impact Measurement 
scale-2(AIMS-2) 
Mobility , physical activity , dexterity, household activity, 
social activities,  daily living activities, pain, depression , 
anxiety, arm function, social support, work 
Medical Outcomes Survey Short 
Form(20) 
Physical functioning, role functioning, social functioning, 
mental health, health perception, pain[196] 
Medical Outcomes Survey Short 
Form(36) 
Physical functioning, role limitations resulted from physical 
problems, bodily pain, general heath, social functioning, 
mental health, role limitations resulted from emotional 
problems, vitality[197] 
EQ-5D Mobility, self-care, usual daily  activities, pain, and 
depression 
Sickness Impact Profile(SIP) Sleep and rest, eating, work; home management, recreation, 
mobility, body care and mobility; body and, social interaction, 
alertness, emotional behaviour, communication. 
WHOQoL-Bref Physiological, psychological health, social relationships and 
environment[198]. 
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2.9.2 Short Form-36(SF36) 
Short Form-36 is a reliable and widely used  instrument to assess self-perceived health status 
[199].  This generic measure can be used in many conditions including SLE.  It has been 
recommended by The Systemic Lupus International Collaborating Clinics group (SLICC).  It 
has the ability to identify the mental and physical effects of SLE on the patients in the previous 
month [200].  It assess  the limitations in physical activities, pain, social activities, mental 
health, vitality, and general heath perceptions [12].  SF-36 consists of 36 items and 8 domains 
including physical function, role physical, bodily pain, vitality, role emotional, mental health, 
social function, and general health. Scores for each domain are added up, and these scores 
are converted into eight 0–100 scales.  Higher score suggests better health status.  Eight 
domains can be combined into the physical component score (PCS) and mental component 
score (MCS) to give a better general overview of health.  SF-36 has been used in several SLE 
studies and they reported that physical health section scores were somewhat lower than those 
of mental health, which may indicate that physical health is more likely to be affected in SLE 
patients [190].  However, this instrument is less sensitive to changes. It has a shorter version 
which is called SF-20. SF-20 comprises 20 items, which are divided into 6 domains relating to 
physical functioning, role functioning, social functioning, mental health, health perception and 
bodily pain.  The results are assessed in 1−10 scale and then multiplied by 100 [196]. 
2.9.3 EQ-5D questionnaire 
EQ-5D questionnaire was developed by an international research group, the EuroQol Group. 
Established in 1987, it comprises of 5 questions on mobility, self-care, usual activities, pain, 
and depression.  EQ-5D is one of the most widely used generic health status measurement, 
and it has good validity and reliability.  The questionnaire has the advantage of being quick to 
complete [201]. 
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2.9.4 WHOQOL 
There are two versions of WHOQoL. The full version has 100 questions and the shorter 
version (BREF) which is used more frequently in practice. WHOQOL-BREF measures the 
following quality of life domains: physical health, psychological health, social relationships, 
and environment [202]. Higher score indicates better quality of life.  
Several studies examined the relationship between SLE activity tools and these measures of 
quality of life.  Most of the studies reported either a negative or a weak correlation between 
these tools and HRQoL. 
Study group HRQoL instruments Activity index Was there correlation 
Gladman[203] SF20, 
HAQ,FSS,DDM,CED-D 
SLEDAI No 
Hanly[204] SF20 SLEDAI Week 
Gladman[205] SF20 SLEDAI Week 
Vu [206] SF36 SLEDAI Only physical component Yes 
Stoll[207] SF20 BILAG Week  
Thumboo[208] SF20, SF36 BILAG weak for SF20, strong for F36 
Doria[209] SF36 ECLAM No 
Saba[210] SF36 SLAM No 
Dobkin[211] SF36 SLICC/ACR-DI Yes 
 
2.9.5 Lupus-specific measures of quality of life: LupusQoL 
This is a questionnaire to measure QoL in adult patients who are diagnosed with SLE, and it 
is derived from patient interviews. It has been developed and validated in the United Kingdom 
(UK) and adapted for North American SLE populations. It can be used in clinical practice and 
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research.  There are 34 disease specific items and 8 domains and it gives us information 
related to SLE and its effect on the health status such as physical health, emotional health, 
body image, pain, planning, fatigue, intimate relationships, and burden to others in the last 4 
weeks.  The scores range from 0 (the worst quality of life) to 100 (the best one) [212-
214].   Each item is assessed by a patient with the use of 4-point Likert scale (0–4, where 0 
means “all the time” and 4 – “never”) [215] . 
2.9.6 Lupus-specific measures of quality of life: SLE Quality of Life questionnaire (L-
QoL) 
This questionnaire assesses the overall effect of SLE and its treatment on the quality of life. It 
has 25 items on the scale.  The quality of life indicator is obtained by adding up all the points 
(from 0 to 25).  It includes assessment of self-care, emotional reactions, and fatigue in true / 
not true response format [212].  Higher score indicates worse quality of life. 
2.9.7 Lupus-specific measures of quality of life: Systemic lupus erythematosus specific 
quality of life instrument (SLEQoL) 
Derived from health professionals and then verified by patients, SLE QoL has been 
developed to assess the quality of life in people with SLE [189].  It consists of 40 items, 
including six domains:  physical functioning, activities, symptoms, treatment, mood, 
and self-images.  Scores range from 40-280, in which the higher values correspond to 
worse quality of life [212, 216].  
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 Comparison of musculoskeletal parameters between clinical indices 
across rheumatic and musculoskeletal diseases 
Arthritis is a term often used to describe any disorder that affects the joints.  Symptoms and 
signs of arthritis include joint pain, joint swelling, redness, warmth, early morning stiffness, 
decreased range of motion and function of the affected joints [217, 218].  Onset can be sudden 
or gradual.  Since arthritis symptoms may vary between patients and across autoimmune 
rheumatic diseases (RMDs), it is important to compare and contrast currently available indices 
to assess musculoskeletal SLE and other RMDs, for which arthritis is a common manifestation 
including rheumatoid arthritis (RA), psoriatic arthritis (PSA) and primary Sjogren’s syndrome. 
These comparisons are detailed below and summarised in Table 2-4
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Table 2-4.Comparison of musculoskeletal arthritis parameters between clinical indices for SLE, RA, PsA and Pss: 
MSK Parameters SLE Rheumatoid Arthritis Psoriatic 
Arthritis 
Primary Sjogren’s 
Syndrome 
BILAG-2004 SLEDAI-2K DAS-28 SDAI CDAI PsARC ESSDAI 
SJC Severe: ≥ 2 joints; 
Moderate: ≥ 1 joint 
≥ 2 joints Total SJC = 28 Total SJC = 28 Total SJC = 28 Total SJC = 66 1-5 joints: 4 points 
≥6 joints: 6 points 
TJC Severe: ≥ 2 joints; 
Moderate: ≥ 1 joint 
≥ 2 joints Total SJC = 28 Total SJC = 28 Total SJC = 28 Total SJC = 66 1-5 joints: 4 points 
≥6 joints: 6 points 
EMS Mild arthritis or arthralgia: 
(worse in the morning with 
EMS) 
No No No No No Arthralgia 
accompanied EMS>30 
mins: 2 points 
Patient VAS No No 100mm scale 100mm scale 100mm scale 0-5 Likert Scale No 
Physician VAS No No 100mm scale 100mm scale 100mm scale 0-5 Likert Scale No 
ESR/CRP No No Yes Yes No No No 
SJC: swelling joint count, TJC: tender joint count, EMS: early morning stiffness, ESR: erythrocyte sedimentation rate, CRP:C-reactive protein.
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2.10.1 Musculoskeletal components in disease activity indices for SLE 
2.10.1.1 Musculoskeletal -BILAG-2004 
Based on the glossary provided in the BILAG-2004 index, severe arthritis i.e. Grade A score 
is defined as active synovitis ≥2 joints with marked loss of functional range of movements 
and significant impairment of activities of daily living, that has been present on several days 
(cumulatively) over the last four weeks. While moderate arthritis or tendonitis/tenosynovitis 
i.e.  Grade B score constitutes active synovitis ≥1 or tenosynovitis joint (observed or through 
history) with some loss of functional range of movements, that has been present on several 
days over the last four weeks. Mild arthritis or arthralgia i.e.  Grade C score is defined as 
inflammatory type of pain (worse in the morning with stiffness, usually improves with activity 
& not brought on by activity) over joints/muscle inflammatory arthritis, which does not fulfill 
the above criteria for moderate or severe arthritis [169]. 
2.10.1.2 Muskuloskeletal-SLEDAI-2K 
The outcome for muskuloskeletal-SLEDAI-2K is binary i.e. present or absent. Four points 
are assigned for Arthritis domain if a patient exhibits ≥2 joints with pain and signs of 
inflammation (i.e. tenderness, swelling or effusion) [219].  
 Disease activity indices for RA 
2.11.1 Disease Activity Score in 28 joints (DAS-28) 
DAS-28 score has been widely used to assess disease in the joints of RA patients in both 
clinical trial and clinics. Indeed, based on 2016 EULAR recommendation pertaining to treat-
to-target approach in the management of RA, DAS-28 score is recommended to be 
calculated at frequent intervals while therapies are being given, until a patient’s score 
suggests disease remission, or to a particular ESR or CRP level [220]. 
Ritchie and colleagues initially developed the Ritchie Articular Index (RAI) or the extended 
66/68 joint counts [221].  However, the problem with RAI was that this assessment could be 
time-consuming to perform. A twenty-eight  joint count score was then developed [222], 
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which focused on metacarpo-phalangeal joints (MCPs), proximal interphalangeal joints 
(PIPs), wrists, elbows, shoulders and knees.   
DAS-28 score is a composite index consisting of the number of swollen joint count (SJC) in 
28 joints, tender joint count (TJC) in 28 joints, blood results i.e. erythrocyte sedimentation 
rate (ESR) or C-reactive protein (CRP) as available and the patient’s global assessment of 
disease activity on a 100mm visual analogue scale (VAS). The formula [223] for score 
calculation depending whether either ESR or CRP is used are as below: 
a) DAS28(ESR) = 0.56*√(TJC) + 0.28*√(SJC) + 0.70*Ln(ESR) + 0.014*VAS 
b) DAS28(CRP) = 0.56*√(TJC) + 0.28*√(SJC) + 0.36*Ln(CRP+1) + 0.0014*VAS + 0.96   
The DAS-28 score ranges between 0 and 10. A patient can be classified as remission, low 
disease activity, moderate or severe based DAS-28 score of <2.6, between 2.6 and less 
than 3.1, between 3.1 and 5.1 and >5.1 respectively.  
In terms of response to therapy, the EULAR has established response criteria depending on 
changes in DAS-28 score. Criteria for either a good, moderate or non-responder are 
described in (Table 2-5) [224, 225]. 
Table 2-5: EULAR response criteria 
 Reduction from Baseline 
>1.2 ≤1.2 and ≥ 0.6 < 0.6 
DAS28 at 
follow up 
≤ 3.2 GOOD   
>3.2 and ≤ 5.1                       MODERATE        NON 
>5.1    
DAS28 is measured at two time points, usually before and after treatment.  Degree of change 
(reduction) and ultimate DAS28 achieved are used to determine EULAR response. 
  
 50 
The advantages of DAS-28 score include its discriminatory ability to differentiate (mild, 
moderate and severe disease activity) and identifying disease remission[226].  Furthermore, 
there is a clear relationship between the mean DAS-28 score during a certain period and the 
amount of radiographic damage that the patient develops in that time-frame.  However, there 
are some disadvantages of this instrument such as the exclusion of assessment of the feet 
in both the SJC and TJC components as well as some degree of inter-rater variability in 
assessing the DAS scores, as different raters may classify a joint as swollen or tender to 
different degrees.  
There were a few studies comparing the use of DAS-28 score and disease activity index in 
SLE.  For example, a study which was conducted in the Sapienza University of Rome and 
compared the discriminatory sensitivity to detect disease activity between DAS-28 and 
musculoskeletal-SLEDAI-2K.  The study showed that up to 50% of the SLE patients without 
joint involvement as defined by SLEDAI-2K showed a moderate to high activity according to 
DAS-28 [188].  Thus, this highlighted a weakness of binary outcome as per SLEDAI-2K and 
that a composite index might be more useful in the assessment of arthritis.  
2.11.2 Simplified Disease Activity Index (SDAI) 
Simplified Disease Activity Index (SDAI) is a composite index established to improve 
convenience in assessing disease activity for RA particularly in the clinic.  This index 
comprises SJC and TJC in 28 joints, physician and patient global assessment of disease 
activity using VAS and CRP [227].  The formula to calculate the CDAI score is as below: 
SDAI = SJC + TJC + Patient VAS + Physician VAS + CRP 
The interpretation for total SDAI score is as follows: (a) 0.0 – 3.3 (Remission); 
(b) 3.4 – 11.0 (Low Activity); (c) 11.1 – 26.0 (Moderate Activity) and (d) 26.1 – 86.0 (High 
Activity). 
This use of this index was validated in three x phrase III clinical trials of leflunomide in RA. 
The results showed a significant association between the SDAI and the DAS-28, as well as 
 51 
the HAQ scores of patients with active RA [227]. 
2.11.3 CDAI (Clinical Disease Activity Index)  
The CDAI consists of the same components of SDAI but does not include CRP level. This is 
particularly useful in the assessment of response to biological therapy that directly suppresses 
inflammatory markers such as interleukin-6 inhibitors; tocilizumab, sarilumab and sirukumab 
[228-230]. The formula to calculate CDAI is as below: 
CDAI = SJC + TJC + Patient VAS + Physician VAS  
The interpretation for total CDAI score is as follows: i) 0.0 – 2.8 (Remission); 
ii) 2.9 – 10.0 (Low Activity); iii) 10.1 – 22.0 (Moderate Activity) and iv) 22.1 – 76.0 (High 
Activity).0.0 – 2.8 Remission 
CDAI had been correlated and validated with US scores in subjects with RA [231]. 
2.11.4 American College of Rheumatology response criteria: 
ACR(American College of Rheumatology)  core set outcome measure is another commonly 
used tool to monitor RA response to therapies in clinical trial [232].  It includes 7- variables; 
Tender and Swollen Joint count, ESR,CRP, health professional and patient assessment of the 
global status of pain and physical function[232].  ACR response is described in percentages 
as ACR20, ACR 50 and ACR 70.  ACR20, for example is, based on at least 20% improvement 
of both tender and swollen joint counts, in addition to 20% improvement in at least 3 out of 5 
other measures. ACR 20 now is one of the most commonly used outcome measures in 
rheumatoid arthritis clinical trials [233].  If the improvement is 50% or 70% in the trial it is called 
ACR50 and ACR70 respectively. 
 Disease activity indices for psoriatic arthritis 
2.12.1 Psoriatic Arthritis Response Criteria (PsARC) 
Psoriatic Arthritis Response Criteria (PsARC) was first developed In the Veterans 
Administration study of sulfasalazine in PsA [234].  This composite index comprises SJC in 
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66 joints [distal interphalangeal joints (DIPs), PIPs and MCPs of the hands, wrists, elbows, 
shoulders, acromioclavicular, sternoclavicular, temporomandibular joints, knees, ankles, mid-
tarsals, metatarsophalangeal joints (MTPs) and interphalangeal joints of the feet], TJC in 68 
joints [as above joints but to add hips], physician and patient global assessment of disease 
activity in a 0-5-point Likert Scale; 0= very good, no symptoms, no limitations on normal 
activities and 5= Very poor, very severe symptoms which are intolerable, inability to carry out 
normal activities.  
A patient is considered a responder if fulfilling: i) improvement in ≥ 2 of the four tests (One of 
which must be the SJC or TJC score and ii) no worsening in any of the four measures. 
Improvement is defined as a decrease of ≥ 30% in the SJC or TJC score and a decrease ≥1 
in either of the VAS global assessments [235].  
 Disease activity indices for primary Sjogren’s syndrome 
2.13.1 Musculoskeletal-ESSDAI 
The EULAR Sjögren's syndrome disease activity index (ESSDAI) was generated in 2009. This 
composite index consists of assessment in 12 domains i.e. cutaneous, respiratory, renal, 
articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), 
hematological, glandular, constitutional, lymphadenopathy and biological.  Each domain is 
graded into 3–4 levels of activity (no, low, moderate and high) [236].  
For the musculoskeletal component of this index, only arthralgia of inflammatory origin should 
be scored based on positive responses to both the following questions: i) Have you got pain 
in your hands/wrists/ankles and/or feet in the past four weeks? And ii) Are you stiff in the 
morning for at least 30 minutes?” The SJC and TJC calculations are based on DAS-28 score.  
Details for  Musculoskeletal-ESSDAI scoring are as follows: i) 0 point (no activity): Absence 
of currently active articular involvement; ii) two points (low): Arthralgia in hands, wrists, ankles 
and feet accompanied by morning stiffness (>30 min); iii) 4 points (moderate): 1–5 (of 28 total 
count) synovitis and iv) 6 points (high): ≥6 (of 28 total count) synovitis.  
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2.13.2 Joint count 
The total joint count is one of the simplest ways to assess peripheral joint activity. There are 
78 joints in total for assessment.  However, this may be reduced to a joint count of 68 in 
accepted abbreviated versions. As it is not possible to clinically evaluate hip swelling, the 
66/68 joint count is also accepted.  In addition, it is difficult to distinguish the DIP joints of the 
toes and sometimes these joints are omitted in assessments.  Tender and swollen joint counts 
have been used for a long time in clinical practice and trials as a method of assessing the 
activity of rheumatoid arthritis [221, 237, 238].  It is a component of both the DAS 28 and the 
ACR criteria as a central component of patient assessment [239, 240].  Some patients may 
have severe joint pain with few swollen joints, while other patients may have many swollen 
joints but with little pain.  The presentations of both of these types of patient are eligible and 
to receive immunosuppressive or an anti-inflammatory treatment [241].  Squeezing joints is 
subjective and considered an indirect method in the detection of disease activity.  Many 
studies have shown that joint counts are poorly reproducible on an inter-observer and intra-
observer basis [242-244].  There is no standard method in the assessment of joint tenderness 
because it is challenging to standardize the location and strength of the pain pressure 
stimulus.  The degree of pressure applied can be different between assessors [221].  Ritchie 
and colleges developed the Ritchie Articular Index or the extended 66/68 joint counts [221].  
The problem with the Ritchie Articular Index is that it was found to be time-consuming as the 
number of joint involved was considerably large.  Twenty-eight joint count then has been 
developed [222] which focuses on hands, wrists, elbows, shoulders and knees.  This index 
however omits the foot joints.  Smolen et al. compared the reliability of the 28 joint count with 
the 66/68 joint count.  They found that the measures could be highly correlated and were 
easier to administer [245].  Clinical examination however is less sensitive in the detection of 
synovitis compared to ultrasound.  Kane et al. studied 22 patients with RA using ultrasound of 
the knees and independent clinical examination. The group concluded that clinical 
examination was less sensitive in the detection of soft tissue abnormalities in the knee 
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compared to ultrasound [246]. 
2.13.3 Early Morning Stiffness 
Early Morning Stiffness (EMS) is an important symptom in the evaluation of SLE disease 
activity evaluation. The majority of patients find difficulty reporting their duration of early 
morning stiffness with respect to a cut-off time. Leiden university hospital has shown that the 
sensitivity of measurement of early morning stiffness using the patient VAS is more reliable 
than measuring its duration [174].  However, it is not currently used in the composite measures 
of disease activity for RA, PsA and SLE. 
 Objective outcome measures for arthritis: 
2.14.1 Conventional radiography: 
Plain radiographs may have a limited role in the diagnosis and monitoring of SLE arthritis. 
Plain film can show soft tissue swelling, atrophy and effusion. In patients with Jaccoud’s 
arthropathy, marked ulnar subluxation and deviation at the MCP joints can be seen [247].  
Radiographic erosions on the radial side of the metacarpal heads with sclerotic margin 
changes called “Hook” erosions” have been described in SLE [248].  However, because of the 
rarity of the x-ray findings above, the applicability of this imaging modality in SLE arthritis 
assessment tools is limited. 
2.14.2 Ultrasound: 
Using clinical synovitis to assess joints disease in SLE could potentially lead to over or 
underestimating the disease activity due to the subjectivity of clinical judgment of joint swelling.   
High-resolution musculoskeletal ultrasound (US) has been validated as a potentially more 
objective assessment tool in inflammatory arthritis [121, 249, 250] and the ability to assess 
mild or subclinical disease activity by detecting subclinical synovitis and assessing any 
minimal changes in RA allowing the assessment of tendons, tendon sheaths and bone 
surfaces as well [251-253].  This, however, was not yet fully established in the case of SLE 
arthritis.  There are limited studies on the use of ultrasound to detected pathology in SLE.  
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However, these studies detected synovitis in wrist and hand in 25-94% of the SLE patients 
without any symptoms [121, 254], which can potentially be very significant.  However, there 
are many limitations in ultrasound use.  It is an operator dependent modality where 
sonographers visually analysis real time images and might score the level of synovitis 
differently.  Most previous studies have reported synovitis based on any level of synovial 
thickening including the very mild ones (EULAR/OMERACT Grey Scale (GS) grade 1) with or 
without Power Doppler (PD) [255-263].  This is known to be not specific and could be found 
in other non-inflammatory conditions such as osteoarthritis [264] and anecdotally in patients 
with hypermobility.  A recent systematic literature review highlighted the variation and the 
under-reporting of ultrasound abnormalities in many studies.  Using ultrasound in assessing 
SLE using a more robust methodology, grading and definition could however have a promising 
role in SLE assessment similar findings to RA if more validation work established similar to 
the case in inflammatory arthritis. Ultrasound is a key theme of this thesis and is discussed in 
detail below in 2.17. 
2.14.3 Magnetic Resonance Imaging 
Magnetic Resonance Imaging plays a vital role the in diagnosis and monitoring of RA.  MRI is 
considered the imaging gold standard in the assessment of synovitis [265, 266].  Regarding 
validity, MRI has shown a high correlation with the histopathology of RA synovium [267].  
However, MRI is not widely used as an investigation modality in SLE.  This is despite evidence 
that MRI can identify bone erosion and tenosynovitis/tendonitis related to SLE arthritis [124].  
Ostendorf et al. investigated SLE patients with varying degrees of JA (n = 14) and identified 
bony erosions in 71% of the study population [268].  Boutry et al. used MRI to compare patients 
(n = 14) with RA, SLE and systemic sclerosis and found that most of the SLE cases had 
evidence of non-radiographic synovitis or bone erosion at the wrists, and second and third 
MCP joints. Erosion was detected within the wrists on MRI in all SLE cases, and in 61% of 
MCP joints [269].  However, MRI is disadvantaged by its high cost, relative inaccessibility, and 
the prolonged examination period which can be in excess of an hour per patient scanned. 
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Many people cannot tolerate an MRI study due to claustrophobia.  It is therefore not an ideal 
tool for the routine clinical or research assessment of musculoskeletal disease in SLE. 
 Failure of Randomised Control Trials in SLE 
There are more than 25 RCTs of biologic therapies in SLE and most of these studies have 
failed to reach their clinical end points [77].  There are several causes for this failure.  Some 
of them relate to the nature of the disease while others relate to the outcome measures and 
study design.  Firstly, SLE has a variety of manifestations which range from mild disease to 
life-threating features that are not easily captured or differentiated with precision in current 
assessment tools.  As a consequence, most of the RCTs on SLE exclude patients with severe 
or uncommon manifestations of SLE.  Secondly, the number of recruited patients is low in 
most therapeutic RCTs in SLE, and this can be attributed to the low prevalence rate of SLE, 
making it challenging to establish large cohorts [77].  Regarding the study design, the 
prescription of immunosuppression, especially corticosteroids and corticosteroid tapering, is 
frequently left to physician experience because of the lack of standardized protocols and on 
account of individual patient factors [77].  In addition, most of the RCTs recruit patients with 
more than one disease feature or system involved.  The result would be more realistic if the 
study was designed to examine only one organ or system [77].  Finally, there is no shared 
definition of complete response or remission in the SLE trials, so study end points are often 
non-transferable and may not reflect true disease activity [77].  Hence, it can be concluded 
that RCTs in SLE fail to reach their clinical endpoints because of trial recruitment for a rare 
disease, the inadequate responsiveness of available outcome measures and the clinical 
endpoints focusing on achieving remission or complete response. 
2.15.1 EXPLORER Study: Exploratory Phase II/III SLE Evaluation of Rituximab 
The EXPLORER trial was a placebo-controlled, double-blind, multicentre study which 
recruited 257 SLE patients from North America population with moderate to severe non-renal 
and non-central nervous system lupus [270].  Patients with severe CNS involvement and 
severe renal disease were excluded due to safety concerns related to fitness to consent and 
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risk of placebo randomisation, respectively.  Patients were randomised to receive either a 
cycle of rituximab, two infusions of 1000mg given two weeks apart or a placebo with 
continuation of the background immunosuppressant. All patients also received 0.5–1.0 mg/kg 
of steroids which were tapered to 10mg daily by week 10.  The primary endpoint was to 
achieve and maintain clinical response (major, partial or no clinical response) at week 52, 
assessed using BILAG criteria. No difference in both major clinical responses and partial 
clinical responses was observed between the placebo and rituximab groups with overall 
response rates of 28.4% and 29.6% respectively; p=0.973.  Post-hoc analysis indicated the 
superiority of rituximab versus placebo in the African-American and Hispanic subgroups.  The 
rates of BILAG A flares were also lower in the rituximab group [270]. 
2.15.2 LUNAR trial: Lupus Nephritis Assessment with Rituximab 
The LUNAR trial was a randomised double-blinded, placebo-controlled phase III trial. The 
study recruited and randomised 144 patients in a 1:1 ratio to receive either rituximab or 
placebo (n=72 each).  Patients had active proliferative lupus nephritis (class III or IV). Patients 
administered mycophenolate mofetil and IV pulse steroid in the first three days of the study 
entry and afterward switched to oral steroid to be tapered within 16 weeks.  This study also 
failed to show the superiority of Rituximab added to MMF in addition to steroid over MMF and 
steroid without Rituximab in achieving a complete or partial response at week 52. There was 
no significant statistical difference in the overall renal response (complete and partial) between 
the rituximab and placebo groups; 57% versus 46% respectively (p=0.180).  The problems 
with this trial were the small sample size, the background of the high dose of steroids and 
immunosuppressant that could mask the effect of the rituximab on this group of patient.  These 
people had a good response to the standard therapy, so the rituximab was not more effective 
than these medications [77, 271].  
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 Lessons from these trials 
Although both trials failed to meet their primary endpoints, there are several lessons to be 
learned mainly the issues regarding study design.  The first issue relates to the aggressive 
background of immunosuppressant in addition to mandated concurrent high dose of oral 
prednisolone.  As a result, more than half of the patients in both rituximab and control groups 
had become steroid-dependent, whereas in the LUNAR study, patients were also co-
prescribed a high dose of MMF up to 3g/day.  Thus, the intensity of these “standard of care” 
therapy might have masked the therapeutic benefit of rituximab against placebo. Secondly, 
the problem with outcome measures.  It is thought that in EXPLORER data BILAG might have 
been scored inappropriately both as inclusion and as response criterion.  The BILAG originally 
was developed as representing the physician’s intention to change therapy. Despite a 
relatively poor clinical response and persistently high disease activity, withdrawals due to 
inefficacy were relatively low, with approximately 70% of patients remaining in the trial for one 
year as per trial protocol.  Only one-third of patients achieved major clinical response (MCR) 
or partial clinical response (PCR), and post treatment mean global BILAG was approximately 
8 (on the scale A=9, B=3, C=1). This suggests that either the treating physician’s impression 
of the residual disease activity was actually less severe than the BILAG scores, or that the 
disease activity present at baseline was not as severe as the BILAG scores indicated, or both.  
Lastly, the primary endpoint used in EXPLORER required patients to meet a low disease 
activity ʻlandmarkʻ (BILAG C or better in all domains) at six months, and then to not flare in the 
second 6 months.  The first problem with this was the initial landmark was difficult to achieve 
since only 27% of patients achieved score C or better in all domains, thus considerably 
reducing the power of primary and secondary end points. The difficulty in achieving the 24-
week landmark may have been (a) because most patients had considerably higher baseline 
scores than the one BILAG A or two BILAG B scores required in inclusion criteria, so even a 
considerable improvement in disease activity was not sufficient and (b) because BILAG B 
scores were sometimes poor at differentiating partial responses. For example, a mild transient 
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malar rash scored the same as deep scarring discoid while the number of joints with synovitis 
(scored as B) were highly variable. However, even in patients who did meet the 6-month 
endpoint, there was no evidence of a significant rise in BILAG total score again in the placebo 
arm since a high dose steroid regime might have been sufficient to restore stable disease 
when given with background immunosuppressant.  
Both of the belimumab RCTs (BLISS52 and BLISS76) used a new composite index used as 
the primary endpoint; improvement in the SRI-4 at week 52 and both achieved their primary 
endpoints.  There are several reasons for the success of these trials.  First of all, BLISS trials 
recruited more than 1600 patients versus less than 400 patients recruited by rituximab trials, 
which may have magnified the side effect of the drug on top of standard of care.  The second 
point is that in the belimumab trials patients were selected on the bases of stable moderate- 
to-high disease activity with serological activity so patients did not require induction therapy at 
baseline.  Therefore these patients were not on an aggressive background regime of treatment 
and modifications to this regimen were restricted in order to avoid any significant benefit on 
disease activity.  Finally, using the composite SRI as an outcome measure gives better 
responsiveness to these trials instead of using the sole BILAG index or sole renal response 
analyzed in rituximab trials. 
 Musculoskeletal Ultrasound 
Ultrasound use for musculoskeletal system assessment was first reported by Dussik in 1958.   
Karl Dussik measured the acoustic attenuation of different structures including muscle, tendon 
and bone opening the door for its future musculoskeletal use.  In 1972 a report was published 
about the use of ultrasound in musculoskeletal system to differentiate between Baker’s cysts 
and thrombophlebitis [272].  In 1978 P.L.Cooperberg used ultrasound to show synovitis and 
to assess the result of rheumatoid arthritis treatment [273].   
Power Doppler (PD technology has added great value for using ultrasound in assessing 
inflammatory joints diseases.  Power Doppler can differentiate between active and inactive 
disease by showing tissue hyperaemia and neovascularization which could indicate active 
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inflammatory status [257, 259, 274].  There is a significant number of studies that validate the 
use of PD in assessing synovitis and tenosynovitis and found to have similar sensitivity and 
specificity of MRI in detecting synovitis [275-277].  Power Doppler is also responsive to change 
in disease activity and to therapy [278]. 
2.17.1 Advantages of ultrasound 
There are many advantages for this tool such as using it for quantitative and qualitative real -
time assessment.  Ultrasound has been used extensively in the diagnosis, assess damage 
and medications response assessment in inflammatory arthritis.  Many rheumatologists use 
ultrasound as a complementary tool to their physical joints examination [279, 280].  It is 
significantly cheaper modality that could be available in clinics for immediate real-time, non-
invasive, radiation free assessment.  Furthermore, it can be used for guided intra-articular 
injections which could enhance more accurate injectable medicines placement and facilitate 
aspiration in difficult procedures.  Patients like having ultrasound assessment as it an 
opportunity for the patient to be educated about their disease and convinces them about 
treatment while the scan is performed face to face with the clinician [281-284]. 
2.17.2 Limitations of ultrasound 
There are limitations for using ultrasound as it operator dependent needing sufficient long time 
of training which can be time-consuming.  Ultrasound can also be affected by many artefacts 
and confounders and limited to transducers foot print and difficulties in achieving acoustic 
access to certain joints limiting the view to some joints [282].  As it is based on sound waves, 
it will get reflected by bones and limited by gas which means full 360 degrees visualisation of 
the area of interest would be limited. 
2.17.3 Ultrasound versus clinical examination 
Ultrasound has the ability to detect subclinical synovitis in patients without obvious clinical 
abnormalities and to differentiate between real inflammatory arthritis from conditions that 
mimic inflammatory arthritis such as fibromyalgia [282, 285].  Using ultrasound is more 
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sensitive than clinical examination in detecting synovitis [246, 286].  Ultrasound was compared 
with clinical assessment and it was found to be more accurate than clinical results in the 
determination of inflammatory activity and assessment of different joints [249, 287].  
Ultrasound was observed to have the capacity to detect a greater number of joints with 
effusion and synovitis than clinical examination [246, 249]. 
2.17.4 Ultrasound in other inflammatory arthritides 
In the study reported by Wakefield ,et al. ultrasound was a reliable modality in detecting 
erosion especially in early diagnosed RA more than conventional radiography and it was [288]. 
The diagnosis of rheumatic diseases in an early stage leads to early treatment and improves 
outcomes [282]. This might be difficult by just depending on the clinical examination and 
conventional radiography. 
2.17.4.1 Ultrasound in Rheumatoid Arthritis 
Ultrasound was found to be a valid tool is assessing different features of RA.   It is well known 
that synovitis and tenosynovitis are the hallmark of RA activity and used for disease diagnosis 
and monitoring while erosions represent the damage due to RA and would have prognostic 
importance in terms of RA severity [282].  Ultrasound has been used extensively in the 
diagnosis and monitoring of RA; it has been proved that it is more sensitive than clinical 
examination and specific modality to assess joint structures [213, 248, 249].  Brown and 
colleagues studied 112 RA patients in remission and found 19% of the patients had subclinical 
synovitis despite being in clinical remission.  The study reported an association between 
abnormal baseline ultrasound and the12 months progression of the disease [289].  In addition 
to the ability to detect subclinical synovitis, ultrasound can be very sensitive and comparable 
to MRI and better than conventional radiography in detecting bone erosions [288, 290]. 
2.17.4.2 Ultrasound in Psoriatic Arthritis 
While clinicians think that the role of ultrasound in inflammatory arthritis is limited to detecting 
synovitis, tenosynovitis and erosions, it might have a role in detecting other pathologies and 
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diseases and might have different sonographic phenotypes that are not necessarily a copy of 
what we see in RA.  The pattern of synovitis in Psoriatic arthritis (PsA) for example is 
heterogeneous and affect the surrounding tissues in terms of tissue oedema, tendinitis, 
osteoproliferation and joint peri-enthesitis and enthesitis [291].  Gisondi et al. studied patients 
with psoriasis with no history of musculoskeletal symptoms and ultrasound was able to detect 
entheseal abnormalities in a large number of them [292].  Naredo et al. studied 162 psoriatic 
patients and compared them with control group and they found synovitis in 3% and 1.3% 
respectively, enthesopathy was detected in 11.6% and 5.4% of psoriasis and a control group 
[293].  Zabotti et al. compared both early rheumatoid arthritis and early Psoriatic arthritis by 
using ultrasound and they found that patients with RA had more synovitis than psoriatic 
patients.  While in psoriatic arthritis patients-soft tissue oedema was the most prominent 
findings [294].  Schoellnast et al. used MRI to compare RA and PsA patients; they stated bone 
erosions were more common in RA and periostitis were more frequent in PsA patients [295]. 
Given the example above about the role of ultrasound in RA and PSA, it is important to note 
that no one so far tried to describe a different sonographic phenotype in SLE to potentially 
explain different musculoskeletal symptoms in this disease. 
2.17.5 Ultrasound scoring system 
Multiple scoring systems have been used to assess synovitis and erosions (Table 2-6).  The 
Outcome Measures in Rheumatology (OMERACT) group have provided standardised 
definitions of pathology visible on ultrasound, based on expert consensus [296] and their 
EULAR-OMERACT scoring system reliability was tested and most commonly used in clinical 
trials  [297, 298].  In this thesis the ultrasound abnormalities was defined and scored according 
to OMERACT-EULAR definition: (a) Synovial effusion: abnormal intra-articular material which 
is compressible and usually anechoic/hypoechoic compared to subdermal fat (PD is absent), 
(b) Synovial hypertrophy: abnormal intra-articular material which is not compressible, is 
usually hypoechoic in comparison to subdermal fat and may be observed with/without PD, (c) 
Tenosynovitis: anechoic/hypoechoic thickened tissue, seen with/without fluid within the tendon 
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sheath and in two perpendicular planes (with/without PD),(d)Cortical erosion: an intra-articular 
discontinuity of the bone surface visible in two perpendicular planes [299].  Similar to synovitis, 
there are multiple erosion systems mostly binary while many other used 0-3 scales based on 
either the size or extent of the erosions (Table 2-6)
 64 
Table 2-6. Semi-quantitative methods of scoring pathology on ultrasound of different studies: 
Parameter Scoring method Grading definition 
GS effusion Szkudlarek et al. 
 
 
0: none, 1: minimal amount of joint effusion,  
2: moderate amount of joint effusion (without distension of the joint capsule),  
3: extensive amount of joint effusion (with distension of the joint capsule) [300-302]. 
 
Leeds Score 
0: none,  
1: mild, flat thickening,  
2: moderate thickening,  
3: marked thickening [303, 304]. 
GS hypertrophy Szkudlarek et al. 0: none,  
1: minimal synovial thickening (filling the angle between the periarticular bones, without bulging over 
the line linking tops of the bones) 
2: synovial thickening bulging over the line linking tops of the periarticular bones but without 
extension along the bone diaphysis,  
3: synovial thickening bulging over the line linking tops of the periarticular bones, with extension to 
at least one of the bone diaphysis 
 4: extension to both diaphysis [300-302]. 
EULAR/ OMERACT  
 
0: no hypertrophy independently of presence of effusion, 1: minimal; hypertrophy with or without 
effusion up to level of horizontal line connecting bone surfaces, 2: moderate; hypertrophy with or 
without effusion extending beyond joint line but with upper surface convex (curved downwards) or 
hypertrophy extending beyond joint line but with upper surface flat, 3: severe; hypertrophy with or 
without effusion extending beyond joint line but with upper surface flat or convex [258, 264, 265]. 
PD synovitis 
 
EULAR/ OMERACT  0: none,  
1: minimal; three single PD spots or up to one confluent spot and two single spots or up to two 
confluent spots, 
2: moderate; greater than grade 1 but 50% of the background GS [298, 305, 306]. 
Newman et al.  
 
0: no or minimal hyperaemia,  
1: mild hyperaemia,  
2: moderate hyperaemia,  
3: marked hyperaemia [307]. 
Erosion Zayat et al. 
 
0: none,  
1: erosions covering less than one third,  
2: erosions covering between one- and two-thirds, 
3: erosions covering more than two-thirds of the bone surface [308]. 
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Parameter Scoring method Grading definition 
Szkudlarek et al. 
 
0: regular bone surface. 
1: irregularity of the bone surface without formation of a defect seen in 2 planes. 
2: formation of a defect in the surface of the bone seen in 2 planes [300-302]. 
3: bone defect creating extensive bone destruction 
 
Wakefield et al. 
Small: diameter <2mm, 
Moderate: diameter 2–4 mm, 
Large: diameter >4 mm [309]. 
GS tenosynovitis EULAR/ OMERACT  
 
 0: normal,  
1: minimal,  
2: moderate,  
3: severe [298, 305, 306]. 
PD tenosynovitis EULAR/ OMERACT  
 
Visible in 2 perpendicular planes and excluding normal feeding vessels… 0: no signal 
1: peritendinous focal signal within the widened synovial sheath (i.e. signals in only one area of the 
widened sheath) 
 2: peritendinous multifocal signal within the widened synovial sheath (i.e. signals in more than one 
area of the widened sheath) 
3: peritendinous diffuse signal within the widened synovial sheath (i.e. signals filling most of the 
widened sheath). In the presence of abnormal intratendinous signal (visible in 2 perpendicular 
planes and excluding normal feeding vessels) in addition to grade 1 or 2 peritendinous PD signal, 
increase grade by one point [298, 305, 306]. 
 
GS hypertrophy and PD 
synovitis combined 
EULAR/ OMERACT  
 
0: normal; no hypertrophy or PD, 
1: minimal; GS=grade 1 and PD≤ grade 1 
2: moderate; GS=grade 2 and PD≤ grade 2 or GS=grade 1 and PD=grade 2, 
3: severe; GS=grade 3 and PD≤ grade 3 or GS=grade 1 or 2 and PD=grade 3 [298, 305, 306]. 
Tendon damage EULAR/ OMERACT In longitudinal and transverse planes… 
 0: normal, 
 1: minimal,  
2: moderate,  
3: severe [298, 305, 306]. 
GS: gray scale, PD: power Doppler 
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2.17.6 OMERACT Filter and Ultrasound 
Ultrasound enables evaluation of joints and peri-articular structures based on GS appearance 
and PD in multiple planes.  It is widely used in clinical practice to assess patients with 
inflammatory arthritis, it is relatively affordable and less time-consuming than other imaging 
methods [310].  There has been a wealth of publications that have confirmed face, content, 
construct and criterion validity, reliability, responsiveness and feasibility [121, 254, 258, 262, 
311-318].  Other aspects of the effectiveness of ultrasound as a tool in the assessment of 
early inflammatory arthritis (IA) are discussed below, according to the criteria outlined within 
the OMERACT filter [297].  Having ultrasound been scrutinised in terms of reliability and 
validity in RA, its application in SLE would probably need to follow similar steps but to a lesser 
extent to proof the concept and allow the use of ultrasound in SLE clinical assessment and 
clinical trials.  In this thesis, face, content and construct validity are tested in chapter 5 and 6, 
criterion validity tested in chapter 9 and responsiveness validity in chapters 6 and 8. 
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Table 2-7: OMERACT Filter: 
Category Type Description Chapter of 
thesis 
Truth  Face Validity  The theoretical plausibility of a 
measurement tool for its intended use.  
Chapter 5: 
Content Validity  The completeness of a tool to reflect the 
entirety of the concept it intends to 
measure and the necessity for inclusion 
of all the components within the 
measurement tool (i.e., do all its aspects 
contribute uniquely to the overall 
measure).  
Chapter 5: 
Construct Validity  Agreement with other measures which 
are theoretically related and lack of 
agreement with those which are not.  
Chapter 5: 
Criterion Validity  Agreement with an ideal or ‘gold’ 
standard. This includes:  
Concurrent validity: agreement with a 
‘gold’ standard assessment conducted 
simultaneously with the proposed new 
measurement tool.  
Predictive validity: agreement with a 
‘gold’ standard assessment carried out 
in the future, i.e., the ability of a tool to 
predict a future state.  
Chapter 9: 
Discrimination Includes the ability of a tool to differentiate between health and 
disease, as well as between disease severity states (including 
reliability and responsiveness).  
 
 
Reliability  The ability of a tool to detect severity 
states with consistency. For example, 
between equipment or between 
observers (inter-observer) and by the 
same observer over time (intra-
observer).  
Chapter 7 
and 8 
Responsiveness  The ability to detect differences in 
severity over time, e.g., for monitoring 
response to treatment.  
Chapter 
6:Chapter 8: 
Feasibility  The practicality of using the measurement tool, including 
involved time and financial costs.  
ROOTS 
 
2.17.7 Erosion 
 Ultrasound is a reliable tool in detecting bone erosion and has more sensitivity than pain X-
ray; this has been demonstrated by many studies.  Ultrasound has been shown to be more 
sensitive than conventional radiography in detecting erosions [309] including very early stages 
of rheumatoid arthritis[319].  Zayat et al. investigated the specificity of ultrasound detected 
bone erosion in RA patients.  They compared their ultrasound findings with other diseases 
including gout, OA, psoriatic arthritis and normal volunteers and reported the possibility of 
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describing certain features of erosions that can be related to RA than other as well as the 
higher specificity and sensitivity of ultrasound detected erosions in specific joints such as the 
5th MTP in RA patients [308].  Backhaus et al. compared clinical assessment, conventional 
radiography, MRI, ultrasound and 3- phase bone scintigraphy in patients with different types 
of arthritis (RA, Spondeloarthropathy, and arthritis associated with connective tissue disease).  
They found that ultrasound was more sensitive than MRI in detection of synovitis and 
tenosynovitis and MRI was more sensitive than conventional radiography in identifying early 
destructive arthritis [320].  In the current practices and clinical trials, ultrasound detected 
erosions have become an integral of ultrasound reported abnormalities in inflammatory 
arthritis especially with advanced high resolution ultrasound technology that has been able to 
detect and measure erosions less the 1 mm in diameter.  Although erosive abnormalities are 
traditionally less commonly reported in SLE, there might be some drift in this traditional belief 
with a better understanding of SLE using currently available imaging modalities.  
  Ultrasound and SLE 
Ultrasound has a well-defined role in many rheumatic diseases like RA, but this role is not 
established yet in SLE [321].  The limited role of ultrasound in SLE might be due to lack of the 
full understanding of the pathogenesis of articular disease in SLE and the impression that 
joints inflammation is not common in connective tissue diseases (CTD) with the focus of other 
systemic illness such as cutaneous, renal and cerebral diseases dismissing the fact the joint 
pain can be responsible for a great deal of SLE patients symptoms.  This might have led to 
less common use of ultrasound in assessing SLE and subsequently lack of standardised 
technique and variable reported ultrasound abnormalities [285].  As expected indeed from the 
previously demonstrated data on ultrasound with RA, many studies demonstrated the higher 
sensitivity of ultrasound over physical examination in detecting synovitis and tenosynovitis in 
SLE patient’s [254, 312, 316, 322].  Knowing how limited and subjective clinical examination 
is and the impact of that on patient treatment, having a more sensitive and less subjective 
modality would mean better treatment selection and more accurate assessment avoiding over 
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treating patients with non-inflammatory joints pain or under treating patient with subclinical 
synovitis [323, 324].  However, before ultrasound can be used confidently in assessing SLE 
in practice and clinical trial, further validation work is still required.  The growing and expanding 
interest of using ultrasound in assessing connective tissue disease including SLE has led to 
attracting the attention of few small studies which inconsistently looked at different aspects of 
SLE ultrasound detected joints pathology (Table 2-8). 
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Table 2-8. SLE ultrasound studies: 
Study group Synovitis Tenosynovitis Erosion Joints assessed Number of patients 
Wright et al [311] 71-92% 65% 47% Hands, Wrists SLE=17 
Iagnocco et al [312] 42% 44% 4% Hands, Wrists SLE=26, HC=15 
Iagnocco et al [313] 87% N/A N/A Hands, Wrists, Feet SLE=62 
Gabba et al [316] 42% 61% 26% Hands, Wrists SLE=108, HC=60 
Torrente-segarra et al  [259] 25% 7-39% N/A Hands, Wrists SLE=58 
Ossandon et al [258] 40% N/A 0% Knee SLE=26,RA=25, HC=15 
Dell Sedie et al [257] 80% 28% 12% Hands, Wrists SLE=50, HC=50 
Mosca et al[325] 42% 38% 31% Hands, Wrists SLE102, HC=46 
Dreyer et al [254] 81% 18% 6% Hands, Wrists SLE=33, HC=11 
Yoon et al [318] 64% 4% N/A Hands, Wrists SLE=48, HC=18 
Bousi et al [262] 47-58% N/A 4-18% Hands, Wrists SLE=62, RA=60 
Ogura et al [326] 80% 93% N/A Hands, Wrists SLE=15, RA=40 
Lins et al [321] 48% 23% 5% Hands, Wrists SLE=64 
Morales-Lozano et al [327] 3-27% 7% 1-12% Feet SLE=54, HC=60 
Salliot et al [328] 40% N/A N/A Hands, Wrists SLE=151 
N/A not assessed, HC: healthy control
 71 
Ultrasound in assessing SLE arthralgia 
Most ultrasound studies demonstrated higher rate of arthralgia and lower rates of clinically 
detected synovitis in SLE if we compare it to other inflammatory arthritides.  This is vital for 
clinical practice and trials because current clinical disease activity tools are all heavily 
weighted for the presence of synovitis.  Assessors might find it difficult to work out how 
inflammatory is the ongoing arthralgia in SLE patients with the risk of over reporting or under 
reporting it as synovitis. However, in many of the above mentioned studies (Table 2-8) 
reported patients with arthralgia without clinical synovitis had abnormal ultrasound.   
Iagnocco et al. demonstrated that SLE patients with arthralgia and swollen and tender joints 
on examination had more abnormal findings on ultrasound in comparison with patients without 
symptoms.  They studied 62 patients with SLE; ultrasound findings (effusion, PD and /or 
synovial hypertrophy) were detected in a significantly high percentage of abnormalities (87% 
(54/62 patients).  Twenty-nine patients of those had abnormal sonographic findings in the 
absence of clinical manifestations in their joints.  They found that MTP[313] Similar results 
were described by Dreyer et al. as they studied 33 SLE patients and ultrasound and clinical 
examination were performed.  They stated that ultrasound was able to detect wrist synovitis 
in 81% of the study patients with arthralgia in comparison to only 18% without symptoms at 
the time of the scan.  Two-third of the patients had synovitis in the MCP joint in the patients 
with arthralgia but only 16% had MCP synovities in the symptomatic group [254].   Torrente-
Segarra et al. recruited 58 SLE patients, 28 had arthralgia in the hand and 30 patients were 
asymptomatic as a control group.  They showed that patients with hand arthralgia had more 
ultrasound abnormalities and high SLEDAI score with a higher level of anti dsDNA antibodies. 
25% of patients had synovial hypertrophy, active joint synovitis was seen in 14% of the 
patients and tenosynovitis were detected in around 39%.  Extensor degitorum and extensor 
carpi ulnaris were the most common tendon involved [221]. 
The issues with these studies are similar, such as the lack of validity, the absence of the gold-
standard modality to check the reliability and the definition of synovitis which states grade 1 
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GS as significant and enough to classify it as synovitis.  There is significant heterogeneity 
among these studies in clinical setting, patient’s selection and methods. Most of the studies 
there was no information on the relationship between the usage of corticosteroids and or 
immunosuppressant and ultrasound findings because these medications have direct 
influences on cytokines and inflammatory cells which may interfere with ultrasound findings. 
Can ultrasound detect subclinical synovitis in SLE? 
Yoon et al. showed that subclinical synovitis was very common among SLE patients, 
ultrasound detected subclinical synovitis in around 58% of the patients and 4.2% had 
tenosynovitis.  They stated that ultrasound could detect joint abnormalities before they become 
clinically obvious since they found that 39 % of the patients developed new musculoskeletal 
manifestations within six months after the ultrasound [318].  Ossandon et al. demonstrated 
that ultrasound was able to detect synovitis in 38% of patients who had normal clinical 
examination of the joint[329].  Mosca et al. found that 20/ 28 patients of their cohort with 
morning stiffness and arthralgia had at least one abnormality in their ultrasound findings (either 
joint synovitis or tendon involvement), only 22/56(39%) had clinical findings in the clinical 
examination [325]. 
In the largest scale study on ultrasound and SLE before this thesis, Gabba et al. used 
ultrasound in 108 consecutive Caucasian SLE patients; 69 were asymptomatic and 39 
reported active manifestations at the time of recruitment.  Generally, 64/108 patients had 
abnormal ultrasound; among them 42/108 ultrasound showed joint involvement while tendon 
involvement was seen in 44/108 patents.  Synovitis was detected in 27 patients and bone 
erosions were revealed in 28 patients. The study found that symptomatic patients had 
abnormal ultrasound changes at joints, while those without symptoms (BILAG C and D) had 
more abnormalities in the tendon [316].  Despite the large sample size and clear design, this 
study has some limitations.  The lack of standardisation in terms of the time of usage and 
doses of NSAID and corticosteroids before the ultrasound examination might have significant 
confounding effects on the ultrasound scores (GS and PD).  Also, grade1 GS was considered 
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as synovitis in their ultrasound scores.  Moreover, patients with rhupus were included in the 
study and most of the ultrasound abnormalities were detected in this subgroup and this might 
affect the result. 
Ultrasound detected bone erosions in SLE 
Erosions were reported in SLE patients in MRI studies. [330].  Several studies reported 
erosions in SLE patients.  The ranges massively varied between 2-41% of SLE patients [8]. A 
limited number of SLE studies separated the non-rhupus and rhupus groups which could have 
led to the inclusion of CCP positive patient with known risk of developing erosions which could 
explain the big gap in the rate erosions reported by different studies [255, 260, 261].  Only 
Gabba et al. clearly defined the subgroup of Jaccoud’s and they detected erosions in a 
significant rate of 17% of their cohort and they reported an expected high prevalence of 
erosions in the rhupus group around 88%.  Among the 28/108 patients who had erosions;  
26/28 had erosions in their hands and 5/28 patients only had erosions in the wrists[316].  This 
somehow disagrees with other previously mentioned studies reports of higher rates of 
abnormalities in feet. 
Ultrasound detected Tendinopathy, Tenosynovitis and Entheseal disease in SLE 
Tendons involvement is common in SLE patients with musculoskeletal involvement and may 
affect up to 65% of them[121].  The most commonly tendons involved are the extensor and 
flexor tendons of the wrists [255, 259, 260, 313, 314] with tendon rupture not uncommonly 
reported as well[255].  A.Delle Sedie et al. studied 50 patients with SLE by using the 
ultrasound; inflammatory signs were detected in the hands and wrists in 50% and 80% 
respectively. Tenosynovitis was detected in 28% [314].  Gabba et al found that PD signals in 
the tendons of 13/108 patients, flexor tenosynovitis was observed in 32/108 patients while 
37/108 patients had extensor tenosynovitis and both were found in 22/108 patients[316]. 
A.Di-matteo et.al studied ultrasound detected entheseal involvement in SLE and reported that 
ultrasound was able to detect one or more abnormalities in at least one enthesis in around 
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68% (44/65) of their cohort which was mainly at the distal insertion of the patellar tendon[331].  
Although a surprising finding, further validated larger scale studies using gold standards will 
still be required as entheseal disease is not necessarily thought to be common in SLE but with 
reported Achilles tendon rupture in SLE that would still be a possibility.  Investigating the use 
of steroid or other potential causes are linked to such a surprising finding will need further 
consideration. 
Ultrasound versus SLE clinical outcome measures in literature 
A Limited number of studies assessed the relation between some of the clinical outcome 
measures and ultrasound abnormalities.  Most studies failed to find a correlation between 
ultrasound synovitis and SLEDAI, except Gabba et al found joint synovitis was associated 
independently with high SLEDAI score(P=0.04; OR1.10;95% CI 1.01,1.21)[260] and Torrente-
segarra et al. who also showed that patients with hand arthralgia had more abnormal findings 
in their ultrasound with high SLEDAI score [259].  There are many reasons that could explain 
the lack of correlation.  In most of the studies, there were no details about the tools they used 
(where they used the global tool or just the musculoskeletal domain?).  Small sample size 
would be probably the main reason for not having meaningful results as well.  Interestingly, 
not many studies looked at the correlation of ultrasound with BILAG probably due to the 
complexity of BILAG tool, but those who looked, similarly found no correlation which could be 
explained by the same reasons mentioned for SLEDAI.  The summary of the association 
between ultrasound and clinical outcome measures are detailed in (Table 2-9). 
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Table 2-9. Clinical outcome measures and ultrasound: 
Study group Clinical tool Association with US 
Wright  [255] SLAM, JAI, ACR/SLICC  No 
Iagnocco [312] SLEDAI  Yes 
Iganocco [313] SLEDAI-2K, ECLAM  No 
Gabba [260]  BILAG,ACR/SLICC, SLEDAI  Yes 
Torrente-segarra [259] SLEDAI Yes 
Ossandon [329] SLEDAI, TJC/SJC  No 
Dell Sedie [257] ECLAM  No 
Yoon [318] SLEDAI No 
Dreyer [254] DAS28,SLEDAI,SLICC/DI No 
Ruano CA [332] SLEDAI-2K, SLICC/DI No 
Morales-Lozano [327] SLEDAI No 
Salliot [328] SLEDAI Yes 
ACR: American College of Rheumatology, BILAG: British Isles Lupus Assessment Group, DAS: 
Disease Activity Score ECLAM: European Consensus Lupus Activity Measurement Index, SLEDAI: 
Systemic Lupus Erythematosus Disease Activity, SLICC: Systemic Lupus International Collaborating 
Clinics. 
Predictive role of ultrasound in SLE 
Several studies have shown the ability of ultrasound in predicting future structural damage 
as well as the development and appearance of musculoskeletal manifestations in 
asymptomatic patients [333, 334].  Piga and colleagues stated that the presence of a higher 
PD-synovitis score at baseline was predictive of musculoskeletal flare within two years since 
baseline ultrasound examination [333].  Corzo et al. reported that patients with abnormal 
ultrasound had a higher chance of disease progression and need to receive more 
medications such methotrexate than the patient who had normal baseline scan during six 
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years follow up period [335]. 
Ultrasound validity in assessing SLE 
Pigga et al. recruited 26 SLE patients with different subtypes of SLE arthritis (Rhupus, 
Jaccoud’s, Non-deforming non-erosive arthritis) to evaluate the presence of bone erosion by 
using CTultrasound.  Ultrasound had accuracy 90%, sensitivity 36%, and specificity 98% 
compared with 93%, 57% and 93% in erosions detection in the dorsal and lateral aspects of 
second and fifth MCP, which were recognised as areas with the best ultrasound reliability.  
Also, ultrasound detected 90% of CT erosions in the wrist joints [336]. 
Ultrasound and laboratory markers in SLE 
In most of the previously mentioned studies on ultrasound and SLE, there was no correlation 
between the ultrasound findings and laboratory investigations, clinical assessment and 
disease activity tools [257, 311, 312, 315].  There are a few numbers of studies that studied 
the relation between abnormal ultrasound and other demographics or laboratory variables.  
Yoon et al. found a relation between the high level of ESR and ant-dsDNA and ultrasound 
abnormalities [318].  Gabba et al. demonstrated that patients with low level of C3 and C4 
had a higher chance of having abnormal musculoskeletal ultrasound findings [316].  Bell et 
al. observed an association between the ultrasound abnormalities and the high level of IL-6 
[37].  This might emphasise the potential for under reported/ undiscovered correlation 
between some laboratory markers and ultrasound simply either due to studies size or design 
problem.  
2.18.1 Why patients have symptoms with normal ultrasound? 
Many patients with SLE have joint tenderness without any abnormalities in the ultrasound; 
this can be explained by tenderness over the joint is due to other unidentifiable reasons such 
as muscle, nerve or other surrounding structures might be the cause of the pain.  Arthralgia 
is very common among SLE patients and it is not related to inflammation, it can be related to 
depression, fatigue or fibromyalgia and these are not related to disease activity [321]. 
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2.18.2 Deficiencies in the literature on Ultrasound in SLE and Issues with current 
studies on Ultrasound role in SLE 
There are many problems in the existing ultrasound studies in SLE patients.  There is a wide 
range in the rate of ultrasound detected synovitis ranging between 10-82% of patients. This 
could be related to the method of reporting ultrasound due to the absence of consensus 
about the definition of ultrasound examination.  In addition, most of the studies used semi-
quantitative grading and the results most often presented as binary (Synovitis, No synovitis).  
The other issue is the heterogeneity in the patient selection as most of the studies did not 
separate rhupus group and the non-rhupus SLE group especially when they scored 
erosions.  There was also heterogeneity in the joints selected for these studies where some 
scanned hands and wrists only, while others used feet or knees.  Some of the studies 
included patients without musculoskeletal manifestations at the time of presentation and the 
control group varied between normal volunteers or RA patients.  Most of the studies ignored 
the permitted dose and time of nonsteroidal anti-inflammatory and steroid before the 
ultrasound; these may interfere with the ultrasound scoring system and clinical signs.  The 
other problem is the lack of uniformed definition of ultrasound synovitis and most of the 
available studies used GS1 with or without PD as a definition of synovitis and this is not 
specific because it can be present in normal people and patients with osteoarthritis.  The 
absence of a gold standard to be used for a comparison domain like arthroscopy or 
histology.  Lastly, the range of the frequencies of the ultrasound transducers varies from 5-
18MHz that could have affected detection of tendons and joints abnormalities.  Transducers 
with high frequencies (13-20 MHz) are usually used in musculoskeletal ultrasound because 
they have a high sensitivity in detecting minor morphological changes in the small joint [121, 
337-339]. 
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2.18.3 MRI in Inflammatory Arthritides 
Magnetic resonance imaging (MRI) is commonly used as the gold standard imaging modality 
in assessing synovitis in both clinical and research settings in rheumatic diseases like RA. 
As a multiplane modality, it gives the clinician more information about joints inflammation 
and damage even in the early stage of the disease by exploring synovial membrane, 
tendons and bone.  It has many advantages in comparison with conventional radiography 
like measuring response to treatment and higher sensitivity in detecting erosions and 
monitoring the bony damage over a short period of time.  In addition, some recent data have 
shown that synovitis and bone marrow oedema detected by MRI have some prognostic 
implications in RA and it could be used in selecting patients for expensive trials that are 
targeting patients with severe disease [266].  MRI is highly sensitive in detecting the 
changes in the synovial membrane volume in response to therapies and follow the rate of 
progressive joint destruction [340].   
MRI has many vital roles in musculoskeletal medicine.  It is used to evaluate back pain and 
in the diagnosis of aseptic necrosis[341].  MRI is an excellent modality for visualizing the 
articular and periarticular structures in three dimensions giving a better definition of bony 
details in comparison to conventional radiography [342].  Recently, MRI has been used as a 
gold standard modality in assessing synovitis [4], it has the ability to detect changes in 
synovial membrane volume in response to therapeutic agents and monitoring the 
progression of joint destruction [343].  Images by MRI for the musculoskeletal structures 
have used T2 weighted images for the anatomical detail, to detect fluid or oedema and fat, 
which give high signals.  Gadolinium is used as intravenous contrast to increase the 
sensitivity of detecting erosions and it is taken up at the sites of synovitis [344]. 
However, there are many disadvantages to this tool: It is time consuming since each 
examination takes a long time, expensive modality in comparison with other images, the use 
of contrast with risk of allergic reaction and renal side effects and it is not suitable for people 
with implanted magnetic metals and pacemakers.  In claustrophobic patient, it can be 
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unpleasant and fearful experience as patients have to stay inside the tube for a long period of 
time (nearly 60 min) [345].  Extremity MRI (e MRI) created to address some of these problems.  
It is time and cost effective with less claustrophobia as patient needs to put the interested part 
to be scanned in the machine, but the problem it has less magnetic strength which affects 
image clarity and provides less field of view [346]and it is not available in each hospital [344]. 
2.18.4 MRI and Erosion 
OMERACT has come with a consensus definition of MRI detected erosions which is according 
to the group is "A sharply marginatedʺ bone lesion, with correct juxta articular localization and 
typical signal characteristics," which is visible in 2 planes with a cortical break seen in at least 
one plane" [330].  MRI has been described to have a higher sensitivity than CR for detecting 
erosion in many studies [342, 347].  Conventional Radiography is insensitive modality in 
detecting bone erosion due to many factors as the lucency of erosion in the CR Is attributed 
to the cortical bone loss, not to the trabecular bone loss which is invisible on CR as well as 
the presence of projectional superimposition that obscures erosion that enface to the beam of 
the x-ray[4].  Ostergaard et al. compared MRI and CR in patients with RA over five years in 
terms of detecting bone erosion.  They found that MRI was able to detect new bone erosions 
at least one year earlier than the CR [348]. 
2.18.5 MRI Synovitis: 
There are many MRI parameters that have been used as markers of synovitis; including the 
volume of the synovial membrane, synovial membrane thickness and signal intensity after 
contrast [4].  Currently, MRI is considered as the gold standard imaging modality in assessing 
synovitis due to the validation work done previously where there was sufficient correlation 
between MRI findings and histopathology [349, 350]. 
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2.18.6 Advantages of MRI compared to ultrasound: 
MRI has the advantage of visualizing deeper structures and larger area and it has the 
advantage of imaging soft tissues and fluid within the joint [342].  It can detect synovitis 
qualitatively and quantitatively, sensitive in detecting the therapeutic response in the early 
stage of the disease and the ability in evaluating the surrounding soft tissues like tendons, 
muscles, and ligaments that could be involved in the inflammatory process [351].  MRI is more 
sensitive in detecting erosions than ultrasound [351], and it has the advantage of detecting 
bone marrow oedema over the ultrasound [352]. 
2.18.7 MRI in inflammatory arthritis other than SLE 
In early inflammatory arthritis (EIA), there is usually no abnormality detected using plain 
radiograph within 12 months of symptoms onset [353].  However, MRI has been shown to be 
more sensitive than conventional x-ray in detecting radiographic features of EIA [354, 355]. 
Furthermore, Krabben et al. used MRI to study EIA and compared this with the clinical 
examination.  They reported that MRI detected 54-60% of joint inflammation which could not 
be detected clinically [356].  MRI may also be used as a prognostic biomarker where Van 
Steenbergen et al studied 102 patients with clinically suspected inflammatory arthritis. 
Patient’s questionnaire, joint count and MRI were performed.  MRI detected subclinical 
inflammation in 44% of patients with clinically suspected arthritis; of which 35% of them 
progressed to clinically detected arthritis within four months of follow up [357]. 
In patients with early RA, (onset within 2 years) Hoving et al. compared the use of MRI, 
ultrasound and plain radiography in the assessment of arthritis.  They reported that MRI was 
the most sensitive tool for detecting bone erosions; twice as sensitive compared to ultrasound 
and conventional radiography [355].  This was also supported by Ostergaard et al. who 
reported MRI erosions could be detected one year earlier than conventional radiography.  
Notably, those with MRI erosions at baseline the relative risk of radiographic erosions at 5-
year follow-up was 4.5 (95% confidence interval [95% CI] 2.6–7.6), compared with those 
without erosions at baseline [358].  Additionally, MRI was also the modality of choice for 
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detecting bone oedema as well as higher sensitivity in detecting synovial disease. However, 
ultrasound was more sensitive in detecting joint effusion and tendon sheath inflammation[351].  
MRI also has the potential of differentiating different patterns in different diseases which 
improve our understanding of different diseases and help to differentiate between them 
radiologically.  In psoriatic arthritis, for example, patients usually have more surrounding soft 
tissues involved and the distribution of the joints involved by arthritis could be asymmetrical, 
oligo or polyarthropathy [291].  Schoellnast et al. compared MRI findings of patients with 
Psoriatic Arthritis (PsA) and RA and they found that hand periostitis and synovitis were more 
common in the PIP joints in those with PsA while those with RA had synovitis and erosions 
more in the wrists [359].  A study was done by Narvaez et al. to evaluate the difference 
between the early stage of RA and PsA by using MRI.  They found that the frequency of 
synovitis, bone erosions, tenosynovitis, subchondral bone oedema were the same in both 
groups.  Nevertheless, the position of bone oedema was different between RA and PsA with 
this being near to cartilage and the subchondral bone in RA while for PsA, this was more at 
the diaphyseal and close to the enthesis. Indeed, they also found the entheseal involvement 
was more specific for PsA than RA[360].  
Nieuwenhuis et al. performed MRI scan for 178 patients with early arthritis; tenosynovitis 
detected in around 65% of the total patients, which was most significant with patients with RA 
than the others.  However, there was no association between positive ACPA and tenosynovitis 
[361].  It will be interesting to know if MRI could show different characteristics in other 
rheumatic diseases such as SLE. 
2.18.8 MRI sequences used in assessing synovitis and joints disease 
Being heavily investigated and used previously, MRI studies which planned to assess RA 
patients with inflammatory and destructive changes in the joints must include at least the 
following: 
 T1-Weighted images before and after IV contrast injection in 2 planes. 
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 T2-wighted fat saturated sequence or STIR sequence if the former not available. 
These two sequences added to contrast will allow identifying synovitis (I,e inflammation) with 
soft tissue oedema on STIR while the contrast will allow differentiating fluid from synovitis.  
Other features of inflammation such as bone marrow oedema or enthesitis could be visualised 
using the STIR sequence while the T1 and T2 weighted will allow good anatomical 
characterisation of disease as well as previous signs of inflammation such as fat atrophy. 
2.18.9 Definitions of joint pathologies in MRI scoring system 
Synovitis: An area in the synovial compartment that shows above-normal signal intensity of  
thickness more than the width of the normal synovium which is judged by comparing T1- 
weighted images, obtained before and after intravenous gadolinium contrast. 
MRI bone erosion: A sharply marginated bone lesion, with correct juxta articular localization 
and typical signal characteristics on T-1 weighted images with loss of normal low signal 
intensity of cortical bone and loss of normal high signal intensity of trabecular bone which is 
visible in 2 planes. 
 MRI bone marrow oedema: A lesion (which may occur alone or surrounding an erosion or 
other bone abnormalities) inside the trabecular bone, with unclear margins and signal 
characteristics consistent with increased water content. 
MRI joint space narrowing: Reduced joint space width in comparison to normal, as evaluated 
in a slice perpendicular to the joint surface. 
MRI tenosynovitis: Peritendinous effusion (which is high signal intensity on T2 weighted fat-
saturated or STIR images) and/or tenosynovial post contrast enhancement (signal intensity 
increases on T-1 weighted images before and after contrast injection), seen on axial 
sequences over ≥ three consecutive slices. 
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2.18.10 MRI scoring systems 
Before the development of the scoring system, manual measurement of the enhancing 
synovium volume was used to evaluate treatment response and it was considered as a strong 
predictor for disease progression [362].  There are few MRI scoring systems with some more 
used than others.  The Whole Body MRI (WBMRI) scoring has been used in some RA and 
Spondelo-arthritis (SpA) studies detect inflammation and structural damage in the axial joints, 
peripheral joints and entheses [363] while some podiatry focused trials used a regional score 
such as Forefoot bursa(FFB) used in RA and predict foot disability [364].   
Gadolinium (Gd)-enhanced MRI is highly sensitive assessment for synovitis as the inflamed 
tissue with synovitis show increased signal intensity on T1-weighted image post-GD injection. 
On the other hand, contrast injection prolongs the time of examination, increases the 
invasiveness, increases costs and the general risk on patients with kidney involvement [365].  
Omitting IV contrast has been used in some trials and it is reported that it does not have 
significant impacts on erosions and oedema scores but decrease the reliability of synovitis 
score [366]. 
2.18.10.1 RAMRIS scoring system  
RAMRIS is a MRI scoring method validated and approved by OMERACT and widely used in 
clinical trial trials.  It was established and validated from 1998-2002 by the OMERACT MRI 
Working Group and updated in 2016.  It is a measure of the inflammatory manifestations of 
RA seen on MRI.  RAMIRS comprises scores of bone marrow oedema, synovitis, 
tenosynovitis and erosions [330, 367, 368].  The score method used as the following: 
Bone Erosion: Each bone (wrists: distal radius, distal ulna, carpal bones, metacarpal bases; 
MCP joints: metacarpal heads, phalangeal bases) is scored independently  
The scale is 0–10, based on the percentage of eroded bone compared to the “assessed bone 
volume,” judged on all available images: 0 = no erosion; 1 = 1–10% of bone eroded; 2 = 11–
20%, etc. Regarding long bones, the “assessed bone volume” is from the articular surface to 
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a depth of 1 cm, while in carpal bones it is the complete bone • In case a bone is fused with 
another bone, bone erosion is scored as 10 in the bone. 
Bone Marrow Oedema/Osteitis: Each bone is scored separately (like erosions) marrow 
oedema 
The scale is 0–3 based on the proportion of bone with osteitis, as: 0 = no osteitis; 1 = 1–33% 
of bone with osteitis; 2 = 34–66%; 3 = 67–100%. 
Synovitis: Synovitis is assessed in 3 wrist areas (1. the distal radioulnar joint; 2. the 
radiocarpal joint; 3. the intercarpal and carpometacarpal joints) and in each MCP joint. The 
first carpometacarpal joint is not scored.  
The scale is 0–3. Score 0 = normal, while 1– 3 (mild, moderate, severe) are by thirds of the 
supposed maximum volume of enhancing tissue in the synovial compartment. 
Tenosynovitis: In the wrist, tenosynovitis is evaluated at six extensor compartments and 3 
flexor compartments, between the radioulnar joint and the hook of hamate. At the level of the 
MCP joints, flexor tendons are assessed in an area from 1 cm proximal to 1 cm distal to each 
joint. 
The score of tenosynovitis is based on the maximum width of the effusion and/or tenosynovial 
enhancement measured perpendicularly to the tendon. 
The scale is 0–3, as for: 0 = no; 1 = < 1.5 mm; 2 = ≥ 1.5 mm but < 3 mm; 3 = ≥ 3 mm 
peritendinous effusion and/or post contrast tenosynovial enhancement. 
The recommended images should include T-1 weighted sequences for erosions assessment, 
T-2 weighed FS or STIR to evaluate Bone marrow oedema. Tenosynovitis and synovitis 
evaluation by post contrast T1 in combination with non-contrast T-1 weighted images [367, 
368]. 
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  MRI in SLE 
There is limited data on using MRI in SLE assessment.  The main focus of these studies was 
either of structural damage or potential complications of SLE such as bone abnormalities 
(avascular necrosis or tendon rupture).  In these few studies however, MRI had the ability to 
demonstrate and identify the structural damage up to 94% of the patients and bone marrow 
oedema up to 14% [325].  
Some MRI studies in SLE looked at erosions and Jaccoud's arthropathy (JA).  The MRI pattern 
of arthritis in SLE patients was described before by Ostendorf and Sà Ribeiro in two 
uncontrolled series (14 and 20 patients, respectively) of patients with arthritis.  Although the 
imaging protocol and definitions were different, they found a prevalence of bony erosions of 
50-57 % with a significant advantage in sensitivity with respect to plain X-ray [369, 370].  The 
sample sizes were small in both studies and the focus mainly was on JA. 
Few studies tried to look at synovitis however.  Boutry et al. compared patients with RA, SLE, 
and systemic sclerosis.  Synovitis was identified in all SLE patients mainly at the wrists, 2nd, 
and 3rd MCP joints.  Despite not being visible on plain x-ray, erosion was seen in more than 
60% of MCP joints and most of the wrist joints by using MRI [371].  Bell and colleagues 
investigated 34 SLE patients with arthralgia to see the extent of MRI-determined joint disease 
(erosion and synovitis) in SLE looking at phenotypes using MRI and RA antibodies. They 
found erosion in more than 90% of patients in the wrist and 61% in the MCP joints.  Surprisingly 
in this small study, they found a fair bit of erosions in SLE patient even in the absence of ACPA 
which is revolutionary given the general concept of SLE as a non-erosive disease.  All of the 
patients had wrist joints synovitis [269].  Ribeiro et al. recruited 20 SLE patients with JA. They 
had normal X-ray, but by MRI 10/20 had erosions.  In addition to detecting tenosynovitis and 
synovitis in the majority of this group of patients [317].  Mosca and colleagues performed MRI 
for 93 SLE patients and compared the results with a healthy control group. They reported that 
MRI showed at least one erosion in (44/93) 47%of patients with SLE in their hand and (90/91) 
99% of them at their wrists.  In the healthy control group, the erosions were found in 9/46 
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(19.6%) and 45/46 (97.8%) at the hand and wrist, respectively.  All of these findings of erosions 
in MRI studies might change the concept of SLE as a non-erosive disease, as it seems to be 
a disease of some erosive nature but the modality being previously used such as CR was not 
sensitive enough in detecting that.   
With the unique ability of MRI in detecting bone marrow oedema, studies reported bone 
marrow oedema ranges 7.5-35.5% mainly at the hands and wrists of SLE patients [372].  Tani 
C et al., studied the MRI pattern of distribution of bone marrow oedema and joint erosion in 
hands and wrists of SLE and RA patients with healthy control.  They reported that the 
prevalence of bone marrow oedema and erosion was similar in SLE and RA patients [365]. 
These figures which are higher than would expected from other studies but raise the question 
about the patient selection in this study and if SLE patients were ACPA and RF positive or a 
sub-selected group with known severe joints inflammation where selection bias might have 
affected the results.
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Table 2-10.MRI studies in SLE 
Study group Joints examined Erosion Synovitis Tenosynovitis BME Type of patients 
Ostendorf [369] Hands, wrists 57% 64% 71% N/A JA=14 
Boutry[373] MCP, wrists 61% N/A 57-86% N/A SLE=14 
RA=19 
Sjogren=5 
Sà Ribeiro 
[370] 
Hands 50% 67% 95% 40% JA=20 
Mosca [372] Hands, wrists 20-98% N/A N/A 7.5-35.5% SLE=93 
HC=46 
Bell [374] Hands, wrists 61-93% 53-100% 20% 7-13% SLE=34 
RA=15 
Tani [375] Hands, wrists 48-82% N/A N/A 4-30% SLE=50 
RA=22 
HC=48 
Zollars [376] Hands, Wrists 90% 60% 85% 55% SLE=20 
N/A: not assessed, BME: bone marrow oedema, HC: healthy control 
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 Knowledge Gaps for Imaging Synovitis in SLE 
Although it is clear that patients with SLE without joint swelling may have imaging synovitis, 
there are several key areas of knowledge needed to translate this into changes in clinical 
practice.  First, as highlighted in our systematic review, previous studies failed to report 
OMERACT grades of abnormality, failed to control for rhupus and failed to control for NSAID 
and glucocorticoid therapies.  Second, most studies did not recruit consecutive series of 
patients in order to estimate the prevalence of clinical and imaging definitions of synovitis. 
Third, the clinical significance of ultrasound only synovitis has not been tested (i.e., whether it 
is associated with worse symptoms or serological measures of disease activity). These 
questions are addressed in Hypothesis 1, Objectives 1 and 2, Results chapters 5, 6 and 9. 
 Problems with responsiveness of current outcome measures 
Systemic lupus erythematosus assessment instruments depend on the assessing physician 
judging whether each symptom is due to active SLE, damage due to previously inactive SLE, 
or another disease entity.  This may be difficult, even in the hands of experts.  Although the 
BILAG tool is very useful in the assessment of global disease activity, it was not designed to 
assess each system in an in-depth way.  In the musculoskeletal domain, the domain score A 
is defined by severe synovitis while B is moderate synovitis, and C is arthralgia.  However 
since the majority of patients never have clinical synovitis, so it has a limited ability to capture 
changes.  For example, a change in the number of swollen joints from 28 to two would not 
change the BILAG score in the musculoskeletal system.  It would remain as BILAG A despite 
the obvious clinical improvement. Conversely, a drop in the swollen joint count from two to 
one would change from BILAG A to BILAG B.  BILAG C represents the presence of 
inflammatory joint symptoms, which again can vary between 28 tender joints and pain VAS of 
100 to one tender joint and a VAS of 10.  Similar to BILAG, the SLEDAI scores four points for 
arthritis in more than two joints and zero points for lesser degrees of arthritis.  This outcome 
measure is therefore unable to capture partial change, and hence unresponsive.  Examples 
of how these tools may misclassify disease response in SLE are shown in (Table 2-11). 
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Notably with other outcome measures in the ACR core set and the DAS28 this partial 
improvement would be captured better. 
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Table 2-11. Performance of difference outcome measures in a typical arthritis response:
Month Tender Swollen BILAG-MSK SLEDAI-MSK 
Response vs. previous month 
Comment 
Prednisolone 
decision SRI-4 50% reduction 
0 20 10 
A 
(severe and 
moderate arthritis 
rated same) 
4 N/A N/A N/A 15mg daily 
1 5 3 
B 
(severe and 
moderate arthritis 
rated improving) 
4 No Yes 
Clinically meaningful 
improvement but no SLEDAI / 
SRI response 
Reduce to 10mg 
2 5 2 
B 
(moderate arthritis 
rated same) 
0 Yes No 
Clinically trivial improvement but 
meets SRI criteria 
Continue 10mg 
3 5 1 
C 
(moderate arthritis 
rated improving) 
0 No Yes 
Clinically trivial improvement but 
meets 50% reduction criterion 
Reduce to 7.5mg 
4 5 1 
B 
(moderate arthritis 
rated same) 
0 No No 
Clinically unchanged but 
increased BILAG score as no 
longer improving 
Continue 7.5mg 
This illustrative example shows a typical patient with severe lupus arthritis assessed at four time points after starting a new therapy. At each time point a 
physician decision on modifying prednisolone dose is suggested. At each follow up time point, one of the clinical trial outcome measures (BILAG-MSK, 
SLEDAI-MSK, SRI-4 and 50% improvement) can be seen to be inconsistent with the joint count and likely physician’s prednisolone decision regarding. 
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 Effect of lack of reliable outcome measures on clinical trials in SLE 
There has been a high failure rate of B cells targeted biological therapies in general in clinical 
trials.  Negative trials include those of belimumab (which was later shown to be effective in 
other RCT [377-381] and rituximab (which nevertheless is in continued widespread use in 
clinical practice based on positive case series evidence).  Hence, many commentators believe 
that clinical trials of these agents do not accurately capture their efficacy.  Although these 
difficulties have to some extent been resolved by later trial designs, these have required very 
large cohorts of patients for such a rare disease, which makes the studies difficult to recruit 
and costly.  Even in the later positive results of large phase III belimumab trials, effect size 
appeared small.  Other, non-B cells-targeted therapies have also been proposed, but none of 
these has yet demonstrated efficacy. 
 Use of joint-specific outcome measures in SLE clinical trials 
2.23.1 Sifalimumab phase II trial 
Sifalimumab is a fully human monoclonal antibody (immunoglobulin G1 k), which targets 
interferon (IFN) signalling, a pathway that has been linked to the pathogenesis of SLE.  
Sifalimumab neutralizes the majority of IFN-a subtypes.  It met its primary endpoint of SRI (4) 
in phase II randomized controlled trial comparing three doses with placebo, although was not 
progressed to phase III studies due to the superiority of another molecule, anifrolumab [114, 
382].  In a post-hoc analysis of the data from the phase II study, patients who had at least 
eight tender and eight swollen joints at baseline were analysed for at least 50% improvement 
in joint counts.  In (Table 2-12) I have summarized some of the key endpoints from that paper 
and also calculated the difference in response rates from placebo. 
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Table 2-12. Post hoc analysis of joint count improvement in the sifalimumab phase II 
trial: 
 N Placebo 200mg 
(%) 
Δ vs. 
placebo 
600mg 
(%) 
Δ vs. 
placebo 
1200mg 
(%) 
Δ vs. 
placebo 
SRI-4 431 45 58 13 57 12 60 15 
BICLA 429 36 45 9 47 11 48 12 
Swollen 
joints 
baseline 
431 6.3 6.6 N/A 6.8 N/A 6.4 N/A 
Tender 
joints 
baseline 
431 10.1 10.4 N/A 8.6 N/A 9.3 N/A 
50% 
Joints* 
155 37 54 17 58 21 61 24 
*50% improvement in joint counts, calculated only for patients who had at least 8 tender and swollen 
joints at baseline.  
These would data would appear to suggest that the 50% improvement in joint counts was 
better able to differentiate treatment arms compared to the SRI-4 or BICLA.  However, it 
must be noted that far fewer patients were included in the joint count endpoint as more 
musculoskeletal disease activity was required at baseline.  Therefore, the musculoskeletal 
subgroup may also have responded differently to the SRI-4 and BICLA.  This analysis was 
not presented in the paper and was, therefore, a question I sought to address in my 
research. 
2.23.2 Anifrolumab phase II trial 
The MUSE study was a multi-center, randomized, double-blind, placebo-controlled Phase IIb 
trial of anifrolumab, a monoclonal antibody that targets the shared interferon receptor, and 
therefore achieves better neutralization of interferon signalling than by targeting the various 
ligands for this receptor [382].  Patients with active SLE (defined as SLEDAI-2K ≥ 6 plus 1 
BILAG-A boost or 2 BILAG-B relapses plus activity as seen by the physician VAS (0-3) ≥1) 
[47].  There was a randomization 1:1:1 to placebo, anifrolumab 300 mg or anifrolumab 1000 
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mg every 4 weeks.  In addition, individual arms were subdivided according to the type I IFN 
signature.  The primary endpoint was the SLE responder index (SRI, SLEDAI 2K reduction 
by ≥4 points, no new BILAG-A or no more than 1 new BILAG-B thrust, no worsening of ≥0.3 
from the physician's perspective) combined with a reduction in the glucocorticoid dose from 
week 12 to week 24 to <10 mg / day, as a secondary endpoint with continuing glucocorticoid 
dose reduction at week 40-52 and a glucocorticoid dose of < 7.5 mg / day.  Other outcomes 
were CLASI improvement of> 50% (if initially> 10) and> 50% reduction of swollen plus 
tender joints (if ever ≥8).  A similar analysis to sifalimumab is presented below in Table 2-13. 
Table 2-13. Post hoc analysis of joint count improvement in the anfirolumab phase II 
trial: 
 n Placebo 300mg (%) Δ vs. 
placebo 
1000mg 
(%) 
Δ vs. 
placebo 
SRI-4 305 18 34 16 29 11 
BICLA 302 26 54 22 41 15 
Swollen joints 
baseline 
305 8.3 8.6 N/A 8.3 N/A 
Tender joints 
baseline 
305 10.5 12.2 N/A 11.6 N/A 
50% Joints* 131 49 70 21 65 16 
*50% improvement in joint counts, calculated only for patients who had at least 8 tender and swollen 
joints at baseline. SRI-4, systemic lupus erythematosus responder index using a 4-point reduction in 
SLEDAI; SLE, systemic lupus erythematosus; SLEDAI-2K, systemic lupus erythematosus disease 
activity index, BICLA: British Isles Lupus Assessment Group-based Combined Lupus Assessment. 
In this case it is somewhat less clear whether the joint count criterion differentiated treatment 
groups better than the BICLA.  However, comparing these data with those in (Table 2-12) 
highlights another important point.  The baseline joint counts in the two studies differed, being 
higher in the anifrolumab trial.  Even if a threshold of eight tender and swollen joints is required 
before analyzing for 50% improvement, there would still be a difference in the mean baseline 
joint counts of patients within that subgroup.  Since the criteria for the different BILAG and 
SLEDAI grades are based on a fixed threshold of 0, 2 or 3 joints, the degree of mismatch 
between a 50% improvement and BILAG and SLEDAI response will differ depending on the 
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baseline joint counts. 
Further post-hoc analysis of arthritis parameters was published separately [383].  In this 
publication, the emphasis was on comparing the improvements seen in patients with or without 
a high interferon signature at baseline.  Surprisingly, almost all the patients in the trial had 
active arthritis (according to SLEDAI) at baseline.  The authors reported three different 
measures of arthritis improvement: SLEDAI-2K improvement; BILAG-2004 improvement and 
mean change in joint counts. Interestingly, a different conclusion regarding the predictive value 
of the interferon signature was drawn depending on which of the arthritis measures was used 
(Table 2-14). 
Table 2-14: post-hoc analysis for the anifrolumab trial: 
 All patients IFN High  IFN Low  
Anifrolumab Placebo Anifrolumab Placebo Δ vs. 
placebo 
Anifrolu 
mab 
Placebo Δ vs. 
placebo 
SLEDAI 
response (%) 
56.7 42.4 56.2 39.7 16.5 58.3 50.0 8.3 
BILAG 
improvement 
(%) 
69.1 49.5 66.2 47.2 19 78.3 56.5 21.8 
Change 
mean joint 
count 
-5.5 -3.4 -4.9 -3.0 -1.9 Not 
given 
Not 
given 
- 
SLEDAI: SLE Disease Activity index, BILAG: British Isles Lupus Assessment Group. IFN: interferon 
2.23.3 Combined post-hoc analysis of sifalimumab and anifrolumab trials 
Post-hoc analysis of the data from two 52-week studies of sifalimumab and anifrolumab.  At 
Week 52, of the 736 patients recruited from both studies, 396 were SRI (4) responders, and 
340 were non responders.  They used different outcome measures to compare between the 
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responder and non-responder groups which included : The percentage of patients with a 7-
point reduction in SLEDAI–2K; changes from baseline in clinical components of the SLEDAI–
2K  and  PhGA scores; percentage of patients with BILAG ‘‘A’’ or ‘‘2B’’ flares; the numbers of 
SLEDAI–2K organ domains with improvement; and the percentages of patients with 
reductions in oral corticosteroid  dosage to 7.5 mg/day, 50% improvement in swollen and 
tender joint count, and 50% improvement in the Cutaneous Lupus Erythematosus  Disease 
Area and Severity Index (CLASI).  A greater percentage of SRI (4) responders had a 7 point 
reduction in SLEDAI–2K score compared with non-responders (p < 0.001).  SRI (4) 
responders had a greater mean percentage change from baseline in clinical SLEDAI and 
Physician GA score than non-responders (p < 0.001).  Moreover, a lower percentage of SRI 
(4) responders had 1 flare as measured by BILAG ‘‘A’’ or ‘‘2B’’ flare rates, in comparison to 
non-responders (p < 0.001), whereas the mean number of organ domains with improvement 
in SLEDAI–2K was greater in SRI (4) responders vs. non responders (p <0.0001). Similarly, 
greater percentages of SRI(4) responders achieved a reductions in oral corticosteroid dose to 
7.5 mg/day (for patients who were receiving 10 mg/day oral corticosteroid at baseline), as well 
as 50% improvements in swollen and tender joint count, and a 50% improvement in CLASI, 
compared with non-responders (p < 0.001). 
 Knowledge gaps for responsiveness in musculoskeletal SLE 
As discussed above, although the BILAG and SLEDAI have been validated and shown to be 
responsive, their face validity and evidence from clinical trials suggest they may not be as 
responsive as arthritis-specific measures such as joint counts.  These tools have never been 
formally compared.  Further, their responsiveness has never been compared with an objective 
measure of synovitis such as musculoskeletal ultrasound.  The relative value of BILAG and 
SLEDAI, clinical MSK evaluation (such as joint counts), and ultrasound defined synovitis has 
not been compared.  Although ultrasound is not always convenient for routine practice and 
clinical trials, it may be possible to create a composite outcome measure for musculoskeletal 
SLE similar to the DAS28 and CLASI.  Such a tool would ideally be validated against a gold 
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standard of inflammation, such as ultrasound, instead of against physician’s evaluation or 
intention to treat as used for the DAS28 and CLASI.  The information needed to define such 
a tool has been set out in the OMERACT filter [297]. 
These questions are addressed in Hypothesis 2 and 3, Objectives 3, 4, and 5 and Results 
Chapters 5, 6, 7 and 8. 
2.24.1 Treatment of subclinical synovitis in RA and impact on SLE 
The management of patients with RA has improved dramatically in recent years with the 
introduction of early intervention concept, the use of objective assessments as well as the 
availability of more effective biologic therapies.  Disease remission is desirable and 
achievable.  Based on current evidence and expert opinion to improve the management of 
RA, an international task force recently published recommendations in RA to achieve the 
optimal therapeutic outcomes. These guidelines endorse clinical remission as the primary goal 
for treatment of RA.  Clinical remission is defined as the absence of signs and symptoms of 
significant inflammatory disease activity and includes an assessment of joints, acute phase 
response items and patient’s and physician’s global assessment.  It is acknowledged that 
clinical remission may not be an appropriate and feasible target for all patient.  Therefore, the 
main principle is to achieve an attainable target that reflects stable and as minimally as 
possible disease activity.  This treatment to a (pre-defined) target encourages the use of a 
measure to assess the status of RA – most often using established composite index I.e. 
(DAS28, Simplified Disease Activity Index [SDAI], Clinical Disease Activity Index [CDAI]) 
[384].  Nevertheless, composite indices have their own limitations including underestimation 
of disease activity due to the insensitivity of clinical evaluation or the lack of acute phase 
laboratory markers.  Other limitations include subjectivity of assessments components 
including tender joint counts and visual analogue scores. Moreover, the presence of joint 
damage may make the assessment of swollen joint counts difficult even in the hands of 
experts. 
In order to overcome these problems, ultrasound imaging has the potential to monitor or to 
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target patients for remission. Cross-sectional studies in RA have demonstrated that ultrasound 
imaging influences clinical decision-making, modifying diagnosis +/- therapy decisions; 
whether these are associated with improvement in outcomes have yet to be determined [286]. 
Nevertheless, in patients who were in clinical remission, studies had shown joints 
demonstrating baseline PD had a 12-fold increased probability of developing erosions.  It is 
therefore hypothesised that treatment according to an ultrasound target would lead to better 
long-term outcomes than treatment according to a clinical target [287-291]. 
The ARCTIC study (Aiming for Remission in rheumatoid arthritis: a randomised trial examining 
the benefit of ultrasound in a Clinical Tight Control regimen).  Two-hundred and thirty eight 
patients were recruited.  ARCTIC was designed to compare two tight control treatment 
schemes in patients with early RA and assessed whether incorporation of ultrasound 
information into treatment choices and targeting therapy towards imaging remission would 
lead to patient’s improvement.  The combined primary endpoints were sustained clinical 
remission, absence of swollen joints and inhibition of joint damage.  The results displayed no 
difference in the primary endpoint and most of the secondary endpoints, which were based on 
symptoms and signs of arthritis between the group that targeted clinical remission alone 
versus those that targeted combined clinical and ultrasound defined remission [385].  There 
was a trend to lowering of erosion in the ultrasound arm though.  
So, could ultrasound defined remission be used in SLE? It is important to note the differences 
between disease activity indices in RA and SLE.  Current clinical disease activity indices in 
RA may be more sensitive to a change in therapy than musculoskeletal components in the 
BILAG-2004 or SLEDAI-2K in SLE. So, if we consider a patient with arthralgia, 20 tender joints, 
no clinical joint swelling, normal inflammatory markers, evidence of osteoarthritis or 
fibromyalgia and a patient VAS of 80/100, the RA and SLE instruments will perform differently.  
In RA, the DAS28 score will be 4.58, warranting increase in therapy.  Thus, additional 
ultrasound information may have not impacted the overall outcomes since these patients 
would be over-treated anyway.  However, in SLE, the investigators will deem these symptoms 
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to be unrelated to SLE, thus a score of BILAG D and SLEDAI 0 points for musculoskeletal 
involvement will be assigned instead.  
Moreover, as described in previous section (2.18) the frequency of swollen joint is much lower 
in SLE than RA [386].  Therefore in symptomatic patients non-detectable synovitis, should 
ultrasound be introduced, subclinical synovitis may be detected more leading to an increase 
in therapy and better outcomes in the long run.  Therefore, this provide rationale for ultrasound 
defined remission to be investigated in SLE. 
 Knowledge Gaps for treatment of Imaging Synovitis in SLE 
Existing data suggest that there is a substantial amount of objective joint inflammation that is 
only detectable using imaging. Results chapters 5 and 6 will define this.  However, in terms of 
treatment, it is not sufficient to just define which patients have imaging synovitis. Clinicians 
need to know whether these patients should be prescribed glucocorticoids 
immunosuppressant and biologics purely on the basis of the imaging findings. In order to test 
this, we need to know whether patients with imaging synovitis have a better clinical response 
to therapy than those no inflammatory findings on imaging.  This is addressed in Chapter 7: 
Additionally, we need to know which patients should be evaluated in clinical trials of new 
therapies. It is not clear whether current usual practice to include only patients with clinical 
synovitis (scoring on BILAG and SLEDAI) is appropriate. We need to determine whether 
clinical trials are feasible in patients with imaging-only synovitis, whether they can be 
conducted without the use of ultrasound endpoints and whether analysis of these patients can 
differentiate active and placebo treatment arms.  In the cutaneous SLE in clinical trials, the 
CLASI detected more difference between treatment groups than the SRI-4, especially in the 
speed of onset of response.  Novel tools for musculoskeletal SLE may achieve a similar result. 
It is also not known whether trials that focus purely on musculoskeletal SLE could use a more 
rigorous standard of care (e.g., lower doses of glucocorticoids) than were previously 
problematic in trials of multisystem SLE.  
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Chapter 3: Aims, Hypotheses, and Objectives 
 Aims- 
The overall aims of this thesis are: 
1. To improve the care of people with musculoskeletal symptoms in SLE by improving the 
accuracy of clinical assessment and identification of people who will benefit from 
treatment. 
2. To improve the conduct of clinical trials in musculoskeletal SLE using novel outcome 
measures and trial designs. 
Individual hypotheses and objectives for this work are summarised in Table 3-1 below. 
 Hypotheses 
1. There is a substantial proportion of SLE patients with objective musculoskeletal 
inflammation that is symptomatic but not detected by existing clinical instruments 
2. Existing validated disease activity instruments are poorly responsive for 
musculoskeletal manifestations 
3. SLE patients with subclinical synovitis will clinically respond to therapy 
 Objectives 
1. To evaluate a cross-sectional cohort of consecutive SLE patients with musculoskeletal 
symptoms for both clinical and ultrasound synovitis, and determine the clinical 
associations of subclinical synovitis 
2. To validate ultrasound synovitis using MRI and describe MRI pathology in patients with 
SLE arthritis in detail 
3. To perform a pilot study to explore the responsiveness of BILAG, SLEDAI, SRI4 with 
ultrasound and other clinical parameters in patients receiving treatment with 
glucocorticoids 
4. To perform a definitive study to determine the responsiveness of each of these 
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parameters (the USEFUL study). 
5. To determine whether patients with abnormal musculoskeletal ultrasound have better 
clinical response to glucocorticoid therapy compare to patients with normal 
musculoskeletal ultrasound (construct validity, USEFUL study). 
101 
 
Table 3-1: Summary of thesis structure 
Knowledge Gap Hypothesis Objective Results Chapter / Project 
2.20: Knowledge Gaps for 
Imaging Synovitis in SLE 
1.There is a substantial 
proportion of SLE patients with 
objective musculoskeletal 
inflammation that is symptomatic 
but not detected by existing 
clinical instruments 
1.To evaluate a cross-sectional 
cohort of consecutive SLE 
patients with musculoskeletal 
symptoms for both clinical and 
ultrasound synovitis, and 
determine the clinical 
associations of subclinical 
synovitis 
(5) Cross-Sectional Study: 
Defining Musculoskeletal 
Manifestations in Systemic Lupus 
Erythematosus. 
2.To validate ultrasound synovitis 
using MRI and describe MRI 
pathology in patients with SLE 
arthritis in detail 
(9) MISTER  
2.24: Knowledge gaps for 
responsiveness 
in musculoskeletal SLE 
2.Existing validated disease 
activity instruments are poorly 
responsive for musculoskeletal 
manifestations 
3.To perform a pilot study to 
explore the responsiveness of 
BILAG, SLEDAI, SRI4 with 
ultrasound and other clinical 
parameters in patients receiving 
treatment with glucocorticoids 
(6) Pilot Longitudinal Study: 
Responsiveness of clinical and 
ultrasound outcome measures in 
musculoskeletal systemic lupus 
erythematosus: 
4.To perform a definitive study to 
determine the responsiveness of 
each of these parameters (the 
USEFUL study) 
(8) USEFUL Study: 
Responsiveness of ultrasound 
and clinical variables 
2.25: Knowledge gaps for 
treatment in musculoskeletal SLE 
3.SLE patients with subclinical 
synovitis will clinically respond to 
therapy better than those with no 
objective evidence of 
inflammation 
5.To determine whether patients 
with abnormal musculoskeletal 
US have better clinical response 
to glucocorticoid therapy 
compare to patients with normal 
musculoskeletal ultrasound 
(criterion validity, USEFUL study) 
(7)USEFUL Study: prediction of 
response using baseline 
ultrasound 
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Chapter 4: General Methods 
 Ethical approvals 
All patients provided written informed consent and these studies were conducted in accordance 
with the principles of the Declaration of Helsinki.  For USEFUL study, ethical and HRA approval 
was gained from the North West - Greater Manchester Central Research Ethics Committee (16-
NW-0060). The University of Leeds was contracted with the administrative sponsorship.  Ethical 
approval for studies in chapters 5, 6 and 9 was gained from Yorkshire and The Humber, Leeds 
East Research Ethics Committee [10/H1306/88] as part of the Connective Tissue Disease and 
Vasculitis Cohort Cross-sectional and Longitudinal Clinical and Basic Science Evaluation 
(CONVAS) data collection protocol. The University of Leeds was contracted with the 
administrative sponsorship.  The CONVAS study is an observational study based on routine 
clinical care that allows for collection of clinical data imaging and biomarkers on patients with a 
broad range of connective tissue diseases.   
 Clinical variables 
Patients with SLE and arthritis may have disease activity purely in their joints, or may also have 
disease activity in other organs, such as the skin or kidneys.  Global disease activity indices such 
as the SLEDAI and BILAG assess all organs, but the musculoskeletal component can be 
analysed separately.  Likewise, some VAS scales assess the joints (e.g., patient’s pain VAS), 
while others may assess all aspects of disease (e.g., patient’s global health VAS).  
Haematological and immunological markers are often used to assess SLE.  These correlate with 
the presence of arthritis, but also with disease activity in other organs.  In selecting study 
endpoints we, therefore, selected those endpoints that were specific to arthritis.  This selection is 
summarised in Table 4-1 
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Table 4-1: Selection of clinical variables 
Musculoskeletal Specific Variables Global lupus variables 
Tender joint count Physician’s global disease activity VAS 
Swollen joint count Total BILAG 
Patient’s painful joint count Total SLEDAI 
Physician MSK disease activity VAS LupusQoL 
BILAG MSK component L-QoL 
SLEDAI MSK component Patient’s general health VAS 
HAQ-DI Patient’s fatigue VAS 
Patient’s MSK Disease activity VAS ESR 
Patient’s MSK Pain VAS Complements: C3 and C4 
Patient’s EMS severity VAS Anti-dsDNA titre 
Patient’s EMS duration Immunoglobulins: IgG, IgA, IgM 
VAS: visual analogue scale, BILAG: British Isles Lupus Assessment Group, SLEDAI: Systemic Lupus 
Erythematosus Disease Activity Index. MSK: musculoskeletal, ESR: early morning stiffness, L-QOL: Lupus 
Quality of Life, HAQ: Health assessment questionnaire 
 Physician assessments 
The clinical assessments were performed by trained rheumatologists who were blinded to the 
ultrasound assessment. 
4.3.1 BILAG-2004-Index-last four weeks 
The BILAG-2004 [169], assesses disease activity in eight different organs/systems: general, 
mucocutaneous, neurological, musculoskeletal, cardiorespiratory, vasculitis, renal and 
haematological.  A score is calculated for each system depending on the clinical features present 
and whether they are new, worse, the same or improving in the last four weeks compared with 
previously.  BILAG-2004 numerical scores were calculated using the formula A=12, B=8, C=1, 
D/E=0 [387]. 
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4.3.2 Musculoskeletal BILAG 
The musculoskeletal component of the overall BILAG-2004 is of particular interest to this thesis.  
This domain assesses musculoskeletal activity in terms of joint swelling, deformities, 
tenosynovitis, loss of function and inflammatory type pain.  It classifies musculoskeletal 
involvement into BILAG A-E. 
4.3.3  SLEDAI-2K 30 days 
The SLEDAI-2K 30 days [388] measures disease activity by weighting the importance of each 
system involved.  It does not account for subjective symptoms such as fatigue, dysphoria, 
arthralgia, or myalgia.  However, separate, quality of life instruments can be used for that purpose. 
4.3.4 Tender Joint Count 
Sixty-eight joints were assessed: shoulder, elbow, and wrist (radiocarpal, carpal and 
carpometacarpal are collectively designated wrist), metacarpophalangeal I-V, proximal 
interphalangeal I-V and knee.  The investigator pressed on a joint sufficiently to induce pain if 
there is an inflammation as per the agreed and known tender joint count examination technique 
in inflammatory arthritis.   
4.3.5 Swollen Joint Count 
Sixty-six joints were assessed. Synovial fluid and/or soft tissue swelling, but not bony overgrowth, 
represents a positive result. The investigator felt joints for swelling as per the agreed and known 
tender joint count examination technique in inflammatory arthritis.   
4.3.6 Physician Musculoskeletal Disease Activity Assessment 
The investigator's evaluation of musculoskeletal disease activity was completed before the 
patient's global assessment. The investigator assessed the patient’s musculoskeletal disease 
activity considering not only impressions from the assessments made in the study, but also any 
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other information available such as inflammatory symptoms and morning stiffness.  Disease 
activity in other organs (e.g. skin disease) did not affect this score.  A100 mm visual analogue 
scale was used: the left end corresponds to very well (0) and the right end to very poor (100). 
4.3.7 Physician Global Assessment 
Physician global assessment was used to calculate composite response criteria (SRI and BICLA).  
The investigator assessed the patient’s overall disease activity taking into account not only 
impressions from the assessments made in the study, but also any other information available. 
This score should reflect musculoskeletal and all other organ systems.  A 100 mm visual analogue 
scale is used: the left end corresponds to very well (0) and the right end to very poor (100).  Values 
were scaled to a 0 – 3 scale for the SRI calculation. 
 Patient reported outcome measures 
4.4.1 Patient Assessment of Musculoskeletal Pain 
The patient was asked ‘What level of pain are you currently experiencing from your joints, muscles 
and/or tendons?’ On a 100mm visual analogue scale.  The left end corresponds to no pain and 
the right end to ‘the worst imaginable pain’.  The patients marked their own assessment on the 
scales in the case report forms by themselves by placing a single vertical line through the bar. 
4.4.2 Patient Assessment of Fatigue 
The patient was asked ‘What level of abnormal fatigue (tiredness) are you currently 
experiencing?’ on 100 mm visual analogue scales:  the left end corresponds to no fatigue and the 
right end to ‘extreme fatigue’ (100). 
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4.4.3 Patient Assessment of Morning Stiffness 
The patient was instructed to rate the severity of their morning stiffness on a 100mm visual 
analogue scale.  The left end corresponds to “no extra stiffness” and the right end to “extremely 
severe morning stiffness”. 
4.4.4 Duration of Morning stiffness 
The patient was asked to estimate the time that elapsed between awakening and the time he/she 
is as flexible as he/she will be during a day involving typical activities.  When did the sensation of 
stiffness begin to wear off? Duration in hours and minutes is recorded. 
4.4.5 HAQ Questionnaire 
A self-reported patient-oriented questionnaire to evaluate functional status. 
4.4.6  Lupus Quality of life (LupusQoL) Questionnaire 
A self-reporting 34 items specifically designed as a disease specific patient-reported outcome 
measures to assess the quality of life in SLE patients. 
4.4.7 SLE Quality of Life questionnaire (L-QoL) 
An alternative quality of life tool consisting of 25 statements; respondents were asked to indicate 
whether or not each of the statements applies to them. 
4.4.8 Likert scale for response to steroid 
15-point Likert scale (ranging from -7 to +7) to record whether they feel their symptoms have 
improved, worsened or remained the same since baseline. 
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Figure 4-1: Likert score for response to steroids 
 
Better About the same Worse 
   
     
If better, is it…? Please tick  If worse, is it…? 
Almost the same, hardly better at all       
   
Almost the same, hardly worse at all 
A little better 
   
A little worse 
Somewhat better 
   
Somewhat worse 
Moderately better                                     
   
Moderately worse 
A good deal better                                     
   
A good deal worse 
A great deal better                                 
   
A great deal worse 
A very great deal better                       
   
A very great deal worse 
 
4.4.9 Routine laboratory assessments 
Blood samples for measurement of immunological parameters were collected  including ANA, 
anti-dsDNA, anti-ENAs (anti-sm, anti-RNP, anti-Ro, anti-La and anti-chromatin antibodies), 
anticardiolipin antibody (ACA), Complement levels (C3 and C4)and immunoglobulins(IgA, IgM 
and IgG).  In addition to full blood count, renal function test, liver function test, ESR and CRP. 
 Musculoskeletal Ultrasound 
Ultrasonography (GS and PD) was performed using high resolution ultrasound machines (HRUS).  
General Electric (GE) Logiq E9 HRUS with multi-linear 6-15 MHz transducer was used. 
Sonographers were trained and experienced in musculoskeletal ultrasound and were blinded to 
patient’s clinical evaluation.  Power Doppler was assessed with the highest gain level without 
background noise, PRF of 750 Hz and medium wall filter. 
Bilateral wrists and hands were scanned.  All joints in hand and wrists were examined using the 
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standard approach of examining the following; radio-carpal (RCJ), inter-carpal (ICJ), ulnar-carpal 
joints (UCJ) and 2nd to 5th metacarpo-phalangeal joints (MCP) and 2nd  to 5th proximal inter-
phalangeal joint joints (PIP).  Bilateral tendon sheaths including the 1st  –5th extensor tendons 
compartments (abductor pollicis longus and the extensor pollicis brevis tendons, extensor carpi 
radialis longus and extensor extensor carpi radialis brevis muscle, extensor pollicis longus, 
extensor digitorum and extensor indicis and extensor digiti minimi) which for the purpose of 
simplifying scored together as extensor tendon sheaths.  The extensor carpi ulnaris was scored 
separately because it is commonly involved in cases of tenosynovitis.  On the palmar aspect the 
2nd to 5th flexor digitorium tendon sheaths were assessed for the presence of tenosynovitis.   
Ultrasound abnormalities were defined according to OMERACT definitions [347].  Ultrasound 
findings were scored according to EULAR-OMERACT ultrasound taskforce semiquantitative 0-3 
scoring system [296, 304, 389, 390].  The GS scoring was as follows; 0 = no synovial hypertrophy, 
1 = mild hypertrophy, 2 = moderate hypertrophy, and 3 = severe hypertrophy.  The Power Doppler 
scoring was as follows; 0 = absence of signal, no intra-articular flow; 1 = mild hyperaemia, one or 
two vessels signal (including one confluent vessel); 2 = moderate hyperaemia, (>grade 1) and 
less than 50% of GS area; 3 = marked hyperaemia, vessels signal in more than half of the synovial 
area.  Tenosynovitis was defined according to the OMERACT criteria [296] and the GS and PD 
signal scored using a semi-quantitative 0-3 scale system (0= normal, 1=mild, 2=moderate and 3= 
severe) [391].   Ultrasound abnormalities (62 areas) were summarised as total grey scale (GS), 
PD, erosions and tenosynovitis as well as numbers of joints with abnormal GS (≥2), PD (≥1), 
erosions or tendons with tenosynovitis (as any GS and/or PD abnormality in the tendon sheath). 
A novel composite clinical assessment tool against total ultrasound score (GSPD), combined grey 
scale and power Doppler scores from the hands and wrists was created to form the dependent 
variable in a multiple linear regression model that includes the ACR core set variables (TJC68, 
SJC66, patient pain VAS, patient musculoskeletal disease activity VAS, physician 
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musculoskeletal disease activity VAS, HAQ-DI, ESR), morning stiffness severity VAS as 
independent variables (8 in total).  To avoid overfitting the data and to perform variable selection, 
penalized (Lasso) regression will be used, with cross-validation used to select optimum lambda 
from a grid of starting values. Baseline data will be used, at which point the level of ultrasound 
inflammation is expected to be highest.  In a sensitivity analysis, GSPD re-calculated according 
to an in-house developed scoring system which updates the OMERACT-EULAR scoring system 
to have better measurement properties, as follows: 
 
Table 4-2: GSPD 
 
 Original PDUS scoring    Revised PDUS scoring 
  PD    PD 
  0 1 2 3    0 1 2 3 
GS 
0 0 0 0 0  
GS 
0 0 0 0 0 
1 1 1 2 3  1 1 1 2 2 
2 2 2 2 3  2 1 1 2 2 
3 3 3 3 3  3 1 2 2 3 
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 USEFUL: Study Design 
The USEFUL study (UltraSound Evaluation For mUsculoskeletal Lupus) is a prospective, 
longitudinal, multi-centre study designed to address the following unmet needs: 
 Clinical problem: how can clinicians decide whether to start or increase 
immunosuppression for joint pain in patients with SLE? 
 Outcome measures problem: what is the best outcome measure for efficacy in 
musculoskeletal SLE? 
For the purpose of testing the prognosis and responsiveness of ultrasound in SLE a prospective 
study of patients with SLE and musculoskeletal symptoms receiving a commonly-used therapy 
of known efficacy (glucocorticoids) conducted in 7 different centers in the UK.  Patient deemed 
by their treating physician to have inflammatory symptoms who were appropriate for therapy in 
an observational study were recruited. Because the change in clinical variables, or the most 
responsive clinical variable, is not yet known, we have chosen a 2-phase design with the 
internal pilot.  In the first phase I used two follow up time points (2 weeks and 6 weeks) to 
ensure that maximal response is captured.  
4.2.1 Objectives 
Primary: 
Determine whether patients with abnormal musculoskeletal ultrasound have a better clinical 
response to glucocorticoid therapy compared to patients with normal musculoskeletal 
Ultrasound. 
Secondary: 
 Determine whether musculoskeletal ultrasound (GS or PD) is responsive to therapy. 
 Investigate the validity of a range of other clinical outcome measures against ultrasound 
 
 
 111 
and clinical response. 
 Assess the inter-reader reliability of ultrasound in musculoskeletal SLE 
4.2.2 Study design 
A multicenter- prospective observational study to investigate the validity of ultrasound as an 
outcome measure in assessing response to therapy in Systemic lupus erythematosus (SLE).  
Patients were treated with 120mg intramuscular methylprednisolone acetate as routine care for 
active musculoskeletal disease on the same date as the ultrasound and clinical assessment and 
then repeated at two and six weeks to assess responsiveness.. 
4.2.3 Study blinding 
Sonographers were blinded to the clinical condition and therapy stage.  The clinical examination 
and BILAG-2004 scoring were performed by investigator who were blinded to the ultrasound 
findings.  However, patients were not blinded to therapy received as prescribed for clinical not 
research indication. 
 
 
 112 
Figure 4-2 USEFUL study schematic: 
 
Week6 
 
 
IM: intramuscular, MSK: Musculoskeletal, PIS: Patient information sheet, US: ultrasound 
  
Final visit (V4) 
(6 weeks after IM Glucocorticoid) 
Clinical assessment 3 
MSK-US Scan 3 
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Table 4-3. Summary schedule of study assessments: 
Visit 
  2  3  4 
Week Screen 0 2 6 
Informed Consent x    
Eligibility Criteria x    
IM Depomedrone prescribed  x   
Physician Assessments 
Relevant medical history and demographics  x   
Relevant concomitant medications 
(Glucocorticoid, NSAIDs analgesia)  
 x   
Physician MSK diagnosis  x   
Joint Assessment (Tender and Swollen)  x x x 
BILAG-2004  x x x 
SLEDAI-2K  x x x 
Physician Global Assessment VAS  x x x 
Physician musculoskeletal disease activity VAS  x x x 
Patient Reported Outcomes 
Patient Visual Analogue Scales (General health, 
musculoskeletal disease activity, pain, fatigue) 
 x x x 
Morning Stiffness (VAS and minutes)  x x x 
HAQ  x x x 
LupusQoL and L-QOL Questionnaires  x x x 
Patient Acceptable Symptoms State  x x x 
Likert scale for response to glucocorticoid   x x 
Investigations 
Ultrasound examination  x x x 
Routine clinical lab disease activity tests (U&E, 
LFT, FBC, ESR, PV, CRP, urine analysis) 
 x  x 
Routine clinical lab SLE serology (dsDNA, ANA, 
ENA, C3, C4, Immunoglobulins) 
 x   
Exploratory biomarkers (serum, sample for RNA)   x x x 
BILAG-2004: British Isles Lupus Assessment Group, HAQ: Health assessment questionnaire, L-QOL: 
Lupus Quality of Life, SLEDA: SLE Disease Activity Index, VAS: Visual analogue scale 
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4.2.4 Inclusion criteria: 
 Patients with systemic lupus erythematosus who meet ACR/SLICC 2012 criteria. 
 Patients with musculoskeletal symptoms deemed by the clinician to represent active SLE 
(patients need not have clinical synovitis but must have evidence to support inflammatory 
cause of symptoms (e.g. morning stiffness, raised inflammatory markers and no more likely 
alternative diagnosis for these symptoms such as osteoarthritis). 
 Planned treatment with intramuscular glucocorticoids (this is typically expected to be 120mg 
Depo-medrone as the most commonly used preparation and dose, but clinicians may choose 
to use an alternative preparation or dose that they consider equivalent for that patient). 
4.2.5 Exclusion criteria: 
 Patients who ever have immunological evidence of rhupus (positive for anti-CCP antibodies 
or Rheumatoid Factor). 
 Patient who is receiving an NSAID within 3 days prior to the intended baseline US date. 
 Patient who is receiving daily oral glucocorticoid greater than prednisolone 5mg (or 
equivalent), or have received IV/IM glucocorticoid in the past 3 months. 
 Treated with rituximab or cyclophosphamide in the past 6 months. 
 Any changes in immunosuppressant therapy /dose in the last three months. 
4.2.6 Withdrawal criteria 
Patient discontinued from the study if he/she was withdrawn his/her consent.  The investigator 
may withdraw a patient from the study for any other reason that threatens patient safety or 
the integrity of study data.  Patients who did not attend the baseline visit were withdrawn.  
Patients who completed the baseline visit were permitted to complete the study if they missed 
one of the other visits. 
 
 
 
 115 
4.2.7 Inter reader reliability for USEFUL study 
The inrter-reader reliability was assessed using the quadratic-weighted Kappa static for the semi-
qualitative measurements.  Values of Kappa less than 0.4 were considered as poor agreement, 
values between 0.4 and 0.75fair to good, and >0.75 were considered as excellent 
agreement[392].  All sonographers from the study centres attended a training day before the start 
of the study.  They participated in an inter-reader reliability exercise where they scanned four 
patients’ joints (17 areas) and joint by joint and overall all agreement were calculated.  The ranges 
of kappa values for Grey scale was between 0.38 and 0.85 and the overall kappa agreement for 
Power Doppler and erosion were 0.98 and 0.85 respectively.  Generally, the agreement between 
the sonographers was good. 
Table 4-4: Ultrasound reliability 
Site Overall Kappa 
GS  
ECU 0.65 
ETS 0.80 
FT2 0.80 
FT3 0.72 
FT4 0.83 
FT5 0.85 
ICJ 0.38 
MCP2 0.60 
MCP3 0.65 
MCP4 0.63 
MCP5 0.55 
PIP2 0.78 
PIP3 0.65 
PIP4 0.80 
PIP5 0.82 
RCJ 0.58 
UCJ 0.65 
All 0.69 
PD  
All 0.98 
E  
All 0.85 
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 Interim Analysis for USEFUL study 
We planned an interim analysis to decide the power for the main study.  We needed to determine 
which of the clinical variables (e.g. tender joint counts or VAS) was most strongly correlated with 
patient-reported change in pain.  That variable would be used to compare improvement in patients 
with or without ultrasound at baseline. These data can then be used to power the primary 
endpoint. 
After the first 70 patients have completed 6 weeks follow-up, the rate of ultrasound activity 
(presence of any joint scoring GS≥2 and/or PD≥1) at baseline have been calculated at the group 
level.  Changes in each of the candidate primary outcomes have been correlated with the Likert 
scores for response to therapy at both 2 and 6 weeks.  The candidate outcome with the strongest 
association was selected as the primary outcome; the visit at which the strongest association is 
identified was selected as the primary endpoint.  The baseline mean and follow-up standard 
deviation of the chosen outcome calculated in all patients were used to calculate a revised sample 
size, taking into account the estimated rate of ultrasound activity. 
For the musculoskeletal domains of the existing measures BILAG (2004) and SLEDAI-2K, 
changes at 2 and 6 weeks were recorded as improved, same or worse. This is because these 
variables show little scope for change; SLEDAI-2K can only take the values 0 or 4, whilst BILAG 
(2004) domains A-E can be assigned values 12, 8, 1, and 0 respectively. 
4.3.1 The results of the Interim analysis: 
The pilot phase analysis included the first 70 patients.  Of the candidate primary outcomes, at 
both week 2 and 6, EMS VAS was the most strongly correlated with patient-reported change in 
pain (Table 4-5).  The correlation was strongest at week 2.  This was also the case for EMS 
(minutes) and patient-reported painful joint count; for the remaining variables, stronger 
associations were found at week 6 than week 2. 
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Deviation from the planned analysis: Although the statistical analysis plan stated that 
bootstrapped confidence intervals for the differences in correlations between variables would be 
presented, this has not been possible.  In some bootstrapped samples the imputation model 
failed, due to the large number of parameters being estimated relative to the number of patients 
in the pilot phase.  However, the imputation model in the main sample was successful.  The lack 
of confidence intervals does not affect the definition of the primary outcome, which was intended 
to be based on the maximum observed point estimate of the correlation. 
4.3.2 Implications for the main trial 
The primary endpoint for the main trial will be EMS VAS (mm) at 2 weeks; EMS VAS at 6 weeks, 
and the remaining candidate variables at both 2 and 6 weeks were deemed secondary endpoints.  
In terms of study statistical power calculation; at alpha=0.05, 1-Beta=0.8 it required 130 patients 
in total to show a difference of 20% of the baseline value in EMS VAS at 2 weeks between those 
with active ultrasound in at least one joint and those without active ultrasound (Table 4-6). 
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Table 4-5: Kendall's tau-a correlations with patient-reported change in pain: 
Variable W2 W6 W2 - W6 cf. EMSVAS W2 cf. EMSVAS W6 
TJC68 -0.036 0.154 -0.190 0.328 0.006 
SJC66 -0.070 0.125 -0.195 0.362 0.034 
Physician MSK DisAct VAS 0.049 0.117 -0.068 0.243 0.042 
SLEDAI MSK 0.053 0.157 -0.104 0.239 0.002 
BILAG MSK 0.021 0.150 -0.129 0.270 0.009 
HAQ-DI 0.062 0.124 -0.062 0.230 0.036 
Patient MSK DisAct VAS 0.117 0.153 -0.036 0.174 0.007 
MSK Pain VAS 0.232 0.088 0.145 0.059 0.072 
EMS VAS 0.291 0.159 0.132 - - 
EMS mins 0.279 0.070 0.209 0.012 0.089 
Painful Joint Count 0.135 0.147 -0.011 0.156 0.013 
TJC: tender joint count, SJC: swelling joint count, EMS: early morning stiffness, BILAG: British Isles 
Lupus Assessment Group, SLEDAI: Systemic Lupus Erythematosus Disease Activity, HAQ: Health 
assessment questionnaire, VAS: visual analogue Scale, MSK: musculoskeletal  
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Table 4-6: Sample size calculation:  
Alpha 0.05 
Power 80% 
Mean EMS BL (n=70) 70.40 
Mean EMS BL (n=70) minus 20% 56.32 
Standard deviation of EMS at 2 weeks 28.16 
Proportion US active (n/70)  0.59 (41) 
Ratio %inactive:%active  0.71 
Correlation (r) EMS VAS BL vs 2 weeks  0.31 
Total required (unadjusted) 130 
Total required adjusting for correlation and 10% dropout 
((1-(r squared))*(N))*(1/0.9) 
130 
EMS: early morning stiffness, VAS: visual analogue scale, US: ultrasound 
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 USEFUL Full Study population overview 
A total of 133 consecutive patients were recruited (126 females and 7 males) in seven centres 
(Table 4-7).  The majority of patients were recruited in Leeds.  Baseline demographic data are 
shown in Table 4-8.  The mean age was 46.1, range 17-78 and standard deviation 13.5.  The 
vast majority of the patients were white (62%) followed by South Asian (26%), 11% were black 
and 2% had another ethnicity.  
Table 4-7. Recruitment summary: 
Center Number of patients 
Leeds 107 
Bradford 10 
Doncaster 7 
Southampton 3 
UCL 2 
King’s 2 
Blackburn 2 
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Table 4-8: Demographics USEFUL (full study) 
 All patients US activity at baseline Difference 
(95% CI) 
Test 
statistic, P 
value 
Inactive Active 
N=133 N=55 N=78 
Age (years) 
    Mean (SD), range 
46.1 (13.5), 17.0 to 78.0 47.9 (12.3), 25.0 to 76.0 44.8 (14.3), 17.0 to 78.0  3.1 (-1.6,  7.8) t=1.32, 
p=0.190 
    Median (IQR) 47.0 (35.0, 55.0) 50.0 (36.0, 57.0) 45.0 (34.0, 54.0)  
Disease duration (y) 
    Mean (SD), range 
9.3 (8.9), 0.1 to 40.0 10.2 (9.8), 0.1 to 40.0 8.7 (8.1), 0.1 to 35.0  1.5 (-1.6,  4.5) t=0.93, 
p=0.352 
    Median (IQR) 6.0 (2.0, 15.0) 7.0 (2.0, 17.0) 5.0 (2.0, 15.0)  
Sex n/N (%)     chisq=5.21, 
p=0.022      Male 7/133 (5) 0/55 (0) 7/78 (9)  
     Female 126/133 (95) 55/55 (100) 71/78 (91)  
Ethnicity n/N (%)     chisq=6.06, 
p=0.195      White 82/133 (62) 40/55 (73) 42/78 (54)  
     South Asian 34/133 (26) 11/55 (20) 23/78 (29)  
     Black 14/133 (11) 3/55 (5) 11/78 (14)  
     East Asian 1/133 (1) 0/55 (0) 1/78 (1)  
     Other 2/133 (2) 1/55 (2) 1/78 (1)  
SD: standard deviation, IQR: interquartile range 
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4.4.1 Baseline clinical characteristics 
Antimalarial medication (Hydroxychloroquine) was used in 89/133 patients (66%).  Forty (40/133) 
patients (30%) received oral immunosuppressant with or without hydroxychloroquine 
(Methotrexate = 16, Azathioprine = 11, Mycophenolate mofetil = 13).  31/133(23%) were on low-
dose glucocorticoid(less than 5 mg prednisolone or equivalent). 27/133(20%) were receiving 
NSAID (which stopped at least three days before the scan).  Rates of -musculoskeletal-BILAG 
abnormalities in the musculoskeletal study group were; BILAG A: 14/133(11%); BILAG B: 
52/133(39%); BILAG C: 65/133(49%).  Overall, 78/133(58.6%) patients had abnormal ultrasound 
findings during the baseline visit and 55/133(41.4%) had normal ultrasound scan.  More details 
on baseline characteristics are given in the results of chapters 7 and 8. 
4.4.2 Symptoms and signs of other musculoskeletal diseases 
As it is often confusing to the assessor if the pain is due to SLE or other conditions such as 
fibromyalgia or osteoarthritis, assessors were asked about their opinion of the musculoskeletal 
diagnoses (tick lists – Yes/No or free text) 
 Inflammatory features: EMS, distribution, symmetry, swelling, serology, other SLE features, 
and prior therapy response. 
 Fibromyalgia features: Fatigue, waking un-refreshed, cognitive symptoms, somatic 
symptoms, and consultant’s overall opinion. 
 Osteoarthritis features: Hard tissue enlargement of two or more selected joints, hard tissue 
enlargement of DIPs, deformities consistent with OA, previous radiographic evidence in 
symptomatic sites, consultant overall opinion. 
32/133 patients were judged by the assessor to have fibromyalgia of whom 18/32 had abnormal 
ultrasound scan.  In terms of osteoarthritis, the assessor said 36/133 had osteoarthritis of them 
20/36 OA patients had abnormal ultrasound scan (GS or PD). 
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4.4.3 Patient disposition 
In week 2 visit, 122 patients attended (2 withdrawn, 5 did not attend and 4 lost follow up).  In week 
6 visit 121 attended (three withdrawn, three did not attend and five patients lost their follow up).  
The main cause of patients withdrawn was the need to start other treatments which were not 
permitted in the study protocol Table 4-9. 
Table 4-9: Retention of patients in USEFUL (full study) 
 All patients 
  
 N=133 
Baseline  
     Attended 133/133 (100) 
Week 2  
     Attended 122/133 (92) 
     Withdrawn 2/133 (2) 
     Did not attend 5/133 (4) 
     Lost to follow-up 4/133 (3) 
Week 6  
     Attended 121/133 (91) 
     Withdrawn 4/133 (3) 
     Did not attend 3/133 (2) 
     Lost to follow-up 5/133 (4) 
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Chapter 5: Cross-Sectional Study: Defining 
Musculoskeletal Manifestations in Systemic Lupus 
Erythematosus 
 Introduction: 
Defining active disease in systemic lupus erythematosus is challenging for both clinical trials 
and routine practice.  In clinical trials, the difficulty with defining active disease has been 
illustrated by a series of recent negative trials of promising new treatments.  For example, in 
the belimumab programme, a negative phase II trial was followed by positive phase III data 
after the target population and primary endpoints were revised [154].  In routine practice, 
there is an increasing emphasis on defining active disease.  First, because of the need to 
decide on biologic prescription.  Second, for treat-to-target strategies that aim to treat to a 
target of low disease activity while minimizing glucocorticoid exposure [393]. 
Inflammatory musculoskeletal (MSK) symptoms are common in SLE, being the first 
presenting symptom in around 50% of cases and affecting up to 95% of patients at some 
point[124, 158].  Joint pain in SLE has a great impact on quality of life and results in loss of 
function [7, 124, 394].  Accordingly, musculoskeletal disease is a common reason for 
inclusion in clinical trials.  For example, in the phase III ILLUMINATE study, at baseline 81% 
of patients had musculoskeletal activity defined by the SLE Disease Activity Index (SLEDAI) 
[395]. 
Currently, musculoskeletal disease activity is defined using musculoskeletal items in the 
SLEDAI [396] and BILAG (BILAG 2004) [169].  Although both are validated, there are face 
validity problems with these tools.  They were designed to assess multi-organ system disease 
and therefore capture less detail on an individual organ system compared with organ-specific 
instruments such as the DAS28 used in RA [397].  For example, SLEDAI scores four points 
for arthritis affecting two or more joints and none for lesser degrees of arthritis.  Therefore, 
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there is no difference in score between a swollen joint count of 28 and two.  Joints are 
considered affected if there is tenderness, warmth, swelling or effusion.  The BILAG index 
allows differentiation of severe synovitis (BILAG-A), moderate synovitis (BILAG-B) and 
inflammatory arthralgia (BILAG-C), as well as reduction of A and B scores to B and C 
respectively if symptoms are improving. Importantly, because of the need to assess a wide 
spectrum of symptoms in SLE, assessors must determine whether features are due to SLE or 
another pathology for both indices. 
Modern imaging has brought a greater understanding to RA and explained the discrepancies 
in clinical and objective imaging-defined synovitis.  In low disease activity states, such as early 
arthritis or remission, musculoskeletal ultrasound-detected synovitis has been shown to 
explain the long-term adverse consequences [398, 399]. 
Data on musculoskeletal ultrasound in SLE are limited and also ultrasound is not commonly 
used in practice or trials.  In a systematic review, we found that several studies reported 
ultrasound -detected abnormalities in SLE but were inconsistent with their reported prevalence 
of abnormality[121].  Probably due to methodological differences such as failure to clearly 
separate rhupus from ‘pure’ SLE, controlling for NSAIDs and glucocorticoids, and reporting 
OMERACT criteria.  Furthermore, no study has confirmed the clinical significance of 
ultrasound synovitis. 
I therefore studied a large cohort of patients with objective measures of synovitis in order to 
define the population of patients who should be included in clinical trials and receive 
escalation, tapering or avoidance of glucocorticoids, conventional and biologic therapies in 
routine practice.  In order to be able to estimate the prevalence of each clinical and ultrasound 
presentation in a general SLE population, I recruited unselected, consecutive patients with 
inflammatory musculoskeletal symptoms.  I addressed the issues with previous ultrasound 
studies by controlling for rhupus, NSAID and glucocorticoid therapy and reporting OMERACT 
grades of abnormality. 
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 Hypothesis 
There is a considerable proportion of SLE patients with objective (ultrasound detected) 
musculoskeletal inflammation that is symptomatic but not detected by existing clinical 
instruments. 
 Objective 
To evaluate a cross-sectional cohort of consecutive Systemic Lupus Erythematosus patients 
with musculoskeletal symptoms for both clinical and ultrasound synovitis, and determine the 
clinical associations of subclinical synovitis. 
 Patient and Methods 
A cross-sectional observational study was conducted in one hundred and twelve consecutive 
SLE patients with active inflammatory musculoskeletal symptoms in two UK centres (Leeds 
and Southampton).  Eighty-eight consecutive patients with inflammatory musculoskeltal 
symptoms and 24 asymptomatic SLE controls were recruited.  Patients had different clinical 
assessments (BILAG, SLEDAI, joint counts, patient and physician visual analogue score), 
routine laboratory tests and ultrasound of two hands and wrists. 
Inclusion criteria were:  
1.  Meet ACR/SLICC criteria for SLE. 
2. Musculoskeletal symptoms deemed by the investigator to represent active SLE (patients 
need not have clinical synovitis but must have evidence to support inflammatory cause of 
symptoms (e.g. morning stiffness, raised inflammatory markers and no more likely 
alternative diagnosis for these symptoms such as osteoarthritis). 
3. Stable dose of immunosuppressant therapy in the past six weeks (methotrexate, 
mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, 
cyclophosphamide, intravenous immunoglobulin, belimumab or other regular biologic 
therapy). 
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4. A cohort of patients who had SLICC diagnostic criteria for SLE but no current inflammatory 
musculoskeletal symptoms (MSK-BILAG D or E) were recruited as a control group.   
Exclusion criteria 
1-Patients were excluded if they had immunological evidence of rhupus (positive for anti-CCP 
antibodies or Rheumatoid Factor) ever. 
2-Had received an NSAID within three days prior to the intended baseline ultrasound date 
3-Hd received daily glucocorticoid greater than prednisolone 5mg (or equivalent), or have 
received IV/IM glucocorticoid in the past three months. 
Patients with improving disease were excluded.  This allowed grouping of symptomatic 
patients into clinically comparable three BILAG categories: severe clinical synovitis with loss 
of function (musculoskeletal (MSK) BILAG A), mild to moderate synovitis (MSK-BILAG B), 
inflammatory symptoms but no synovitis (MSK-BILAG C).   
 Ethical Approval: 
All individuals provided informed written consent and this research was carried out in 
compliance with the Declaration of Helsinki. All procedures were performed in accordance 
with relevant guidelines and regulations. The University of Leeds was contracted as administer 
sponsorship. 
 Clinical assessment 
Clinical assessments were performed by rheumatologists blinded to the ultrasound 
assessment with training and experience in relevant indices.  Overall disease activity was 
assessed using BILAG-2004, SLEDAI-2K and damage was assessed using the SLICC 
(SLICC-DI).  Musculoskeletal components of BILAG-2004 and SLEDAI-2K were summarized 
separately as MSK-BILAG (A-E) and MSK-SLEDAI (0 or 4 points) for analyses.  Joint disease 
was also assessed using 66/68 tender and swollen joint counts, symptomatic joint count, 
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physician global visual analogue score (VAS, 0–100 mm) and patient’s disease activity VAS 
(0–100 mm) and DAS28-ESR (four variables). 
 Ultrasound assessment: 
Ultrasound  was performed using high resolution ultrasound machines; General Electric ( GE 
Healthcare, Chicago, IL) Logiq E9 ultrasound with multi-linear 6–15 MHz transducer in Leeds 
and Esaote (Genoa, Italy) MyLab 70. Ultrasound with multi-linear 5.0–13.0 MHz transducer in 
Southampton.  All sonographers (one in Southampton and two in Leeds) were trained in 
musculoskeletal ultrasound and blinded to clinical status.  Power Doppler was assessed with 
the highest gain level without background noise, pulse repetition frequency of 750 Hz and 
medium wall filter. 
 Laboratory assessment: 
Different laboratory tests were done and that included C-Reactive Protein (CRP) (mg/l), 
Erythrocyte Sedimentation Rate (ESR) (mm/h), Rheumatoid Factor(RF) (IU/ml), Cyclic 
Citrullinated Peptide(CCP) antibodies (CCP, IU/ml), complements (C3 and C4, g/l), Anti-
nuclear Anti-body( ANA), Extracted Nuclear Antibodies including anti-dsDNA, anti Ro, anti La, 
anti-chromatin, anti Sm, anti-RNP (using Bioplex 2200) and immunoglobulins (IgA, IgM, IgG, 
using nephelometry) were measured on the same day of the visit in an accredited clinical 
diagnostic laboratory. 
 Statistical analysis 
Patients were classified according to BILAG groups (MSK-BILAG=A, B, C and D/E) and 
SLEDAI groups (MSK-SLEDAI = 0 or 4 points).  Overall clinical characteristics (demographics, 
therapies, clinical joint assessments and immunological parameters) and ultrasound 
characteristics were summarized for each group using proportions of patients or median and 
interquartile range as appropriate.  Ultrasound abnormalities were calculated as total GS, PD, 
erosions and tenosynovitis as well as numbers of joints with abnormal GS (⩾2), PD (⩾1), 
erosions or tenosynovitis (as any GS and/or PD abnormality in the tendon sheath).  
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Association of BILAG grade and erosions with patient groups were tested using Fisher’s exact 
test.  Level of agreement between clinical assessment and ultrasound when detecting 
synovitis was quantified as the proportion of joints in which both methods exactly agreed over 
the presence or absence of synovitis (percentage exact agreement [PEA]), proportions of 
category-specific negative and positive agreement (Sp0 and Sp1 for absence and presence 
of synovitis, respectively), and the proportions of joints where clinical examination (CE) and 
ultrasound disagreed in either direction (US>CE, US<CE).  The Category-specific agreement 
was defined as the proportion of the total number of positive or negative ratings (CE=US) that 
were concordant; it represents the conditional probability that ultrasound would place a patient 
in category X, given than CE had placed them in that category and vice versa.  The kappa 
statistic was also calculated and supplemented with the prevalence-adjusted bias-adjusted 
kappa to give an indication of the extent to which differences in the overall level of synovitis 
identified by each assessment method together with imbalances in the proportions of joints 
with and without synovitis affected the calculated value of kappa. 
Patients with inflammatory symptoms without clinical joint swelling (MSK-BILAG-C) were 
divided into ‘subclinical synovitis’ and ‘normal’ groups based on: GS ⩾ 2 in ⩾1 joint; PD ⩾1 in 
⩾1 joint; GS ⩾ 1 or PD ⩾ 1 in ⩾ 1 tendon sheath. For each abnormality, we compared: clinical 
(patient- and physician-VAS, tender and symptomatic joint count, DAS28-ESR); 
immunological parameters that differed in BILAG groups (total serum IgG, ESR); and 
ultrasound erosions, using Mann–Whitney-U tests. 
All tests were conducted at a two-sided 5% level of significance. Statistical analyses were 
performed using IBM SPSS Statistics v24. 
 Results 
5.10.1 Recruitment 
In order to be able to estimate the prevalence of each clinical and ultrasound presentation in 
a general SLE population, our group recruited unselected, consecutive patients with 
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inflammatory musculoskeletal symptoms. 307 patients enrolled in observational research 
studies were clinically assessed.  
Figure 5-1. Recruitment flow chart: 
 
5.10.1.1 Patient characteristics 
Patient recruitment is shown in Figure 5-1 of consecutive patients clinically assessed, 184 
had musculoskeletal symptoms deemed to be inflammatory.  Rates of BILAG abnormality in 
the overall group were BILAG A: 25/184 (13.5%); BILAG B: 44/184 (24%); BILAG C: 
114/184 (61.9%). A further 116 patients had no active musculoskeletal symptoms (101 with 
previous involvement recorded, 87%).  There were 112 consecutive SLE patients recruited 
into the musculoskeletal study (Leeds: 92; Southampton: 20).  These included 89 
consecutive patients with active musculoskeletal symptoms who consented to participate. 
We also recruited 23 of the patients with prior musculoskeletal involvement.  All 100% were 
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ANA positive.  They were predominantly female (108/112, 96%). Median (interquartile range) 
age was 46.5 (34, 57) and disease duration 60 (24, 168).  Median SLICC damage index was 
0 (0, 1).  There were 46/112 patients (41%) treated with HCQ alone and 43/112 (38%) 
received oral immunosuppressant with or without HCQ (methotrexate = 15, azathioprine = 
10, mycophenolate mofetil = 18). Thirteen had received previous rituximab and 42/112 were 
on low-dose glucocorticoid. Rates of -MSK-BILAG abnormalities in the musculoskeletal 
study group were very similar to the overall group: BILAG A: 14/89 (15.7%); BILAG B: 20/89 
(22.5%); BILAG C: 54/89 (60.7%). Other baseline demographics and clinical characteristics 
are presented in Table 5-1 
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Table 5-1. Clinical and serological characteristics according to musculoskeletal disease status: 
 All Patients 
Patients with MSK Symptoms No MSK 
Symptom 
 BILAG SLEDAI 
MSK- 
BILAG=A 
MSK- 
BILAG=B 
MSK- 
BILAG=C 
MSK-SLEDAI=4 MSK-SLEDAI=0 
MSK-
BILAG=D and 
MSK-
SLEDAI=0 
No. of patients 112* 14 20 54           28 61 23 
Disease duration  60 (24,168) 36 (12,180) 36 (18,180) 84 (24,168) 84 (24,168) 51 (21.5,168) 108 (53.3,171) 
Age mean(range) 46.5 (34,57) 49 (36,59) 46.5 (33,55) 49 (37.5,58) 45 (18,73) 41.5 (31.2,51.7) 35 (26,53) 
Therapy 
Steroid, N (%) 42/112 (38%) 3/14 (21%) 10/20 (50%) 17/54 (30%) 19/28 (68%) 38/61 (62%) 12/23 (52%) 
HCQ only, N (%) 55/112 (49%) 7/14 (50%) 9/20 (45%) 32/54 (58%) 15/28 (54%) 33/61 (54%) 7/23 (30%) 
Oral Immunosuppressant, N (%) 42/112 (38%) 4/14 (29%) 9/20 (45%) 20/54 (36%) 9/28 (32%) 24/61 (39%) 9/23 (31%) 
Rituximab, N (%) 22/112 (20%) 2/14 (14%) 2/20 (10%) 5/54 (9%) 3/28 (11%) 6/61 (10%) 4/23 (17%) 
Clinical Assessment 
TJC 5 (1,11) 9 (5,18) 7(2,13) 7 (2,12) 5 (9,13) 6 (2,12) 0 (0, 0) 
SJC 0 (0,2) 4 (3, 9) 2 (1,2) 0 (0,0) 3(2,5) 0(0,0) 0 (0, 0) 
Patients arthritis VAS 50 (24,70) 70 (40,84) 57 (46, 70) 50 (40,70) 63 (43,77) 20 (8.5,31) 0 (0, 22) 
Physician VAS 20 (3,50) 67 (55, 76) 50 (32, 60) 15 (7, 22) 60 (35,70) 50 (40,70) 0 (0, 0) 
Symptomatic joints 5 (0,13) 10 (5,20) 9 (2,17) 7 (2,13) 10 (5,17) 6.5 (1,13) 0 (0, 0) 
Total SLEDAI 4 (0,6) 6 (4,8) 6.0 (4, 8) 2 (0, 5.5) 6 (4,8) 5.5 (4, 8) 0(0, 2) 
SLICC-DI 0 (0,1) 0 (0, 1) 0 (0, 1) 0 (0, 0) 0 (0,0) 0(0,1) 0 (0, 0) 
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 All Patients 
Patients with MSK Symptoms No MSK 
Symptom 
 BILAG SLEDAI 
MSK- 
BILAG=A 
MSK- 
BILAG=B 
MSK- 
BILAG=C 
MSK-SLEDAI=4 MSK-SLEDAI=0 
MSK-
BILAG=D and 
MSK-
SLEDAI=0 
CRP 5 (5,8) 5 (5,11) 5 (5,10) 5 (5,10) 5 (5,15) 5 (5,7.5) 5 (5, 5) 
ESR 20 (9,42) 47 (11,81) 31 (12,42) 14 (9,40) 32 (10,58) 16 (9,41) 12 (4,23) 
Serology 
IgG 12.6 (9.7,17.5) 13 (10,20) 18 (9,21) 12.7 (11,15) 14 (11,20) 12.5 (10,16) 11 (9,16.5) 
Raised Anti-dsDNA, N (%) 36/108 (33%) 6/14(43%) 5/18 (28%) 16/52 (31%) 8/27 (30%) 19/58(33%) 8/23 (35%) 
Low C3, N (%) 11/104 (11%) 3/14 (21%) 5/15 (33%) 8/52(15%) 20/28 (71%) 3/58 (5%) 7/22 (32%) 
Low C4, N (%) 20/104 (19%) 2/11 (17%) 4/14 (21%) 8/49 (16%) 18/28 (64%) 7/58 (12%) 8/20 (36%) 
All values presented are median (1stQuartile, 3rd Quartile) unless otherwise stated. SLICC-DI = SLICC damage index. *1    patient with missing 
BILAG/SLEDAI data was excluded from further analysis. BILAG: British Isles Lupus Assessment Group: SLEDAI: Systemic Lupus Erythematosus 
Disease Activity, TJC: tender joint count. SJC: swollen joint count, CRP, ESR: erythrocyte sedimentation rate
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Table 5-2. Frequencies of different US abnormalities in BILAG and SLEDAI groups: 
 
All patients 
(n=112) 
Patients with MSK symptoms No MSK 
symptom 
 BILAG SLEDAI 
MSK-
BILAG=A 
(n=14) 
MSK-
BILAG=B 
(n=20) 
MSK-
BILAG=C 
(n=54) 
MSK-
SLEDAI = 4 
(n=28) 
MSK-
SLEDAI = 0 
(n=61) 
MSK 
BILAG=D 
(n=23) 
Overall Synovitis (GS ≥ 2 and/or PD≥1) 57% 100% 85% 53% 86% 52% 17% 
Total PD synovitis 39% 100% 65% 30% 79% 36% 4% 
Total mod-severe PD synovitis 26% 100% 35% 13% 64% 26% 4% 
Total erosions 9% 29% 20% 4% 25% 4.8% 100% 
Tenosynovitis 25% 57% 35% 24% 43% 21% 0% 
Hands synovitis 57% 100% 85% 52% 86% 67% 17% 
Hands mild PD synovitis 50% 100% 75% 44% 86% 55% 9% 
Hands mod-severe PD synovitis 29% 93% 50% 15% 64% 31% 0% 
Hand erosions 13% 29% 20% 11% 29% 12% 0% 
Hands tenosynovitis 18% 57% 30% 11% 39% 19% 0% 
Feet synovitis 27% 44% 20% 26% 43% 19% 22% 
Feet mild PD synovitis 9% 14% 13% 13% 7% 12% 0% 
Feet mod-severe PD synovitis 2% 14% 0% 0% 2% 0% 0% 
Feet erosions 5% 7% 10% 4% 7% 5% 4% 
Total GS score, median (1st, 3rd Q) 4(1,15) 27 (19, 41) 11 (4, 20) 3.5(1, 7.25) 3(1,8) 4(1, 11) 2 (0, 6) 
Total PD score, median (1st, 3rd Q) 0(0,3) 13.5 (6, 26) 1 (0, 6.8) 0 (0, 1) 0(0,1) 0(0,2.3) 0 (0, 0) 
Total Erosion score, median (1st, 3rd Q) 0(0,0) 0 (0, 2) 0 (0, 1) 0(0,0) 0(0,0) 0(0,0) 0 (0, 0) 
Total TS GS score, median (1st, 3rd Q) 0(0,0) 0 (0, 3) 0 (0, 0) 0(0,1) 0(0,0) 0(0,0) 0 % 
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All patients 
(n=112) 
Patients with MSK symptoms No MSK 
symptom 
 BILAG SLEDAI 
MSK-
BILAG=A 
(n=14) 
MSK-
BILAG=B 
(n=20) 
MSK-
BILAG=C 
(n=54) 
MSK-
SLEDAI = 4 
(n=28) 
MSK-
SLEDAI = 0 
(n=61) 
MSK 
BILAG=D 
(n=23) 
Total TS PD score, median (1st, 3rd Q) 0(0,0) 0 (0, 2) 0 (0, 0) 0(0,0) 0(0,0) 0(0,0) 0 (0,0) 
% PD score of 1 in hands 37% 86% 60% 30% 68% 36% 0% 
% PD score of 2 in hands 29% 93% 50% 15% 64% 31% 0% 
% PD score of 3 in hands 9% 36% 10% 4% 21% 7% 0% 
% Erosion=1 in hands 12% 21% 20% 11% 29% 10% 0% 
% Erosion=2 in hands 5% 14% 15% 2% 14% 2% 0% 
% Erosion=3 in hands 2% 7% 5% 0% 1% 2% 0% 
All values presented as % of patients unless otherwise stated. BILAG: British Isles Lupus Assessment Group: SLEDAI: Systemic Lupus Erythematosus Disease 
Activity .GS: gray scale, PD: power Doppler. 
GS scoring was as follows; 0 = no synovial hypertrophy, 1 = mild hypertrophy, 2 = moderate hypertrophy, and 3 = severe hypertrophy. The PD scoring was as 
follows; 0 = absence of signal, no intra-articular flow; 1 = mild hyperaemia, one or two vessels signal (including one confluent vessel); 2 = moderate hyperaemia, 
(>grade 1) and less than 50% of GS area; 3 = marked hyperaemia, vessels signal in more than half of the synovial area [296, 309] The erosion scoring was as 
follows; 0 = no erosion, 1 = small erosion/ minimal bone surface area affected <1/3 of joint quadrant, 2 = moderate size erosions/ moderate bone surface area 
affected <2/3 of joint quadrant hypertrophy, and 3 = large size erosion/ severe bone surface area affected ≥2/3 of joint quadrant)[308]. 
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5.10.2 Most symptomatic patients do not have clinical synovitis 
In this consecutive series, most patients with active musculoskeletal symptoms (as defined 
above) did not have clinical synovitis on clinical examination (and therefore did not meet levels 
of BILAG and SLEDAI criteria usually required for entry into clinical trials or to start biologic 
therapy).  Of the 88 patients deemed by clinicians to have symptoms due to active 
inflammatory SLE, clinical inflammation was seen defined by BILAG A or B in 38% (34/88) or 
defined by the SLEDAI-MSK criterion in 32% (28/88). The others were classified as BILAG-C 
or MSK-SLEDAI = 0. 
5.10.2.1 Ultrasound revealed a large group of patients with subclinical synovitis 
I next compared the ultrasound findings according to clinical assessment (Table 5-2).  This 
revealed a large group of patients with subclinical synovitis confirmed on ultrasound that was 
not detected clinically.  Overall, 68% (60/88) of symptomatic patients had ultrasound 
inflammation (GS ⩾ 2 and/or PD ⩾ 1 or tenosynovitis) compared with 17% (4/23) of 
asymptomatic patients.  Therefore, in patients with inflammatory symptoms, I observed three 
major groups (Figure 5-2) (1) Clinical synovitis: (38%) 34/88 patients had one or more swollen 
joint, scoring BILAG A or B; (2) Subclinical synovitis (27%) 24/88 patients had no swollen joint 
but confirmed ultrasound abnormality; (3) No confirmed synovitis, with no swollen joint and no 
significant ultrasound abnormality in 30/88 (34%). 
5.10.3 Sensitivity and specificity of clinical definitions of active disease 
Overall, there was ultrasound confirmed joint inflammation defined by BILAG A or B in (38%) 
34/88, defined by SLEDAI-MSK criterion (32%) 28/88; and defined by GS ⩾ 2 and/or PD ⩾ 1 
or tenosynovitis in (61%) 54/88.  Only 4/88 patients were reported to have clinical joint swelling 
not confirmed by Ultrasound. 
BILAG A/B had sensitivity (95% CI) of 56% (41, 69%) and specificity of 89% (72, 96%). 
SLEDAI-MSK criterion had sensitivity of 44% (31, 59%) and specificity of 89% (72, 96% 
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Figure 5-2 Patients categories 
 
5.10.4 Validation of BILAG A and B 
Ultrasound validated the distinction between BILAG-A and B MSK disease. All BILAG-A 
patients had moderate to severe PD synovitis compared with only 35% of BILAG-B (P < 
0.0001). 
5.10.5 Erosions 
Ultrasound revealed erosive disease in non-rhupus SLE (Figure 5-3).  The presence of 
erosions correlated with clinical synovitis (29% of MSK-BILAG-A vs. 4% of MSK-BILAG-C, P = 
0.0126; 25% of MSK-SLEDAI = 4 vs. 5% of MSK-SLEDAI = 0, P = 0.005).  Erosions tended 
to be mild and not affecting multiple joints.  
27%
38% 
34%
Patients categorisation
Subclinical Synovitis
Clinical Synovitis
No confirmed Synovitis
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Figure 5-3. Ultrasound image: 
 
Erosion in SLE patient US synovitis and erosions detected in SLE patients (A): Grade 2 GS synovitis 
in fourth MCP joint, (B): grade 3 PD synovitis in fourth MCP joint, (C): Longitudinal view of an erosion 
in a second MCP joint, (D): Transverse view of the same erosion seen on (C). GS: grey scale. 
5.10.6 Joint-by-joint agreement between clinical and ultrasound assessment 
Overall agreement between clinical and ultrasound assessment on joint-by-joint analysis, as 
measured by Kappa and prevalence-adjusted-bias-adjusted Kappa, was reasonably good 
(table5.10.6).  However, when analysing specific agreement for the presence or absence of 
synovitis there was considerable disagreement, indicating a degree of inaccuracy of clinical 
assessment in SLE against ultrasound as a gold standard.  For the absence of synovitis, the 
agreement between clinical assessment and ultrasound appeared generally good across all 
joints assessed.  However, this is because most joints were normal by both techniques. For 
the presence of synovitis, the agreement was poor. Therefore, there is no joint in which 
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ultrasound confirmed synovitis could be reliably detected using clinical assessment.  Even in 
the joints with the best agreement (second and third PIP joints), there was only a ∼50% chance 
that if ultrasound detected synovitis were present, it would be detected clinically. 
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Table 5-3. Joint by joint agreement between ultrasound and clinical assessment for synovitis as defined by swollen joints 
Joint 
US 
criterion 
PEA US<clinical US>clinical Sp(-ve) Sp(+ve) Kappa (95% CI) PABAK 
IP1 
 
GS>0 82.0% (141/172) 1.2% (2/172) 16.9% (29/172) 89.8%(274/305) 20.5% (8/39) 0.16 (0.00, 0.31) 0.64 
GS>1 84.3% (145/172) 1.2% (2/172) 14.5% (25/172) 91.3% (282/309) 22.9% (8/35) 0.18 (0.01, 0.36) 0.69 
PD>0 90.1% (155/172) 1.7% (3/172) 8.1% (14/172) 94.7% (304/321) 26.1% (6/23) 0.22 (-0.02, 0.46) 0.80 
GS&PD>1 84.3% (145/172) 1.2% (2/172) 14.5% (25/172) 91.3% (282/309) 22.9% (8/35) 0.18 (-1.56, 1.93) 0.69 
MCP1 
 
GS>0 80.0% (140/175) 1.1% (2/175) 18.9% (33/175) 88.4% (266/301) 28.6% (14/49) 0.22 (-1.31, 1.75) 0.60 
GS>1 89.5% (154/172) 1.2% (2/172) 9.3% (16/172) 94.2% (294/312) 43.8% (14/32) 0.39 (0.17, 0.61) 0.79 
PD>0 94.8% (163/172) 1.7% (3/172) 3.5% (6/172) 97.2% (314/323) 57.1% (12/21) 0.54 (0.28, 0.81) 0.90 
GS&PD>1 89.5% (154/172) 1.2% (2/172) 9.3% (16/172) 94.2% (294/312) 43.8% (14/32) 0.39 (0.17, 0.61) 0.79 
MCP2 
 
GS>0 71.5% (123/172) 4.1% (7/172) 24.4% (42/172) 81.4% (214/263) 39.5% (32/81) 0.25 (0.11, 0.39) 0.43 
GS>1 80.2% (138/172) 7.0% (12/172) 12.8% (22/172) 88.2% (254/288) 39.3% (22/56) 0.28 (0.10, 0.46) 0.60 
PD>0 84.3% (145/172) 7.0% (12/172) 8.7% (15/172) 90.8% (268/295) 44.9% (22/49) 0.36 (-1.56, 2.28) 0.69 
GS&PD>1 80.2% (138/172) 7.0% (12/172) 12.8% (22/172) 88.2% (254/288) 39.3% (22/56) 0.28 (-1.52, 2.08) 0.60 
MCP3 
 
GS>0 61.0% (105/172) 3.5% (6/172) 35.5% (61/172) 74.3% (194/261) 19.3% (16/83) 0.07 (-0.04, 0.17) 0.22 
GS>1 82.0% (141/172) 4.1% (7/172) 14.0% (24/172) 89.6% (268/299) 31.1% (14/45) 0.22 (0.04, 0.41) 0.64 
PD>0 86.0% (148/172) 4.1% (7/172) 9.9% (17/172) 92.2% (282/306) 36.8% (14/38) 0.30 (0.09, 0.50) 0.72 
GS&PD>1 80.2% (138/172) 4.1% (7/172) 15.7% (27/172) 88.5% (262/296) 29.2% (14/48) 0.20 (0.03, 0.37) 0.60 
MCP4 
 
GS>0 62.8% (108/172) 1.2% (2/172) 36.0% (62/172) 76.6% (210/274) 8.6% (6/70) 0.03 (-0.67, 0.74) 0.26 
GS>1 82.0% (141/172) 1.2% (2/172) 16.9% (29/172) 89.9% (276/307) 16.2% (6/37) 0.12 (-1.35, 1.59) 0.64 
PD>0 90.1% (155/172) 1.2% (2/172) 8.7% (15/172) 94.7% (304/321) 26.1% (6/23) 0.23 (-0.01, 0.46) 0.80 
GS&PD>1 82.0% (141/172) 1.2% (2/172) 16.9% (29/172) 89.9% (276/307) 16.2% (6/37) 0.12 (-0.03, 0.26) 0.64 
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Joint 
US 
criterion 
PEA US<clinical US>clinical Sp(-ve) Sp(+ve) Kappa (95% CI) PABAK 
MCP5 GS>0 71.5% (123/172) 0.6% (1/172) 27.9% (48/172) 82.8% (236/285) 16.9% (10/59) 0.11 (0.01, 0.22) 0.43 
GS>1 85.5% (147/172) 0.6% (1/172) 14.0% (24/172) 91.9% (284/309) 28.6% (10/35) 0.24 (0.06, 0.43) 0.71 
PD>0 92.4% (159/172) 0.6% (1/172) 7.0% (12/172) 96.0% (308/321) 43.5% (10/23) 0.40 (0.15, 0.66) 0.85 
GS&PD>1 85.5% (147/172) 0.6% (1/172) 14.0% (24/172) 91.9% (284/309) 28.6% (10/35) 0.24 (0.06, 0.43) 0.71 
MTP1 
 
GS>0 47.4% (55/116) 0.9% (1/116) 51.7% (60/116) 63.9% (108/169) 3.2% (2/63) Not calculated -0.05 
GS>1 71.6% (83/116) 0.9% (1/116) 27.6% (32/116) 83.2% (164/197) 5.7% (2/35) 0.03 (-0.06, 0.11) 0.43 
PD>0 92.2% (107/116) 1.7% (2/116) 6.0% (7/116) 96.0% (214/223) 0.0% (0/9) Not calculated 0.84 
GS&PD>1 72.4% (84/116) 0.9% (1/116) 26.7% (31/116) 83.8% (166/198) 5.9% (2/34) 0.03 (-0.06, 0.12) 0.45 
MTP2 
 
GS>0 71.6% (83/116) 0.0% (0/116) 28.4% (33/116) 83.1% (162/195) 10.8% (4/37) 0.08 (-0.03, 0.18) 0.43 
GS>1 85.3% (99/116) 0.0% (0/116) 14.7% (17/116) 91.9% (194/211) 19.0% (4/21) 0.16 (-0.04, 0.37) 0.71 
PD>0 97.4% (113/116) 1.7% (2/116) 0.9% (1/116) 98.7% (226/229) 0.0% (0/3) Not calculated 0.95 
GS&PD>1 85.3% (99/116) 0.0% (0/116) 14.7% (17/116) 91.9% (194/211) 19.0% (4/21) 0.16 (-0.04, 0.37) 0.71 
MTP3 
 
GS>0 77.8% (91/117) 0.0% (0/117) 22.2% (26/117) 87.1% (176/202) 18.8% (6/32) 0.15 (0.00, 0.30) 0.56 
GS>1 88.0% (103/117) 0.0% (0/117) 12.0% (14/117) 93.5% (200/214) 30.0% (6/20) 0.27 (0.02, 0.51) 0.76 
PD>1 96.6% (113/117) 1.7% (2/117) 1.7% (2/117) 98.2% (224/228) 33.3% (2/6) 0.32 (-0.18, 0.81) 0.93 
GS&PD>1 88.0% (103/117) 0.0% (0/117) 12.0% (14/117) 93.5% (200/214) 30.0% (6/20) 0.27 (0.02, 0.51) 0.76 
MTP4 
 
GS>0 83.6% (97/116) 0.9% (1/116) 15.5% (18/116) 91.0% (192/211) 9.5% (2/21) 0.07 (-0.09, 0.22) 0.67 
GS>1 91.4% (106/116) 1.7% (2/116) 6.9% (8/116) 95.5% (212/222) 0.0% (0/10) Not calculated 0.83 
PD>1 98.3% (114/116) 1.7% (2/116) 0.0% (0/116) 99.1% (228/230) 0.0% (0/2) Not calculated 0.97 
GS&PD>1 
91.4% (106/116) 1.7% (2/116) 6.9% (8/116) 95.5% (212/222) 0.0% (0/10) Not calculated 0.83 
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Joint 
US 
criterion 
PEA US<clinical US>clinical Sp(-ve) Sp(+ve) Kappa (95% CI) PABAK 
MTP5 GS>0 90.5% (105/116) 0.0% (0/116) 9.5% (11/116) 95.0% (210/221) 0.0% (0/11) Not calculated 0.81 
GS>1 98.3% (114/116) 0.0% (0/116) 1.7% (2/116) 99.1% (228/230) 0.0% (0/2) Not calculated 0.97 
PD>0 99.1% (115/116) 0.0% (0/116) 0.9% (1/116) 99.6% (230/231) 0.0% (0/1) Not calculated 0.98 
GS&PD>1 98.3% (114/116) 0.0% (0/116) 1.7% (2/116) 99.% (228/230) 0.0% (0/2) Not calculated 0.97 
PIP2 
 
GS>0 80.8% (139/172) 2.9% (5/172) 16.3% (28/172) 88.3% (248/281) 47.6% (30/63) 0.38 (-1.19, 1.95) 0.62 
GS>1 85.5% (147/172) 3.5% (6/172) 11.0% (19/172) 91.4% (266/291) 52.8% (28/53) 0.45 (0.27, 0.63) 0.71 
PD>0 87.2% (150/172) 6.4% (11/172) 6.4% (11/172) 92.8% (282/304) 45.0% (18/40) 0.38 (0.17, 0.59) 0.74 
GS&PD>1 85.5% (147/172) 3.5% (6/172) 11.0% (19/172) 91.4% (266/291) 52.8% (28/53) 0.45 (0.27, 0.63) 0.71 
PIP3 
 
GS>0 76.7% (132/172) 1.7% (3/172) 21.5% (37/172) 85.1% (228/268) 47.4% (36/76) 0.36 (0.22, 0.50) 0.53 
GS>1 82.6% (142/172) 2.9% (5/172) 14.5% (25/172) 89.4% (252/282) 51.6% (32/62) 0.42 (0.26, 0.59) 0.65 
PD>0 86.6% (149/172) 4.7% (8/172) 8.7% (15/172) 92.2% (272/295) 53.1% (26/49) 0.45 (-1.41, 2.32) 0.73 
GS&PD>1 82.6% (142/172) 2.9% (5/172) 14.5% (25/172) 89.4% (252/282) 51.6% (32/62) 0.42 (0.26, 0.59) 0.65 
PIP4 
 
GS>0 79.1% (136/172) 2.3% (4/172) 18.6% (32/172) 87.8% (258/294) 28.0% (14/50) 0.20 (0.04, 0.36) 0.58 
GS>1 86.6% (149/172) 2.3% (4/172) 11.0% (19/172) 92.5% (284/307) 37.8% (14/37) 0.32 (0.11, 0.52) 0.73 
PD>0 87.2% (150/172) 3.5% (6/172) 9.3% (16/172) 92.9% (290/312) 31.3% (10/32) 0.25 (0.03, 0.47) 0.74 
GS&PD>1 86.6% (149/172) 2.3% (4/172) 11.0% (19/172) 92.5% (284/307) 37.8% (14/37) 0.32 (0.11, 0.52) 0.73 
PIP5 
 
GS>0 82.6% (142/172) 1.7% (3/172) 15.7% (27/172) 90.2% (276/306) 21.1% (8/38) 0.15 (0.00, .031) 0.65 
GS>1 89.5% (154/172) 2.3% (4/172) 8.1% (14/172) 94.4% (302/320) 25.0% (6/24) 0.20 (-0.03, 0.44) 0.79 
PD>0 90.7% (156/172) 2.9% (5/172) 6.4% (11/172) 95.1% (308/324) 20.0% (4/20) 0.16 (-0.09, 0.40) 0.81 
GS&PD>1 
89.5% (154/172) 2.3% (4/172) 8.1% (14/172) 94.4% (302/320) 25.0% (6/24) 0.20 (-0.03, 0.44) 0.79 
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Joint 
US 
criterion 
PEA US<clinical US>clinical Sp(-ve) Sp(+ve) Kappa (95% CI) PABAK 
Wrist 
 
GS>0 57.6% (99/172) 2.3% (4/172) 40.1% (69/172) 70.7% (176/249) 23.2% (22/95) 0.10 (0.01, 0.19) 0.15 
GS>1 79.7% (137/172) 3.5% (6/172) 16.9% (29/172) 88.0% (256/291) 34.0% (18/53) 0.25 (0.08, 0.41) 0.59 
PD>0 80.2% (138/172) 5.2% (9/172) 14.5% (25/172) 88.6% (264/298) 26.1% (12/46) 0.16 (-0.01, 0.34) 0.60 
GS&PD>0 79.1% (136/172) 3.5% (6/172) 17.4% (30/172) 87.6% (254/290) 33.3% (18/54) 0.24 (0.07, 0.40) 0.58 
PEA: Percentage exact agreement; Sp(+ve): proportions of category-specific positive agreement(clinical +ve, ultrasound +ve); Sp(-ve): proportions of 
category-specific negative agreement(clinical –ve, ultrasound –ve); PABAK: Prevalence-adjusted bias-adjusted kappa.
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5.10.7 Subclinical synovitis is associated with objective and symptomatic evidence of 
inflammation 
In the subclinical synovitis group, substantial numbers (30% of MSK-BILAG=C and 26% of 
MSK-SLEDAI = 0) had moderate-severe power Doppler (a severe and specific abnormality). 
Tenosynovitis was common in the subclinical synovitis group, affecting just under half of 
patients. 
To analyse the clinical significance of subclinical synovitis, I selected patients without joint 
swelling.  Because most abnormities were detected in the hands and wrists, and to compare 
with a 28-joint count and DAS28, I analysed ultrasound data in the hands and wrists only. I 
analysed physician VAS, and IgG and ESR, which were associated with clinical synovitis in 
the whole cohort.  These variables were compared according to the presence or absence of 
ultrasound synovitis, as well as the main categories of abnormality: GS, PD and 
tenosynovitis (Table 5-4 ).  Subclinical synovitis was associated with serological evidence of 
disease activity: IgG titre was significantly higher in the presence of overall synovitis (P = 
0.002), GS synovitis (P = 0.003) and PD/tenosynovitis (P = 0.045).  Patients with 
tenosynovitis or PD synovitis also had higher tender joint count (P = 0.024) and showed 
some evidence of higher physician VAS (P = 0.056), and DAS28-ESR (P = 0.061).  Although 
the difference in DAS28 was not significant at alpha = 0.05 the large descriptive difference 
between patients with/without PD/tenosynovitis (median 4.82 vs. 3.09) warrants investigation 
in a larger cohort. 
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Table 5-4. Clinical and serological characteristics of symptomatic patients without joint swelling according to ultrasound status: 
 Overall US Abnormality Grey Scale Tenosynovitis or PD 
 
No 
(n=36) 
Yes 
(n=17) 
P 
No 
(n=38) 
Yes 
(n=15) 
P 
Both – 
(n=43) 
Either + 
(n=10) 
P 
Physician VAS 5 (0,16) 10 (0,25) 0.354 5 (0,17) 7 (0,26) 0.668 5 (0,16) 18 (6,26) 0.056 
Tender 
Joint Count 
1.5 (0,8) 2 (1,9) 0.310 2 (0,8) 2 (1,10) 0.511 1 (0,7) 7 (3,14) 0.024 
IgG 10.9 (9.0,14.0) 
14.8 
(13.9,16.5) 
0.002 
11.2 
(9.0,14.4) 
14.8 
(13.6,16.5) 
0.003 
11.5 
(9.3,14.8) 
16.2 
(13.3,16.5) 
0.045 
ESR 11 (6-33) 20 (11,34) 0.106 11 (6,33) 20 (11,34) 0.106 13 (8,29) 16 (11,88) 0.417 
DAS28-ESR 
3.25 
(1.48,4.41) 
3.43 
(2.52,4.96) 
0.293 
3.25 
(1.48,4.41) 
3.43 
(2.52,4.96) 
0.293 
3.09 
(1.69,4.14) 
4.82 
(2.85,5.31) 
0.061 
Analysis of patients with no joint swelling (MSK-SLEDAI=0). Values are median (IQR). Joints assessed by Ultrasound in this analysis were hands and wrists. 
Clinical assessment was 28 joint set. Tenosynovitis GS1 was considered abnormal
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 Discussion: 
In this study, I reported results from a large cohort of patients. I demonstrated that more than 
25% of SLE patients with inflammatory musculoskeletal symptoms had proven synovitis, 
which is associated with worse clinical and serological assessments but not detected by 
validated disease activity tools. The importance of this result is treating SLE patients with 
common manifestation, as well as for conducting and interpretation of clinical trials. 
 According to the  EULAR taskforce recommendation that in order to achieve the best long-
term outcomes, SLE patients should be treated to a target of low disease activity measured 
using validated instruments while minimum glucocorticoid exposure [24].  BILAG and SLEDAI 
are the instruments most widely used.  These results show the limitation of directing treatment 
according to these instrument in musculoskeletal SLE and their likely consequences. In 
patients with ongoing inflammatory symptoms but not meeting SLEDAI-MSK criteria or BILAG 
A/B, therapy might not be escalated or changed despite definite synovitis.  Despite the current 
therapy Quality of life and work disability are impaired in SLE, and musculoskeletal symptoms 
are one of the strongest determinants of this [25, 26].  Failure to escalate therapy is therefore 
likely to result in serious adverse long-term outcomes. 
Conversely, the treat to target recommendation is focusing on the need to minimize 
glucocorticoid exposure. This is because there is a dose-related association between 
glucocorticoid exposure and accrual of damage [27, 28].  I showed that imaging can identify 
35% of patients who present with seemingly inflammatory symptoms (attributed to SLE activity 
and rated BILAG C) in whom there was no objective evidence of synovitis and glucocorticoids 
would therefore not be the appropriate treatment.  Better tools to assess musculoskeletal 
disease activity would, therefore, help physicians to reduce prescribing of glucocorticoids. 
Treat-to-target regimens have been shown to be effective in RA using clinical criteria, but not 
in more recent studies using ultrasound target [29, 30].  However, there are significant 
 
 
 147 
differences between these diseases and protocols.  In RA all patients have joint swelling at 
some point (to meet criteria) while in SLE this is not essential for the diagnosis. Also, in RA 
the DAS28 captures any tender joint regardless of aetiology, as well as patient VAS.  Whereas 
in SLE, only symptoms deemed to represent SLE disease activity by a physician are rated.  
Therefore, in RA the DAS28 maximizes sensitivity over specificity, while in SLE there is a 
greater emphasis on specificity for true joint inflammation, which has important implications in 
comparison to ultrasound for treating-to-target. 
Identifying active disease is essential to produce reliable clinical trial results.  Placebo 
response rates in SLE trials are notably high, sometimes >40% for SRI-4 in recent phase II 
and III trials [31, 32].  Although I found that joint swelling is usually indicative of ultrasound-
proven synovitis, this is not always required for entry into clinical trials; the SLEDAI allows 
scoring for arthritis based on warmth, tenderness or swelling reported by the patient in the 
past 30 days rather than measured on clinical examination. These criteria have not been 
independently validated.  Further work is required to determine whether superior clinical 
instruments could be defined using ultrasound as a gold standard. 
Several previous studies assessed musculoskeletal ultrasound in SLE, but we identified 
limitations and inconsistencies that the present study was designed to resolve [14, 33–41]. 
Since our group systematic review, one additional study has reported clinical and ultrasound 
findings in a large cohort of patients [42].  There were unusually high rates of ultrasound 
abnormality, e.g., in 85% of asymptomatic patients, with PD in 37% of asymptomatic patients. 
The reason for these unusually high rates is not clear (although some rhupus patients were 
included).  However, because so few patients had normal ultrasound it was not possible to 
address the central objective of my study in their dataset: to describe the prevalence and 
clinical associations of ultrasound synovitis in patients without joint swelling compared with 
patients with swelling, and those with active symptoms but normal ultrasound.  Strengths of 
my study were the recruitment of consecutive patients to allow estimates of prevalence, 
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exclusion of rhupus, control for NSAID and glucocorticoid use and reporting OMERACT 
grades of ultrasound abnormality.  There are a number of choices of OMERACT grades of 
abnormality to be reported.  These may vary by clinical site – for example, GS change is 
commonly seen in the feet in healthy individuals.  I chose to use GS > 2 or PD > 1 based on 
OMERACT definitions and data in other inflammatory arthritides and provide the first analysis 
of the clinical significance of these definitions against symptoms and serology in SLE in our 
paper, as well as a joint-by-joint comparison with clinical evaluation. 
This study has a number of limitations.  Even in this larger patient group, it is difficult to reliably 
assess the symptomatic impact of subclinical synovitis and longitudinal follow-up is required.  
Confirmation that ultrasound positive patients respond better to therapy is needed to confirm 
that ultrasound synovitis should be an indication for immunosuppressive therapy. Longitudinal 
data after treatment is also needed to determine relative responsiveness of ultrasound and 
BILAG/SLEDAI to determine whether existing instruments are underestimating the 
effectiveness of therapy in clinical trials. 
 Conclusion 
The results demonstrate the limitations of the current classification of active musculoskeletal 
SLE based on joint swelling, BILAG and SLEDAI and that a new classification of proven 
musculoskeletal inflammation may allow improvement in outcomes of immunosuppressive 
therapy. 
 Key messages 
1-More than a quarter of SLE patients with arthralgia had objective inflammation on ultrasound 
not detected by the available clinical instruments. 
2-The BILAG and SLEDAI instruments had high specificity but low sensitivity for ultrasound-
confirmed synovitis. 
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3-Ultrasound-only inflammation is associated with worse clinical symptoms and serology in 
comparison with patients with normal scan.  
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Chapter 6: Pilot Longitudinal Study: Responsiveness of 
clinical and ultrasound outcome measures in 
musculoskeletal systemic lupus erythematosus: 
 Introduction 
Inflammatory musculoskeletal features are common in SLE, being the first presenting 
symptom in around 50% of cases and affecting up to 95% of patients at some time [124, 158]. 
Joint pain in SLE has a significant impact on quality of life and results in loss of function [7, 
36, 400].  Accordingly, musculoskeletal disease is a common reason for inclusion into clinical 
trials. 
Recent phase III trials of many putative treatments in non-renal SLE have been negative (with 
the exception of belimumab [401]).  This has led to questions over the most appropriate 
outcome measures to use in SLE trials.  Also, in clinical practice, it is equally important to 
differentiate patients with good or incomplete responses to therapy for treat-to-target 
approaches and to minimize glucocorticoid use [402]. 
While non-renal SLE trials included many different types of organ involvement, 
musculoskeletal disease was most common.  For example, in the pooled data from the study 
of belimumab in subjects with SLE, BLISS52 and BLISS76 trials, 1008/1684 (60%) patients 
had musculoskeletal (MSK)-BILAG A or B at baseline; 991/1684 (59%) had mucocutaneous 
BILAG A or B; and 272/1684 (16%) had haematology A or B; with lower percentages for other 
organ systems.  In the phase III Efficacy and safety of subcutaneous tabalumab in patients 
with SLE (ILLUMINATE) study, at baseline, 81% of patients had musculoskeletal activity on 
the SLEDAI [395] 
In SLE, outcome measures must account for disease activity in many different organs. For 
this reason, less detail is included for each organ compared with more organ-specific 
instruments such as the 28 joint count used in RA.  The SLEDAI and BILAG, and composite 
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endpoints derived from them such as the SLE responder index 4 (SRI-4) and BILAG-based 
composite SLE assessment, are commonly used in trials. 
For musculoskeletal involvement, the SLEDAI-2K [219] is binary, scoring four points for 
tenderness with swelling, effusion, warmth or erythema in two or more joints in the past 30 
days, and none for lesser degrees of arthritis.  This scoring means that patients with a high 
level of disease activity at baseline who have a substantial improvement may be considered 
non-responders.  The BILAG-2004 index[403] is semi-quantitative with four grades for each 
active organ system assessed.  For the musculoskeletal domain, BILAG A (the highest score) 
requires observed active synovitis in more than two joints with marked loss of functional range 
of movements.  BILAG B is scored for tendonitis/tenosynovitis or active synovitis in more than 
one joint (observed or through history) with some loss of functional range of movement (or 
improving BILAG A disease).  BILAG C is scored for inflammatory pain (e.g. with morning 
stiffness) without synovitis (or improving BILAG B disease).  Pain without inflammatory 
symptoms (e.g. pain that clinically appears to be because of osteoarthritis) is scored as BILAG 
D or E, as are patients with previous joint inflammation but no current symptoms.  Assigning 
these grades is dependent on the skill of the assessor, and in both these indices, the assessor 
must only score symptoms that are deemed to be due to active SLE rather than other 
pathologies, which is known to be a difficult distinction for arthralgia in many inflammatory 
arthritides. 
Joint counts and visual analogue scales (VAS) have also been used in many SLE trials, but 
with limited independent validation [386].  Musculoskeletal ultrasound provides an objective 
measure of synovitis that has already been shown to have face and construct validity in SLE 
[308]. In my cross-sectional study(Chapter 5:)  I showed that the BILAG and SLEDAI are 
specific but not sensitive for the detection of synovitis that is ultrasound confirmed and 
associated with worse symptoms and serological abnormality[404].  These various 
instruments have never been compared longitudinally. 
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 Objective: 
The objective of this study was therefore to compare the internal responsiveness of a range 
of clinical outcome measures and ultrasound in SLE patients receiving a therapy of known 
efficacy (glucocorticoids). 
 Patients and methods: 
A prospective pilot study was conducted in 20 Patients fulfilling the Systemic Lupus 
International Collaborating Clinics (SLICC) 2012 diagnostic criteria for SLE with inflammatory 
musculoskeletal symptoms [19] were recruited in Leeds if they had been prescribed 120mg 
intramuscular methylprednisolone acetate(Depo-Medrone) for active musculoskeletal disease 
that day as part of their routine care.  Other eligibility criteria included: patients should be on 
stable doses of NSAID, DMARDs and glucocorticoids (up to prednisolone ≤5mg/day or 
equivalent) for at least six weeks.  Anti-cyclic citrullinated peptide Antibody (CCP) positive 
patients and those with improving disease were excluded. Ultrasound and clinical assessment 
were performed on the day of intramuscular glucocorticoid treatment and repeated after 2 and 
4 weeks to evaluate responsiveness.  I did not withdraw patients based on their baseline 
clinical and ultrasound assessment. 
 Ethical approval: 
The study was approved by the local ethics committee and informed written consent was 
obtained from all patients (Leeds East Research Ethics Committee 10/H1306/88). 
 Clinical and laboratory assessment: 
Clinical assessments were performed by trained rheumatologists who were blinded to the 
ultrasound assessment.  SLE  activity was assessed using BILAG-2004 [169], SLEDAI-2K 30 
days[388] Joint disease was assessed using 28 tender and swollen joint counts, painful joint 
count, physician musculoskeletal visual analogue score (VAS), patient’s musculoskeletal 
disease activity VAS and minutes of early morning stiffness.  BILAG-2004 numerical scores 
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were calculated using the formula A=12, B=8, C=1, D/E=0[170].  The BILAG-2004 is assessed 
over the previous 28 days.  The SLEDAI-2K and SRI-4 have been validated measuring 
symptoms over the previous 10 or 30 days[405, 406].  Response to Depo-Medrone is typically 
seen within a few days. For the purposes of this study, I allowed a 5-day window for follow up 
study visits and patients who reported rapid improvement in symptoms within a few days of 
the injection and for the majority of the period since the baseline visit to have a 4-week 
response at the last assessment. 
 Patients were tested at baseline for routine inflammatory and serological markers. SLE 
Responder Index (SRI-4) was calculated as previously described[3].  SRI-4 response criteria 
were met if the patient had: at least a 4-point reduction in the SLEDAI-2K, no worsening in 
physician VAS, no worsening in BILAG. 
 Ultrasound assessment 
Ultrasound (GS and PD) was performed using high-resolution US machine (HRUS).  General 
Electric (GE) Logiq E9 HRUS with multi-linear 6-15 MHz transducer was used.  For the details 
of the ultrasound examination, please see 4.1. 
 Statistical analysis 
Clinical characteristics (demographics, clinical assessments, therapies and immunological 
parameters) and ultrasound features were summarized for each group using percentages of 
patients or median and interquartile range as appropriate. 
Different methods have been used to calculate effect sizes to measure internal 
responsiveness.  Standardised response means may be used for parametric variables. The 
candidate outcome measures in this study included parametric, ordinal and categorical 
variables.  Therefore I  used effect sizes calculated from a paired non-parametric test instead 
of paired t-tests usually used to calculate effect size statistics[407].  Change in continuous 
variables was assessed using Wilcoxon Signed Ranks test. Effect size was calculated using 
standardized test statistic, Z, using the formula r=Z/sqrt (n1+n2). Effect sizes were judged 
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using Cohen’s Criteria as large (>-0.5), medium (>-0.3) or small (>-0.1)[408]. 
 Results 
6.8.1 Baseline characteristics 
All of the 20 patients were female and ANA positive.  Mean (SD) age was 49.7 (14.1) and 
mean (SD) disease duration 85 months (22).  There were 11/20 (55%) were receiving NSAID 
(non-steroid anti-inflammatory drug) therapy. Fourteen patients were on a stable dose of 
hydroxychloroquine, of whom three were also on a stable dose of methotrexate or 
mycophenolate and one was on epratuzumab.  Three patients received methotrexate or 
mycophenolate without hydroxychloroquine.  Three patients were not on hydroxychloroquine 
or other oral immunosuppressant medications. Three patients received a stable dose of 
prednisolone ≤5mg/day. Fifteen (15/20) patients had clinical joint swelling at baseline. The 
others all had either US synovitis (GS in 18/20, PD in 17/20) or >60 minutes of EMS, or new 
activity in other organ systems coincident with the onset of joint pain. 
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Table 6-1: Baseline characteristics 
 All patients N= 20 
Age(years) Mean(SD) 49.7 (14.1) 
Disease duration(months) Mean(SD) 85 (22) 
Therapy  
NSAID n/N % 11/20 (55%) 
Hydroxychloroquine n/N% 14/20 (70%) 
Methotrexate n/N% 3/20 (15%) 
Prednisolone n/N% 3/20 (15%) 
Clinical assessment  
Swollen joint% 15/20 (75%) 
Ultrasound abnormalities  
Grey scale 18/20 (90%) 
Power Doppler 17/20 (85%) 
 
6.8.2 Week 2, 4 Changes in outcome measures 
At four weeks there was a substantive and significant improvement in all clinical and 
ultrasound parameters measured (all p<0.025, Table 6-2).  However, 65% of patients still had 
symptoms with BILAG A-C.  Eighty percent (16/20) of the patients had improvement by at 
least one MSK-BILAG grade, but only 7/20 had improvement in the musculoskeletal SLEDAI 
component. Residual symptoms were confirmed by tender and symptomatic joint count, 
morning stiffness, patient and physician VAS.  On 4-week ultrasound, there was a large 
reduction in PD. PD was present in nine patients at four weeks, but with a total score of <2 in 
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8 of these (Figure 6-1). GS scores were significantly reduced but higher than PD post-
treatment, being present at ≥2 in 13/20 patients.  Changes in these parameters at 2 weeks 
were more variable.  Tender and swollen joint counts and EMS minutes had numerically, but 
not statistically significantly improved. Visual analogue scales showed a partial but significant 
improvement. Ultrasound parameters had all significantly improved at 2 weeks, although to 
lesser degree than at 4 weeks. Table 6-3 demonstrates effect sizes, ordered according to 
magnitude.  At both 2 and 4 weeks, physician VAS had the largest effect size, although it must 
be noted that this assessment was not blinded to time point and may be more susceptible to 
observer bias than the other variables.  Other than physician VAS, at 2 weeks only changes 
in ultrasound showed large effect sizes.  Changes in clinical variables were only small-
medium. 
At week 4, effect sizes remained large for ultrasound parameters and physician VAS.  They 
were medium for other clinical variables (joint counts, EMS, patient VAS).  Effect sizes for 
musculoskeletal components of BILAG and SLEDAI differed: the effect for MSK-BILAG was 
of a similar magnitude to ultrasound.  Although the MSK-SLEDAI significantly improved, its 
effect size was substantially smaller than for BILAG, ultrasound and physician VAS. 
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Figure 6-1, Ultrasound images showing changes in PD between baseline and week4: 
 
 
US images of MCP joint in an SLE patient at baseline and 4 weeks. Baseline image shows grade 3 
power Doppler, which has completely resolved at 4 weeks. 
 
6.8.3 Comparison of SLEDAI responders and non-responders 
The 19 patients with MSK-SLEDAI score of at least four points at baseline were grouped into 
SRI-4 responders (n=9) and SRI-4 non-responders (n=10).  SRI-4 and change in MSK-
SLEDAI were generally equivalent in this patient group.  All SRI-4 responders also had 
improvement in the musculoskeletal component of the SLEDAI except for one who improved 
Baseline 
4 weeks 
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in other organ domains and had a mixed response in musculoskeletal variables (Figure 6-2).  
All SRI-4 non-responders did not have improvement in the musculoskeletal component of the 
SLEDAI. After that, I compared changes in tender and swollen joint counts, ultrasound 
greyscale and PD in each of these groups.  For tender and swollen joint counts, there were 
large effect sizes in SRI-4 responders (r=-0.505 and -0.492 respectively and p=0.024 and 
0.028 respectively) and a medium effect sizes in SRI-4 Non-responders (r=-0.365 and -0.331 
and p=0.122 and 0.160). For ultrasound, large effect sizes for improvements in both GS and 
PD were observed in both SRI-4 responders (r=-0.517 and -0.564 and p=0.021 and 0.021) 
and SRI-4 non-responders (r=-0.629 and -0.596 and p=0.008 and 0.012). 
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Figure 6-2. Change in joint counts and ultrasound and SRI-4 response: 
 
Patients who had a MSK-SLEDAI score of 4 points at baseline were grouped according to whether 
they met the SRI-4 response criterion at 4-week follow up. P-values show the results of a Wilcoxon 
matched pairs test within each group and effect size r
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Table 6-2 . Summaries of clinical and ultrasound assessments at weeks 0, 2 & 4: 
All values presented are median (IQR) unless otherwise stated. TJC = tender joint count in 28 joints, SJC = swollen joint count in 28 joints, Symptomatic joint 
count = number of joints indicated as painful or stiff by patients on a graphical questionnaire. EMS = early morning stiffness, PD = total US power Doppler 
score, GS = total US greyscale score. Joints with US synovitis = number of joints scoring either GS>1 or PD>0.
Outcome Measure Week 0 Week 2 Week 4 Change Week 2 Change Week 4 
BILAG-MSK n (%) 
     A 
     B 
     C 
     D 
 
7/20 (35) 
8/20 (40) 
5/20 (25) 
 
N/A 
 
1/20 (5) 
2/20 (10)  
9/20 (45) 
7/20 (35) 
N/A 
 
Improved 16/20 (80%) 
Same 4/20 (20%) 
Worse 0/20 (0%) 
BILAG-MSK 
(A=12, B=8, C=1, D=0) 
8 (3,12) N/A 1 (0,1) N/A -7 (-8, -1) 
SLEDAI arthritis present n (%) 19/20 (95) N/A 10/20 (50) N/A 
Improved 7/20 (35%) 
Same 13/20 (65%) 
SLEDAI arthritis 4 (4, 4) N/A 2 (0, 4) N/A 0 (-4, 0) 
TJC (0-28) 8 (4, 12) 4 (1,14) 2 (1, 11) -3 (-4, 3) 
 
-4 (-6, -1) 
 
SJC (0-28) 2 (0, 5) 0 (0,1) 0 (0-0) -1 (-3, 0) 
 
-2 (-3, 0) 
 
Symptomatic joint count 15 (6, 22) 2 (0,13) 4 (1,15) -7 (-19, 0) 
 
-6 (-14, -1) 
 
EMS (minutes) 25 (0, 60) 5 (0, 45)  3 (0, 41) 0 (-21, 0) 
 
0 (-24, 0) 
 
Patient VAS (mm) 57 (30, 79) 30 (9, 40) 33 (8, 49) -23 (-29, -10) 
 
-22 (-52, 2) 
 
Physician VAS (mm) 55 (35, 68) 23 (5, 50) 15 (5, 35) -24 (-45, -15) 
 
-31 (-45, -15) 
 
US - total PD 8 (2, 26) 1 (0, 6) 1 (0, 1) -8 (-27, -2) 
 
-8 (-10, -2) 
 
US - total GS 19 (9, 43) 13 (5, 24) 8 (2, 13) -12 (-23, -4) 
 
-10 (-21, -3) 
 
Joints with US synovitis 5.5 (1, 9) 3 (1, 8) 1 (0, 4) -7 (-10, -3) 
 
-5 (-12, -2) 
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Table 6-3. Effect size for change at 2 and 4 weeks according to magnitude 
 Week 0 – Week 2  
Outcome measure No. pairs P Z Effect size Cohen Criteria 
Physician VAS 16 0.001 -3.409 -0.603 Large 
Grey Scale Score 16 0.002 -3.13 -0.571 Large 
No. Joints with US Synovitis 16 0.011 -3.160 -0.559 Large 
PD Score 16 0.002 -3.099 -0.548 Large 
Symptomatic Joint Count 10 0.047 -1.988 -0.445 Medium 
Patient VAS 16 0.016 -2.409 -0.426 Medium 
EMS minutes 16 0.046 -1.997 -0.353 Medium 
Swollen Joint Count 16 0.059 -1.889 -0.334 Medium 
Tender Joint Count 15 0.274 -1.093 -0.200 Small 
 Week 0 – Week 4  
Outcome measure No. pairs P Z Effect size, r Cohen Criteria 
Physician VAS 20 <0.001 -3.388 -0.593 Large 
MSK BILAG Numeric 20 0.008 -3.643 -0.576 Large 
PD Score 20 <0.001 -3.627 -0.573 Large 
No. Joints with US Synovitis 20 0.001 -3.627 -0.573 Large 
Grey Scale Score 20 <0.001 -3.503 -0.554 Large 
Symptomatic Joint Count 14 0.010 -2.576 -0.487 Medium 
MSK-SLEDAI Score 20 0.003 -3.000 -0.474 Medium 
Tender Joint Count 20 0.007 -2.683 -0.424 Medium 
EMS minutes 20 0.012 -2.527 -0.400 Medium 
Swollen Joint Count 20 0.007 -2.425 -0.383 Medium 
Patient VAS 20 0.020 -2.331 -0.369 Medium 
MSK BILAG Numeric calculated using A=12, B=8, C=1, D=0. MSK-SLEDAI Score calculated using 
arthritis present in previous 30 days = 4, arthritis absent = 0. P values are results of Wilcoxon signed 
ranks test, Z = standardized test statistic, effect size r calculated as r=Z/sqrt  
 
Table 6-4SRI-4 response and musculoskeletal variables 
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GS= total US greyscale score, PD = total US power Doppler score TJC = tender joint count in 28 joints, SJC = swollen joint count in 28 joints
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 Discussion 
In this study, I compared the internal responsiveness of clinical outcome measures and 
ultrasound in patients with systemic lupus erythematosus who received known efficacious 
therapy.  All commonly used clinical variables significantly improved by week 4 but there was 
variation in responsiveness between them.  BILAG-2004 and physician VAS had similar 
responsiveness to ultrasound variables but were more susceptible to observer bias.  SRI-4 
underestimated response, with substantial objective improvements in synovitis in SRI-4 non-
responders. If replicated in larger studies these results may have implications for the design 
of clinical trials in SLE as well as routine clinical practice. 
A problem in clinical trials in SLE has been that many therapies that appear to be effective in 
other contexts have produced negative results in randomised control trials. There are many 
possible causes for this, including the recruitment of some ANA-negative patients and use of 
active comparator arms.  However, there are reasons to believe that choice of outcome 
measures is at least partly responsible for these discrepancies.  In the belimumab programme, 
phase II data using the SELENA-SLEDAI were negative[409].  The SRI was derived from 
these phase II data and used to design a phase III trial that produced the opposite result [381].  
The rituximab EXPLORER study was negative for its BILAG-based primary and secondary 
endpoints but had positive results in post hoc analyses such as BILAG A flare rate [410, 411].  
While the SRI-4 has been highly successful in several clinical trials, in the two phase III trials 
of belimumab the response rate was rather low at 43-58% vs. 34-44% for belimumab and 
placebo[154].  The data I report here show that the SRI-4 underestimates clinical improvement 
in patients with arthritis and therefore may suggest that clinical trials would show higher 
response rates and greater differentiation of active and placebo arms if imaging outcome 
measures, or more responsive clinical outcome tools, were used. 
In order to have effective treatment of SLE in the clinic, it is essential to be able to measure 
disease activity accurately, especially when using biologic therapies. An international task 
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force recently recommended treating to a target of low disease activity in SLE, as well as 
minimizing glucocorticoid exposure [402].  For the low disease activity target, it was 
recommended that a validated SLE disease activity index and/or by organ-specific markers 
be used.  My results would support this, although this would need to be confirmed in 
longitudinal studies. I showed that patients with musculoskeletal disease who are not meeting 
SRI-4 or SLEDAI criteria may still have improvement, and physician VAS data suggest that 
overall physician judgment may be a better guide to response.  Nevertheless, several other 
studies showed that patients with musculoskeletal symptoms but not clinical joint swelling (not 
meeting BILAG A/B or SLEDAI criteria) may have subclinical synovitis [121].  Hence, in 
forming their judgment of response physicians may wish to consider ultrasound in patients 
with ongoing inflammatory symptoms despite a degree of improvement. 
Physician VAS appeared to be highly responsive in this study. It must be noted that assessors 
were not blinded to time point and this may affect subjective outcome measures due to 
observer bias.  Observer bias may also affect the BILAG “improving” score, wherein synovitis 
that is still present but determined to be improving results in a lower BILAG score than if it is 
deemed stable or worsening.  Further, the skill and experience of the assessor have effects 
on the BILAG score.  All of our assessments were performed by trained assessors 
experienced in SLE clinical trials.  An advantage of ultrasound is that it is more objective.  
However, it is operator-dependent and may be more difficult to standardize in multi-center 
studies.  Joint counts were not as responsive as other instruments here, but are easier to 
standardize in multi-center studies given their widespread use in other inflammatory arthritis. 
When first developed, the BILAG and SLEDAI were validated against physician’s intention to 
treat and physician’s judgment of overall disease activity.  In my cross-sectional studyChapter 
5:), I noted that ultrasound synovitis is common in patients without joint swelling and no clinical 
instrument could detect this.  This suggests that validation against an objective measure of 
disease activity would be more valuable.  Although there is no other study focusing specifically 
on musculoskeletal disease, one previous study compared the sensitivity to change of five 
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clinical instruments for overall disease activity (SLAM, SLEDAI, BILAG, ECLAM and LAI) 
[412].  Similarly, to this study, in that paper the SLEDAI was less responsive than the BILAG. 
My results suggest that an organ-specific outcome measure may be more valuable in this 
common manifestation.  This has already been established in the other second most common 
symptoms of SLE: cutaneous disease.  The Cutaneous Lupus Activity and Severity Index 
(CLASI) [413] provides an organ-specific, continuous measure of cutaneous disease activity. 
In recent clinical trials of sifalimumab and anifrolumab, the CLASI showed a high rate of 
responsiveness [47, 414]. In this study, physician VAS was more responsive than the 
musculoskeletal component of the SLEDAI.  Tender joint, swollen joint and symptomatic joint 
counts had similar responsiveness to the SLEDAI but may be advantageous in multicenter 
trials in being less dependent on the experience and opinion of the assessor, and less 
susceptible to observer bias. The data in this study and my previous larger cross-sectional 
study (Chapter 5:) demonstrate that joint counts and ultrasound findings vary more than BILAG 
and SLEDAI grades.  It is therefore likely that a composite outcome measure could be 
designed for musculoskeletal disease that offers similar advantages to the CLASI. One 
previous paper has also shown the potential advantages of specific musculoskeletal outcome 
measures in patients treated with belimumab [415]. 
This study has some limitations. The number of patients was relatively small.  Assessors were 
not blinded to therapy or time point, which may have affected some instruments. However, 
clinical and ultrasound assessors were blinded to each other’s findings. Lastly, I have not yet 
assessed external responsiveness – i.e., responsiveness compared to some external anchor 
[407]. 
Despite these limitations, the results of this study are unique in comparing responsiveness to 
an objective standard and indicate the limitations of existing tools for musculoskeletal SLE. 
My results suggest that an organ-specific outcome measure for musculoskeletal disease 
would have advantages in both clinical trials and routine clinical practice. This is being 
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definitively assessed in the USEFUL study. 
 Conclusions: 
 In musculoskeletal-SLE, ultrasound was the variable most consistently sensitive to change. 
All commonly used clinical variables significantly improved by week 4 but there was variation 
in responsiveness between them.  BILAG-2004 and physician VAS had similar 
responsiveness to ultrasound. SRI-4 underestimated response, with substantial objective 
improvements in synovitis in SRI-4 non-responders. Developing organ-specific outcome 
measures may improve the ability to measure treatment effects in SLE clinical trials. 
 Key messages: 
1-Ultrasound was highly responsive for the musculoskeletal manifestations of systemic lupus 
erythematosus. 
2-Most clinical outcome measures were less responsive than ultrasound; SLEDAI and SLE 
responder index 4 may underestimate response. 
3- BILAG-2004 and physician visual analogue scales appeared more responsive than 
SLEDAI-2K and SLE responder index 4 for musculoskeletal SLE. 
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Chapter 7: USEFUL Study: prediction of response using 
baseline ultrasound 
As discussed in detail in chapter 4, the key unmet need in SLE is identifying patients with 
active disease, given that these do not have swelling. We do not know whether ultrasound 
only synovitis is more responsive to therapy and therefore should be used to select patients 
for immunosuppressant or entry in to clinical trials. 
 Objective 
Determine whether patients with abnormal musculoskeletal ultrasound have better clinical 
response to glucocorticoid therapy compared to patients with normal musculoskeletal 
ultrasound. Because the most responsive variable identified in the interim analysis was EMS 
VAS at 2 weeks, this forms the primary endpoint of the study. 
 Patients and methods 
For the design of the USEFUL study please see 4.2.2.  For the summary of recruitment please 
see 4.4.3. For baseline clinical and demographic characteristics, please see 4.4.1. 
 Statistical analysis 
First, baseline characteristics of patients with active and inactive ultrasound were described 
using summary statistics.   As planned in the protocol to analyse the efficacy of glucocorticoids 
in the patients with normal (inactive) and abnormal (active) ultrasound.   Active ultrasound was 
defined as (GS ≥2 and or PD>0); otherwise it was defined as inactive.   I used the early 
morning stiffness VAS (mm) at 2 weeks because this was the most responsive variable in the 
interim analysis.  A predictive value of baseline ultrasound was concluded if there was 
differential response to treatment according to the presence of ultrasound inflammation.  The 
difference between groups and associated 95% confidence interval were reported. 
Early morning stiffness (EMS) VAS at week 2 was compared between patients with and 
without active ultrasound (GS≥2 and/or PD≥1 in at least 1 joint) at baseline using quantile 
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(median) regression, with cluster-robust standard errors used to account for clustering of 
patients within centres.  Quantile regression was specified in the statistical analysis plan as 
an approach to analysing severely skewed variables which were not suited to parametric 
analysis. The primary analysis model adjusted for EMS VAS at baseline; the unadjusted 
difference is presented for comparison. In a sensitivity analysis, immunosuppression and oral 
steroid use (both recorded yes/no) were also added to the model. In a further sensitivity 
analysis, the above approaches were repeated in the per protocol set. In an additional, 
unplanned, sensitivity analysis, the above analyses were repeated in patients who were 
deemed unlikely to have fibromyalgia at baseline. 
In addition to the sensitivity analyses detailed above to check the assumptions of the analysis 
model, the analysis of the primary efficacy variable will be repeated in the per protocol set. 
Because there were a substantial number of patients with fibromyalgia, which may confound 
responses in SLE, we performed post-hoc analyses excluding patients with fibromyalgia for 
the most important endpoints. 
 Results 
At baseline, 78 patients had active ultrasound (at least one joint with GS≥2 or PD>0) and 55 
patients had inactive ultrasound. A comparison of the clinical response in these two groups is 
the main focus of this chapter. 
7.4.1 Patient disposition 
Patient disposition according to baseline ultrasound status is shown in (Table 7-1). There was 
no substantive difference in the completion of follow up between the two ultrasound groups.  
Overall, 91% of patients completed visit 6. 95% and 88% of the baseline ultrasound inactive 
and active groups completed. 
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Table 7-1: Patient disposition according to baseline ultrasound status 
 All patients US activity at baseline 
  Inactive Active 
 N=133 N=55 N=78 
Baseline    
     Attended 133/133 (100) 55/55 (100) 78/78 (100) 
Week 2    
     Attended 122/133 (92) 51/55 (93) 71/78 (91) 
     Withdrawn 2/133 (2) 1/55 (2) 1/78 (1) 
     Did not attend 5/133 (4) 1/55 (2) 4/78 (5) 
     Lost to follow-up 4/133 (3) 2/55 (4) 2/78 (3) 
Week 6    
     Attended 121/133 (91) 52/55 (95) 69/78 (88) 
     Withdrawn 4/133 (3) 1/55 (2) 3/78 (4) 
     Did not attend 3/133 (2) 0/55 (0) 3/78 (4) 
     Lost to follow-up 5/133 (4) 2/55 (4) 3/78 (4) 
All values reported as n/N (%) 
 
7.4.2 Demographics 
Demographic data according to baseline ultrasound are shown in (Table 7-2). There were no 
significant differences between the groups in terms of age, disease duration and ethnicity.  In 
the study there were seven males, all of them had active ultrasound at baseline. However, this 
is a small proportion of the study population which does not have a significant effect on the 
conclusion.
171 
 
 
Table 7-2: Demographic data according to baseline ultrasound status: 
 All patients US activity at baseline Difference 
(95% CI) 
Test 
statistic, P 
value 
Inactive Active 
N=133 N=55 N=78 
Age (years) 
    Mean (SD), range 
46.1 (13.5), 17.0 to 78.0 47.9 (12.3), 25.0 to 
76.0 
44.8 (14.3), 17.0 to 
78.0 
 3.1 (-1.6,  
7.8) 
t=1.32, 
p=0.190 
    Median (IQR) 47.0 (35.0, 55.0) 50.0 (36.0, 57.0) 45.0 (34.0, 54.0)  
Disease duration (y) 
    Mean (SD), range 
9.3 (8.9), 0.1 to 40.0 10.2 (9.8), 0.1 to 40.0 8.7 (8.1), 0.1 to 35.0  1.5 (-1.6,  
4.5) 
t=0.93, 
p=0.352 
    Median (IQR) 6.0 (2.0, 15.0) 7.0 (2.0, 17.0) 5.0 (2.0, 15.0)  
Sex n/N (%)     chisq=5.21, 
p=0.022      Male 7/133 (5) 0/55 (0) 7/78 (9)  
     Female 126/133 (95) 55/55 (100) 71/78 (91)  
Ethnicity n/N (%)     chisq=6.06, 
p=0.195      White 82/133 (62) 40/55 (73) 42/78 (54)  
     South Asian 34/133 (26) 11/55 (20) 23/78 (29)  
     Black 14/133 (11) 3/55 (5) 11/78 (14)  
     East Asian 1/133 (1) 0/55 (0) 1/78 (1)  
     Other 2/133 (2) 1/55 (2) 1/78 (1)  
All values reported as n/N (%), IQR: interquartile rang, SD: slandered deviation
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7.4.3 Current medications 
Regarding the current medication history, no significant differences were noticed between the 
two groups (Table 7-3).  This comparison was done because medications such as NSAIDs 
and glucocorticoid can affect ultrasound findings, although we asked them to discontinue their 
NSAIDs at least three days before the scan if possible and we restricted the dose of steroid to 
5 mg or equivalent.  In addition, there was no difference between the groups for the 
immunosuppressant and anti-malarial medications.  This may suggest that the referring 
physician’s intention to treat over previous months was not associated with ultrasound.
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Table 7-3: Medication use according to ultrasound status 
 All patients US activity at baseline 
Test statistic, P value Inactive Active 
N=133 N=55 N=78 
Antimalarial n/N (%)     
     None 44/133 (33) 17/55 (31) 27/78 (35) chisq=1.57, p=0.456 
     HCQ 88/133 (66) 37/55 (67) 51/78 (65)  
     MEP 1/133 (1) 1/55 (2) 0/78 (0)  
Immunosuppressant n/N (%)     
     None 93/133 (70) 38/55 (69) 55/78 (71) chisq=5.75, p=0.125 
     Azathioprine 11/133 (8) 3/55 (5) 8/78 (10)  
     Methotrexate 16/133 (12) 5/55 (9) 11/78 (14)  
     Mycophenolate 13/133 (10) 9/55 (16) 4/78 (5)  
Regular biologics n/N (%)     
     None 130/130 (100) 54/54 (100) 76/76 (100) NA 
NSAIDS n/N (%)     
     None 106/133 (80) 43/55 (78) 63/78 (81) chisq=8.13, p=0.421 
     Naproxen 11/133 (8) 6/55 (11) 5/78 (6)  
     Ibuprofen 9/133 (7) 3/55 (5) 6/78 (8)  
     Celecoxib 1/133 (1) 1/55 (2) 0/78 (0)  
     Etodalac 1/133 (1) 0/55 (0) 1/78 (1)  
     Etoricoxib 1/133 (1) 0/55 (0) 1/78 (1)  
     Meloxicam 2/133 (2) 0/55 (0) 2/78 (3)  
     Ibuprofen-cocodamol 1/133 (1) 1/55 (2) 0/78 (0)  
     Ibuprofen-naproxen 1/133 (1) 1/55 (2) 0/78 (0)  
Daily oral glucocorticoids n/N 
(%) 
    
     None 102/133 (77) 43/55 (78) 59/78 (76) chisq=0.12, p=0.733 
     Prednisolone 31/133 (23) 12/55 (22) 19/78 (24)  
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7.4.4 How physicians identify inflammatory and non-inflammatory causes of pain 
For my last three baseline data analyses, I explored how well physicians were able to 
identify the cause of pain by examining their diagnoses of inflammatory features, 
fibromyalgia features and osteoarthritis features. 
In the USEFUL study, physicians were asked to refer patients if they believe their pain 
was only inflammatory, therefore, warranting glucocorticoid treatment.  At the baseline 
visit we asked clinicians to answer why they believed the pain was inflammatory.  
Details are shown in (Table 7-4).  Interestingly, only a few of the inflammatory features 
were associated with ultrasound findings (swelling p=0.03, symmetry p=0.01) with 
trend for distribution (p=0.066), serology (p=0.09).  Other classical inflammatory 
features such as morning stiffness, disease activity in other organs showed no 
association with objective joint inflammation.
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Table 7-4: Baseline inflammatory features compared to ultrasound findings 
 All patients US activity at baseline Test statistic, P 
value Inactive Active 
N=133 N=55 N=78 
EMS 
     No 18/133 (14) 8/55 (15) 10/78 (13) chisq=0.08, p=0.775 
     Yes 115/133 (86) 47/55 (85) 68/78 (87)  
Distribution 
     No 20/133 (15) 12/55 (22) 8/78 (10) chisq=3.37, p=0.066 
     Yes 113/133 (85) 43/55 (78) 70/78 (90)  
Symmetry 
     No 12/133 (9) 9/55 (16) 3/78 (4) chisq=6.16, p=0.013 
     Yes 121/133 (91) 46/55 (84) 75/78 (96)  
Swelling 
     No 49/132 (37) 26/54 (48) 23/78 (29) chisq=4.76, p=0.029 
     Yes 83/132 (63) 28/54 (52) 55/78 (71)  
Serology 
     No 43/130 (33) 22/53 (42) 21/77 (27) chisq=2.87, p=0.090 
     Yes 87/130 (67) 31/53 (58) 56/77 (73)  
Other lupus features 
     No 67/133 (50) 29/55 (53) 38/78 (49) chisq=0.21, p=0.649 
     Yes 66/133 (50) 26/55 (47) 40/78 (51)  
Prior therapy response 
     No 46/133 (35) 16/55 (29) 30/78 (38) chisq=1.25, p=0.263 
     Yes 87/133 (65) 39/55 (71) 48/78 (62)  
Jaccoud’s arthropathy 
     No 127/133 (95) 53/55 (96) 74/78 (95) chisq=0.17, p=0.683 
     Yes 6/133 (5) 2/55 (4) 4/78 (5)  
Deformity 
     No 127/133 (95) 53/55 (96) 74/78 (95) chisq=0.17, p=0.683 
     Yes 6/133 (5) 2/55 (4) 4/78 (5)  
Other lupus inflammatory 
     No 130/133 (98) 53/55 (96) 77/78 (99) chisq=0.81, p=0.368 
     Yes 3/133 (2) 2/55 (4) 1/78 (1)  
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The referring doctors were asked about the other musculoskeletal problems seen in SLE 
patients that may cause similar symptoms of pain (tables Table 7-5 and Table 7.6). However, 
none of these features was associated with having active ultrasound at baseline.  
In summary, if  patients with SLE presented with pain and physician needed to decide whether 
it is due to active musculoskeletal inflammation; the presence of swelling, symmetrical small 
joint distribution and serology appear to be helpful.  But, presence fibromyalgia or 
Osteoarthritis features should not be used to rule out inflammatory joint pain. 
Table 7-5: Baseline fibromyalgia features compared to ultrasound findings 
 All patients US activity at baseline Test statistic, P value 
 Inactive Active 
N=133 N=55 N=78 
Overall opinion of 
fibromyalgia 
   
     No 101/133 (76) 41/55 (75) 60/78 (77) chisq=0.10, p=0.752 
     Yes 32/133 (24) 14/55 (25) 18/78 (23)  
Fatigue     
     No 102/132 (77) 43/55 (78) 59/77 (77) chisq=0.04, p=0.833 
     Yes 30/132 (23) 12/55 (22) 18/77 (23)  
Waking unrefreshed     
     No 108/132 (82) 46/55 (84) 62/77 (81) chisq=0.21, p=0.647 
     Yes 24/132 (18) 9/55 (16) 15/77 (19)  
Cognitive symptoms     
     No 112/132 (85) 48/55 (87) 64/77 (83) chisq=0.43, p=0.511 
     Yes 20/132 (15) 7/55 (13) 13/77 (17)  
Somatic symptoms     
     No 117/132 (89) 47/55 (85) 70/77 (91) chisq=0.95, p=0.330 
     Yes 15/132 (11) 8/55 (15) 7/77 (9)  
Other fibromyalgia 
features present 
    
     No 128/133 (96) 51/55 (93) 77/78 (99) chisq=3.20, p=0.074 
     Yes 5/133 (4) 4/55 (7) 1/78 (1)  
Other fibromyalgia 
features (specify) 
    
     None 128/133 (96) 51/55 (93) 77/78 (99)  
     Generalised 
Tenderness 
2/133 (2) 2/55 (4) 0/78 (0)  
     Hyperalgesia 1/133 (1) 1/55 (2) 0/78 (0)  
     IBS 1/133 (1) 1/55 (2) 0/78 (0)  
     Postnatal depression 1/133 (1) 0/55 (0) 1/78 (1)  
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Table 7-6: Baseline osteoarthritis features compared to ultrasound findings 
 All patients US activity at baseline 
Test statistic, P value  Inactive Active 
N=133 N=55 N=78 
Overall opinion of osteoarthritis N/n (%)     
     No 97/133 (73) 39/55 (71) 58/78 (74) chisq=0.19, p=0.659 
     Yes 36/133 (27) 16/55 (29) 20/78 (26)  
Hard tissue enlargement >1 joint N/n (%)     
     No 106/131 (81) 41/54 (76) 65/77 (84) chisq=1.48, p=0.224 
     Yes 25/131 (19) 13/54 (24) 12/77 (16)  
Hard tissue enlargement DIPs N/n (%)     
     No 110/132 (83) 44/55 (80) 66/77 (86) chisq=0.75, p=0.385 
     Yes 22/132 (17) 11/55 (20) 11/77 (14)  
Deformities consistent with OA N/n (%)     
     No 118/132 (89) 49/55 (89) 69/77 (90) chisq=0.01, p=0.924 
     Yes 14/132 (11) 6/55 (11) 8/77 (10)  
Previous radiographic evidence N/n (%)     
     No 118/128 (92) 51/54 (94) 67/74 (91) chisq=0.66, p=0.416 
     Yes 10/128 (8) 3/54 (6) 7/74 (9)  
Other OA features present N/n (%)     
     No 127/132 (96) 53/54 (98) 74/78 (95) chisq=0.94, p=0.332 
     Yes 5/132 (4) 1/54 (2) 4/78 (5)  
Other OA features (specify) N/n (%)     
     None 127/131 (97) 53/54 (98) 74/77 (96)  
     Trochanteric bursitis 1/131 (1) 0/54 (0) 1/77 (1)  
     Hip pain 1/131 (1) 1/54 (2) 0/77 (0)  
     Lumbar syno-dylosis as disc disease 1/131 (1) 0/54 (0) 1/77 (1)  
     Symptoms consistent with OA 1/131 (1) 0/54 (0) 1/77 (1)  
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7.4.5 Baseline inflammatory features according to baseline ultrasound 
Although there were not many differences in features of fibromyalgia, osteoarthritis or baseline 
medications and demographics, as expected, patients with active ultrasound had many 
differences when inflammatory clinical features were compared.  These are shown in (Table 
7-7).  Almost all of the features of musculoskeletal SLE activity were significantly worse in 
patients with active ultrasound.  One interesting exception to this was the EMS minutes. 
Although this is commonly reported in inflammatory arthritis studies, in fact is very poor in 
comparison to an EMS VAS.  In the analysis of the primary endpoint, the results of these 
parameters after treatment were compared after adjustment for the baseline differences.
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Table 7-7: Baseline musculoskeletal SLE parameters according to baseline ultrasound status 
 All patients US activity at baseline  
 Inactive Active 
N=133 N=55 N=78 
EMS VAS (mm) 73.0 (57.0, 87.0), 0.0 to 100.0 67.0 (48.0, 83.0), 2.0 to 99.0 75.5 (63.0, 92.0), 0.0 to 100.0 z=-2.55, p=0.011 
EMS duration (mins) 90.0 (30.0, 120.0), 0.0 to 600.0 70.0 (30.0, 120.0), 0.0 to 360.0 90.0 (30.0, 150.0), 0.0 to 600.0 z=-1.02, p=0.306 
Tender 68 joint count 17.0 (7.0, 28.0), 0.0 to 68.0 15.0 (4.0, 27.0), 0.0 to 68.0 19.0 (10.0, 31.0), 0.0 to 68.0 z=-2.21, p=0.027 
Swollen 66 joint count 1.0 (0.0, 4.0), 0.0 to 32.0 0.0 (0.0, 0.0), 0.0 to 10.0 3.0 (1.0, 6.0), 0.0 to 32.0 z=-6.52, p<0.001 
Patient painful joint count 16.0 (9.0, 28.0), 0.0 to 42.0 11.0 (7.0, 20.0), 0.0 to 40.0 22.0 (14.0, 32.0), 1.0 to 42.0 z=-3.84, p<0.001 
Physician MSK Disease Activity VAS (mm) 33.0 (21.0, 49.0), 0.0 to 90.0 24.0 (15.0, 36.0), 0.0 to 75.0 39.5 (30.0, 55.0), 13.0 to 90.0 z=-4.86, p<0.001 
HAQ-DI score 1.4 (0.6, 2.0), 0.0 to 3.0 1.4 (0.3, 1.8), 0.0 to 2.8 1.4 (0.8, 2.1), 0.0 to 3.0 z=-1.82, p=0.069 
Patient MSK disease activity VAS (mm) 65.0 (32.0, 79.0), 2.0 to 95.0 54.0 (28.0, 75.0), 7.0 to 92.0 70.5 (37.0, 81.0), 2.0 to 95.0 z=-1.87, p=0.061 
MSK pain VAS (mm) 63.0 (47.0, 74.0), 5.0 to 99.0 57.0 (34.0, 69.0), 10.0 to 93.0 67.5 (53.0, 75.0), 5.0 to 99.0 z=-2.72, p=0.007 
Total grey scale (joints) 5.0 (2.0, 9.0), 0.0 to 49.0 1.0 (0.0, 4.0), 0.0 to 10.0 7.0 (5.0, 11.0), 2.0 to 49.0 z=-7.67, p<0.001 
Total power Doppler (joints) 0.0 (0.0, 1.0), 0.0 to 34.0 0.0 (0.0, 0.0), 0.0 to 0.0 0.0 (0.0, 2.0), 0.0 to 34.0 z=-6.00, p<0.001 
Total osteophyte (joints) 0.0 (0.0, 0.0), 0.0 to 19.0 0.0 (0.0, 1.0), 0.0 to 8.0 0.0 (0.0, 0.0), 0.0 to 19.0 z=0.88, p=0.379 
Total erosion score (joints) 0.0 (0.0, 0.0), 0.0 to 44.0 0.0 (0.0, 0.0), 0.0 to 1.0 0.0 (0.0, 0.0), 0.0 to 44.0 z=-1.86, p=0.063 
Total OMERACT/EULAR GSPD score (joints) 5.0 (2.0, 9.0), 0.0 to 49.0 1.0 (0.0, 4.0), 0.0 to 10.0 7.0 (5.0, 11.0), 2.0 to 49.0 z=-7.67, p<0.001 
Total amended OMERACT/EULAR GSPD score (joints) 4.0 (1.0, 7.0), 0.0 to 36.0 1.0 (0.0, 4.0), 0.0 to 10.0 6.0 (4.0, 9.0), 1.0 to 36.0 z=-6.51, p<0.001 
Total grey scale (tendons) 0.0 (0.0, 1.0), 0.0 to 21.0 0.0 (0.0, 0.0), 0.0 to 7.0 0.0 (0.0, 2.0), 0.0 to 21.0 z=-3.52, p<0.001 
Total power Doppler (tendons) 0.0 (0.0, 0.0), 0.0 to 20.0 0.0 (0.0, 0.0), 0.0 to 6.0 0.0 (0.0, 1.0), 0.0 to 20.0 z=-3.74, p<0.001 
Total OMERACT/EULAR GSPD score (tendons) 0.0 (0.0, 1.0), 0.0 to 21.0 0.0 (0.0, 0.0), 0.0 to 8.0 0.0 (0.0, 2.0), 0.0 to 21.0 z=-3.51, p<0.001 
Total amended OMERACT/EULAR GSPD score (tendons) 0.0 (0.0, 1.0), 0.0 to 20.0 0.0 (0.0, 0.0), 0.0 to 7.0 0.0 (0.0, 1.0), 0.0 to 20.0 z=-3.47, p=0.001 
BILAG MSK score     
     D/E 2/133 (2) 2/55 (4) 0/78 (0) chisq=26.54, p<0.001 
     C 65/133 (49) 40/55 (73) 25/78 (32)  
     B 52/133 (39) 10/55 (18) 42/78 (54)  
     A 14/133 (11) 3/55 (5) 11/78 (14)  
SLEDAI MSK domain score     
     0 55/133 (41) 36/55 (65) 19/78 (24) chisq=22.46, p<0.001 
     4 78/133 (59) 19/55 (35) 59/78 (76)  
All values reported as median (IQR), range, except for BILAG MSK and SLEDAI MSK which are reported as n/N (%). 
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7.4.6 Primary endpoint: EMS VAS 
Results of the primary endpoint are shown in Figure 7-1 and Table 7-8.  As mentioned above, 
at baseline, the EMS VAS was 8.5mm higher in patients with active ultrasound compared to 
patients with inactive ultrasound.  At 2 weeks, this was reversed: median EMS VAS had 
dropped to a greater extent in the patients with active ultrasound and after adjustment for 
baseline value was 0.85mm lower than for patients with inactive ultrasound (6.31mm after 
adjustment for immunosuppressant and oral steroids).  Although these changes are in the 
direction hypothesised (i.e. if we believed that patients with baseline ultrasound activity would 
be more responsive), they are small and non-significant.  The primary endpoint of the study 
was therefore not met, and this conclusion did not differ if a per-protocol set was analysed. 
However, a substantial number (32 patients) had a clinician diagnosis of fibromyalgia at 
baseline.  This is a condition that causes chronic pain and is not usually considered to be 
glucocorticoid-responsive.  This may therefore confound the primary endpoint. I therefore 
repeated the analysis excluding these patients. When only analysing patients without 
fibromyalgia, the differences in adjusted and adjusted sensitivity analyses were significant. 
Therefore, while this was not the prior analysis planned, these results suggest that in SLE 
patients in whom fibromyalgia has been clinically excluded, baseline ultrasound may be useful 
to select patients for immunosuppressive therapy. 
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Figure 7-1: Primary endpoint of USEFUL 
 
The primary endpoint (EMS VAS) in all patients and in per protocol (there was no significant 
defences).  After excluding patients with fibromyalgia (the differences in adjusted and adjusted 
sensitivity analyses were significant). 
Table 7-8: Statistical table for primary endpoint 
Population US activity at baseline Difference between medians (95% CI) 
 Inactive 
median 
(SE) 
Active 
median 
(SE) 
Unadjusted Adjusted 
primary*, P 
value 
Adjusted 
sensitivity**, P 
value 
Full Analysis 
Set (FAS) 
57.75 
(4.09) 
58.60 
(5.86) 
0.85 (-7.06, 
8.76) 
-7.70 (-18.92, 
3.52), p=0.178 
-6.31 (-18.10, 
5.49), p=0.293 
Per Protocol 
(PP) 
58.00 
(3.97) 
59.00 
(5.75) 
1.00 (-4.88, 
6.88) 
-7.51 (-17.13, 
2.11), p=0.126 
-6.30 (-16.83, 
4.24), p=0.241 
FAS: No 
fibromyalgia 
56.30 
(4.53) 
51.40 
(6.01) 
-4.90 (-15.36, 
5.56) 
-12.08 (-24.11, 
-0.06), p=0.049 
-12.82 (-22.20, -
3.44), p=0.007 
PP: No 
fibromyalgia 
57.00 
(3.24) 
50.00 
(6.87) 
-7.00 (-20.16, 
6.16) 
-12.30 (-22.76, 
-1.85), p=0.021 
-14.78 (-20.75, -
8.80), p<0.001 
*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. 
EMS=Early morning stiffness; VAS=Visual analogue scale 
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7.4.7 Secondary endpoints: other musculoskeletal SLE parameters 
The other musculoskeletal SLE variables were then compared in a similar analysis.  Results 
are shown in (Table 7-10) and (Figure 2-1).  The physician VAS for musculoskeletal disease 
activity and global disease activity both showed significantly greater improvement in patients 
with active ultrasound at baseline.  Also, there was a trend (p=0.070) to greater improvement 
in the MSK-BILAG, but not the SLEDAI.  This is interesting as the BILAG was more concordant 
with ultrasound improvement and the primary endpoint (EMS VAS), and is therefore better 
able to detect the predictive value of ultrasound.  It is important to note here that the physician 
who scored the VAS, SLEDAI and BILAG was blinded to all of the ultrasound scores.  Lastly, 
there was significantly greater improvement in the ultrasound parameters themselves in 
patients with active ultrasound at baseline. 
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Table 7-9: Other Musculoskeletal SLE variables at 2 weeks according to baseline ultrasound status 
Variable US activity at baseline Difference between medians (95% CI) 
Inactive median 
(SE) 
Active median 
(SE) 
Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P value 
Tender 68 joint count 4.90 (0.79) 10.95 (1.65) 6.05 (2.74, 9.36) -0.57 (-2.31, 1.17), p=0.521 -0.66 (-2.31, 0.99), p=0.427 
Swollen 66 joint count -0.00 (0.67) 1.00 (0.96) 1.00 (0.18, 1.82) 0.00 (-0.67, 0.67), p=0.995 0.00 (-0.67, 0.67), p=0.995 
Patient painful joint count 6.50 (0.99) 14.50 (1.76) 8.00 (4.87, 11.13) -0.93 (-4.44, 2.58), p=0.602 -0.76 (-4.49, 2.96), p=0.686 
Physician MSK DA VAS (mm) 12.75 (1.79) 25.40 (2.47) 12.65 (7.85, 17.45) 7.07 (1.38, 12.77), p=0.015 7.08 (2.61, 11.55), p=0.002 
HAQ-DI 1.16 (0.20) 1.32 (0.16) 0.16 (-0.18, 0.50) 0.01 (-0.05, 0.07), p=0.681 0.01 (-0.06, 0.09), p=0.746 
Patient MSK DA VAS (mm) 48.45 (2.75) 48.10 (3.04) -0.35 (-8.23, 7.53) -1.58 (-10.11, 6.95), p=0.715 -4.16 (-13.73, 5.42), p=0.391 
Patient MSK Pain VAS (mm) 41.95 (5.16) 54.20 (2.51) 12.25 (3.61, 20.89) 2.48 (-7.55, 12.50), p=0.627 1.05 (-10.94, 13.04), p=0.864 
EMS (mins) 60.00 (17.87) 60.50 (11.75) 0.50 (-24.04, 25.04) -4.16 (-19.44, 11.12), p=0.594 0.13 (-10.82, 11.09), p=0.981 
Total GSPD (joints) -0.00 (0.52) 3.95 (1.32) 3.95 (2.09, 5.81) 0.25 (-1.60, 2.09), p=0.793 0.25 (-1.60, 2.09), p=0.793 
Total GSPD (tendons)>0 -0.00 (0.14) 2.80 (1.24) 2.80 (0.50, 5.10) 1.96 (0.88, 3.04), p=0.001 1.79 (-0.11, 3.68), p=0.064 
Physician's global VAS (mm) 15.60 (1.96) 26.65 (1.67) 11.05 (6.27, 15.83) 6.99 (2.55, 11.43), p=0.003 7.02 (2.71, 11.33), p=0.002 
Total BILAG score 1.85 (0.94) 3.10 (1.58) 1.25 (-1.61, 4.11) 0.00 (-1.49, 1.49), p=1.000 0.02 (-1.39, 1.43), p=0.977 
Total SLEDAI score 2.20 (0.58) 5.25 (1.30) 3.05 (0.16, 5.94) 1.15 (-0.01, 2.31), p=0.051 1.05 (-0.22, 2.32), p=0.105 
Patient general health VAS (mm) 49.70 (2.54) 54.10 (5.16) 4.40 (-4.80, 13.60) 2.19 (-10.02, 14.40), p=0.725 0.92 (-10.52, 12.36), p=0.874 
Abnormal fatigue VAS (mm) 64.80 (2.50) 71.45 (1.59) 6.65 (1.02, 12.28) -0.38 (-6.14, 5.38), p=0.897 -0.87 (-7.08, 5.35), p=0.784 
 US activity at baseline Odds ratio (95% CI) 
 Inactive % Active % Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P value 
BILAG MSK improved  28%  42% 1.85 (1.36, 2.52) 0.14 (0.02, 1.37), p=0.092 0.14 (0.02, 1.18), p=0.070 
SLEDAI MSK improved  21%  21% 1.02 (0.27, 3.86) 0.74 (0.19, 2.89), p=0.660 0.72 (0.19, 2.72), p=0.627 
*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale 
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Given the results of the primary endpoint, I also repeated the analysis of secondary outcome 
measures in patients without fibromyalgia. The results are shown in (Table 7-10) and (Figure 
7-2).  After fibromyalgia patients were excluded, the differences in both BILAG and SLEDAI 
improvement were larger comparing patients according to baseline ultrasound status. 
Regarding BILAG (p=0.09), SLEDAI (p=0.06).
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Table 7-10: Secondary clinical outcomes at 6 weeks (in patients without fibromyalgia) 
Variable US activity at baseline Difference between medians (95% CI) 
 Inactive median 
(SE) 
Active median (SE) Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P 
value 
Tender 68 joint count 8.15 (2.50) 11.85 (2.23) 3.70 (-2.33, 9.73) 0.23 (-3.57, 4.03), p=0.903 0.53 (-4.01, 5.07), p=0.817 
Swollen 66 joint count 3.65 (1.63) 6.65 (1.87) 3.00 (-0.56, 6.56) 1.07 (-2.61, 4.75), p=0.563 1.21 (-0.92, 3.34), p=0.257 
Patient painful joint count 10.80 (3.17) 13.85 (1.90) 3.05 (-3.63, 9.73) -2.61 (-6.75, 1.54), p=0.216 -1.58 (-6.54, 3.39), p=0.531 
Physician MSK DA VAS (mm) 13.00 (2.58) 27.70 (4.79) 14.70 (4.91, 24.49) 1.00 (-7.28, 9.29), p=0.808 -0.09 (-7.54, 7.37), p=0.982 
HAQ-DI 0.79 (0.24) 1.31 (0.16) 0.52 (-0.07, 1.10) 0.01 (-0.13, 0.14), p=0.922 0.02 (-0.12, 0.15), p=0.812 
Patient MSK DA VAS (mm) 44.85 (7.00) 42.45 (4.91) -2.40 (-22.68, 17.88) -2.76 (-18.00, 12.47), p=0.719 -1.71 (-17.62, 14.20), p=0.831 
Patient MSK Pain VAS (mm) 54.65 (4.12) 62.45 (3.02) 7.80 (-3.26, 18.86) 2.19 (-6.68, 11.07), p=0.623 0.07 (-11.90, 12.04), p=0.991 
EMS VAS (mm) 60.30 (4.58) 66.25 (3.34) 5.95 (-2.84, 14.74) 1.89 (-5.87, 9.64), p=0.625 -1.64 (-10.07, 6.78), p=0.698 
EMS (mins) 33.50 (9.93) 89.75 (14.11) 56.25 (34.61, 77.89) 0.26 (-27.89, 28.41), p=0.986 0.78 (-19.39, 20.95), p=0.939 
Total GSPD (joints) 0.30 (0.85) 4.30 (1.68) 4.00 (1.14, 6.86) -0.34 (-3.40, 2.72), p=0.826 -0.22 (-2.60, 2.15), p=0.854 
Total GSPD (tendons) 1.75 (0.59) 5.65 (1.57) 3.90 (0.58, 7.22) 3.36 (0.14, 6.59), p=0.041 Model did not converge 
Physician's global VAS (mm) 15.75 (2.63) 29.65 (4.42) 13.90 (3.77, 24.03) -0.32 (-9.58, 8.95), p=0.945 -1.55 (-10.48, 7.38), p=0.729 
Total BILAG score 2.00 (2.25) 5.40 (2.95) 3.40 (-2.97, 9.77) -0.70 (-3.44, 2.03), p=0.614 -0.51 (-3.16, 2.14), p=0.704 
Total SLEDAI score 3.75 (1.29) 3.85 (1.26) 0.10 (-1.73, 1.93) -0.65 (-2.04, 0.73), p=0.348 -0.65 (-1.68, 0.39), p=0.219 
Patient general health VAS (mm) 58.95 (4.12) 51.75 (2.82) -7.20 (-16.51, 2.11) -4.86 (-11.89, 2.18), p=0.175 -8.37 (-17.84, 1.10), p=0.083 
Abnormal fatigue VAS (mm) 67.90 (3.48) 73.00 (4.52) 5.10 (-4.80, 15.00) 0.68 (-11.22, 12.58), p=0.909 0.07 (-10.94, 11.07), p=0.990 
 US activity at baseline Odds ratio (95% CI) 
 Inactive % Active % Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P 
value 
BILAG MSK improved  26%  56% 3.74 (2.03, 6.90) 1.91 (0.69, 5.26), p=0.213 2.17 (0.88, 5.34), p=0.091 
SLEDAI MSK improved  15%  37% 3.24 (1.62, 6.50) 2.27 (1.08, 4.75), p=0.030 2.33 (0.96, 5.69), p=0.063 
*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale 
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Figure 7-2: BILAG and SLEDAI responses according to baseline ultrasound status
 
Comparison between BILAG and SLEDAI improvement according to the ultrasound status in the full set of patients and significant improvement when patients with fibromyalgia were excluded from 
the analysis. 
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7.4.8 Quality of Life  
In week 2 results, all patients note there is only one variable of borderline significant (Burden 
to others).  Quality of life domains that might be expected to correlate better with 
musculoskeletal disease activity (Physical health, Pain) did not differ according to baseline 
ultrasound. 
Results were similar at week 6 with borderline difference for Physical health (P=0.050) and 
Body image (P=0.043) both were lower at week 6 in patients with active ultrasound.  Results 
were also similar for the LQoL.  However, for the musculoskeletal endpoint, Fibromyalgia may 
confound these results. I therefore repeated these analyses and excluding Fibromyalgia 
patients.  After excluding fibromyalgia patients, the difference for Borden to others was far 
more significant (P=0.003) but there were still no other significant differences.  Interestingly, 
at week 6 after excluding fibromyalgia patients, there was a significantly lower score for Quality 
of life Physical health in patients with active ultrasound at baseline(-7.49 (-12.90, -2.07), 
p=0.008.
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Table 7-11: Secondary QoL outcomes at week 2(All patients) 
Variable US activity at baseline Difference between medians (95% CI) 
 Inactive median (SE) Active median (SE) Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P value 
LupusQoL: Physical health 45.47 (4.64) 40.94 (5.18) -4.53 (-17.36, 8.30) -0.45 (-3.93, 3.03), p=0.799 -0.57 (-4.10, 2.95), p=0.749 
LupusQoL: Pain 49.58 (5.33) 41.67 (4.61) -7.92 (-16.91, 1.07) 0.65 (-3.84, 5.15), p=0.776 1.28 (-3.74, 6.30), p=0.616 
LupusQoL: Planning 42.92 (5.78) 39.17 (6.02) -3.75 (-16.56, 9.06) -0.17 (-5.35, 5.00), p=0.948 -0.14 (-4.58, 4.31), p=0.951 
LupusQoL: Burden to others 40.83 (7.80) 31.67 (7.87) -9.17 (-28.60, 10.27) -8.33 (-18.45, 1.78), p=0.106 -8.33 (-16.68, 0.01), p=0.050 
LupusQoL: Emotional health 56.46 (5.41) 47.29 (5.12) -9.17 (-21.04, 2.70) 0.05 (-3.30, 3.39), p=0.978 0.18 (-3.33, 3.68), p=0.922 
LupusQoL: Body image 67.06 (4.33) 44.12 (8.93) -22.94 (-43.38, -2.49) -0.51 (-6.57, 5.54), p=0.867 -0.71 (-7.01, 5.58), p=0.823 
LupusQoL: Fatigue 29.69 (8.39) 25.00 (4.71) -4.69 (-17.43, 8.05) 1.42 (-3.41, 6.26), p=0.562 0.86 (-3.04, 4.75), p=0.665 
LQoL 15.80 (1.34) 16.05 (1.42) 0.25 (-2.07, 2.57) -0.35 (-1.93, 1.23), p=0.661 0.00 (-0.82, 0.83), p=0.993 
Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale 
Table 7-12: Secondary QoL outcomes at week 6 
Variable US activity at baseline Difference between medians (95% CI) 
 Inactive median 
(SE) 
Active median 
(SE) 
Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P 
value 
LupusQoL: Physical health 44.58 (6.71) 35.47 (4.49) -9.11 (-24.88, 6.65) -6.57 (-13.27, 0.13), p=0.054 -7.25 (-14.48, -0.01), p=0.050 
LupusQoL: Pain 52.50 (8.74) 40.83 (5.48) -11.67 (-26.73, 3.40) -5.22 (-13.60, 3.16), p=0.218 -3.07 (-10.18, 4.04), p=0.395 
LupusQoL: Planning 57.92 (13.02) 41.67 (7.56) -16.25 (-44.15, 11.65) -1.75 (-9.93, 6.43), p=0.673 -2.22 (-9.63, 5.20), p=0.554 
LupusQoL: Intimate relationship 37.50 (11.70) 30.00 (13.95) -7.50 (-37.12, 22.12) -0.42 (-9.01, 8.18), p=0.924 -0.63 (-8.92, 7.67), p=0.882 
LupusQoL: Burden to others 40.83 (8.31) 30.00 (8.16) -10.83 (-31.52, 9.85) -7.54 (-15.27, 0.18), p=0.056 -5.67 (-11.68, 0.34), p=0.064 
LupusQoL: Emotional health 57.08 (6.60) 39.79 (4.15) -17.29 (-30.46, -4.12) -3.61 (-9.09, 1.88), p=0.195 -2.60 (-8.44, 3.24), p=0.379 
LupusQoL: Body image 68.33 (6.13) 44.87 (5.99) -23.46 (-39.59, -7.33) -8.83 (-16.65, -1.01), p=0.027 -7.95 (-15.64, -0.26), p=0.043 
LupusQoL: Fatigue 29.38 (8.45) 25.31 (4.26) -4.06 (-18.72, 10.59) -2.56 (-8.15, 3.03), p=0.366 -2.78 (-7.95, 2.40), p=0.291 
LQoL 12.85 (2.03) 17.30 (1.53) 4.45 (-0.76, 9.66) -0.30 (-2.64, 2.04), p=0.801 0.23 (-1.29, 1.75), p=0.764 
*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale.  
Due to failure of the analysis models to converge, possibly due to the large number of patients who said the domain was not applicable, data have not been 
provided for LupusQOL 4: Intimate relationship 
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Table 7-13: Secondary QoL outcome measures at week 2(in patients without fibromyalgia) 
Variable US activity at baseline Difference between medians (95% CI) 
Inactive median (SE) Active median (SE) Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P value 
LupusQoL: Physical health 48.28 (3.78) 43.44 (5.02) -4.84 (-16.91, 7.22) -1.37 (-5.58, 2.85), p=0.514 -0.93 (-5.33, 3.47), p=0.671 
LupusQoL: Pain 52.92 (9.27) 41.67 (3.97) -11.25 (-27.28, 4.78) 5.24 (-2.32, 12.79), p=0.167 3.61 (-2.22, 9.43), p=0.221 
LupusQoL: Planning 48.33 (8.89) 42.08 (6.37) -6.25 (-24.59, 12.09) 0.00 (-2.73, 2.73), p=1.000 0.43 (-3.83, 4.69), p=0.843 
LupusQoL: Burden to others 42.08 (6.77) 36.67 (7.04) -5.42 (-19.84, 9.00) -8.33 (-13.57, -3.09), p=0.002 -7.85 (-12.96, -2.75), p=0.003 
LupusQoL: Emotional health 53.54 (4.89) 51.04 (6.24) -2.50 (-17.21, 12.21) 1.19 (-4.33, 6.70), p=0.671 1.57 (-3.64, 6.78), p=0.551 
LupusQoL: Body image 66.69 (4.59) 45.31 (10.40) -21.37 (-44.45, 1.70) 0.69 (-6.38, 7.75), p=0.846 -1.10 (-10.00, 7.81), p=0.805 
LupusQoL: Fatigue 29.69 (6.04) 25.31 (3.72) -4.38 (-15.84, 7.09) 1.89 (-3.49, 7.27), p=0.486 1.25 (-3.61, 6.10), p=0.613 
LQoL 15.20 (1.43) 15.75 (2.04) 0.55 (-3.66, 4.76) -0.70 (-2.28, 0.89), p=0.386 -0.50 (-1.72, 0.72), p=0.414 
*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale 
Table 7-14: Secondary QoL outcomes at 6 weeks (in patients without fibromyalgia) 
Variable US activity at baseline Difference between medians (95% CI) 
Inactive 
median (SE) 
Active median 
(SE) 
Unadjusted Adjusted primary*, P value Adjusted sensitivity**, P value 
LupusQoL: Physical health 45.52 (7.19) 34.53 (5.09) -10.99 (-26.59, 4.61) -7.74 (-14.47, -1.00), p=0.025 -7.49 (-12.90, -2.07), p=0.008 
LupusQoL: Pain 52.50 (9.27) 37.92 (5.57) -14.58 (-32.61, 3.45) -7.09 (-16.12, 1.93), p=0.121 -4.49 (-14.43, 5.44), p=0.364 
LupusQoL: Planning 64.17 (14.83) 42.08 (7.05) -22.08 (-49.34, 5.17) -1.84 (-10.70, 7.02), p=0.682 -1.71 (-9.61, 6.19), p=0.670 
LupusQoL: Intimate relationship 41.87 (11.83) 40.00 (13.82) -1.87 (-32.73, 28.98) -0.00 (-5.16, 5.16), p=1.000 -0.00 (-6.02, 6.02), p=1.000 
LupusQoL: Burden to others 45.00 (8.93) 29.17 (6.36) -15.83 (-32.38, 0.71) -8.36 (-16.05, -0.67), p=0.033 -6.68 (-13.28, -0.08), p=0.047 
LupusQoL: Emotional health 57.50 (6.20) 42.71 (5.39) -14.79 (-29.07, -0.52) -2.96 (-9.39, 3.47), p=0.366 -0.41 (-6.38, 5.56), p=0.893 
LupusQoL: Body image 68.04 (6.46) 44.06 (6.64) -23.98 (-41.53, -6.43) -9.02 (-20.08, 2.03), p=0.108 -7.72 (-16.46, 1.02), p=0.083 
LupusQoL: Fatigue 35.00 (6.76) 25.94 (4.48) -9.06 (-24.31, 6.19) -4.29 (-12.27, 3.68), p=0.289 -3.96 (-12.57, 4.64), p=0.364 
LQoL 12.65 (2.02) 17.15 (1.39) 4.50 (-0.39, 9.39) -0.26 (-2.61, 2.09), p=0.827 -0.03 (-1.55, 1.48), p=0.967 
*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale
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 Discussion 
Key findings of this study were: 
When assessing SLE patients with suspected synovitis: 
1. The presence of osteoarthritis or fibromyalgia features were a poor guide to whether 
ultrasound-confirmed synovitis would be present. 
2. However, symmetry, swelling and probably distribution and serology were associated 
with ultrasound-confirmed synovitis. 
3. The primary endpoint of the study was not met: we did not demonstrate a better clinical 
response to glucocorticoids in patients with ultrasound synovitis at baseline. 
4. However, if fibromyalgia was excluded then ultrasound appeared predictive of clinical 
response to glucocorticoids. 
In my literature review and published review article I highlighted the unmet need in this area 
(Figure 2-2. ).  It has been clear for some time that in patients with clinical synovitis, there is 
proven benefit of using glucocorticoids, immunosuppression and biologic therapies.  It is also 
clear in many studies that there is a substantial proportion of patients (27% in my study) who 
have ultrasound proven synovitis without joint swelling, as well as a group with no ultrasound 
synovitis.  It was not clear whether patients with ultrasound synovitis should be treated with 
glucocorticoids and immunosuppressant, while those without should be treated 
symptomatically. The results in this chapter provide an answer to this question. 
When analysing the response to glucocorticoids, only physician’s assessments of disease 
activity (VAS, BILAG and SLEDAI) showed a better response in ultrasound in active patients.  
Therefore, the primary endpoint of the study (early morning stiffness VAS at 2 weeks) was not 
met and none of the patient’s reported outcomes showed greater improvement in patients with 
positive ultrasound.  However, I found that the presence of fibromyalgia was a significant 
confounder. If patients with fibromyalgia were removed from the analysis, then baseline 
ultrasound was a significant predictor of response to glucocorticoids.  It should be noted that 
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at baseline the presence of fibromyalgia was not helpful in predicting the likelihood of 
ultrasound synovitis at baseline.  This is consistent with the clinical impression that this 
subgroup of patients had both inflammatory arthritis and fibromyalgia as independent causes 
of musculoskeletal pain.  We may therefore interpret our responsiveness data as follows: 
ultrasound-proven synovitis predicts a better symptomatic response to glucocorticoids. 
However, if there is an additional, non-steroid responsive cause of pain present then the 
predictive effect of ultrasound cannot be detected. 
There were two key limitations in this study.  First, this was an open labelled single arm study. 
Therefore, there may be observation biases of physician and patient who were both aware 
that active treatment has been given.  Secondly, the choice of glucocorticoid as a therapy. It 
is well known that glucocorticoids are effective for many types of arthritis and this includes 
osteoarthritis.  It remains possible that baseline ultrasound would provide more response to 
SLE specific therapy such as azathioprine or rituximab. 
My results have implications for both clinical trials and routine practice. In clinical trials that 
focus on musculoskeletal SLE then I would advise fibromyalgia as an exclusion criterion, since 
it will not be possible to detect the efficacy of SLE medications in patients with this problem. 
In routine practice, my results indicate that an ultrasound scan should be considered in SLE 
patients with joint pain but no clinical synovitis. If these patients have positive ultrasound then 
they should be considered for escalation of immunosuppressive therapy (not just 
glucocorticoids). 
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Chapter 8: USEFUL Study: Responsiveness of ultrasound 
and clinical variables 
The purpose of this chapter is to further evaluate the responsiveness of ultrasound compared 
to other clinical variables. 
In my pilot study (Chapter 6:), most of the patients had clinical synovitis at baseline. If we 
propose to include patients with ultrasound-only synovitis in clinical trials and for 
immunosuppressive therapy in routine practice, then it is necessary to assess the 
responsiveness of outcome measures in the USEFUL population that includes patients with 
ultrasound synovitis or no synovitis. 
Also, in the pilot study I found that ultrasound had greater overall responsiveness than many 
of the other variables. However, we don’t know whether this is clinically significant.  In other 
words, the responsiveness of ultrasound may be too great, suggesting that patients have 
improved when in reality they still have symptoms and are at risk of long-term damage.  This 
is analogous to measuring a reduction in CRP after glucocorticoids – a reduction may occur 
even if the cause of the raised CRP was infection, and does not necessarily indicate that the 
patient is getting better.  In the context of ultrasound in SLE, over-responsiveness could occur 
if there was significant autoimmune-mediated pain that was not captured by the ultrasound, 
e.g. if it was in a joint not included in the scan or a pathology that is not well visualised on 
ultrasound such as bone oedema. 
There are several ways that the clinical significance of ultrasound response could be 
investigated: against symptoms, against longer term outcomes, or in differentiating treatment 
arms in a randomised trial.  Given the design of the USEFUL study, I investigated the 
relationship of ultrasound-response to patient-reported improvement in pain. 
 Objective 
 Determine whether musculoskeletal ultrasound variables (GS or PD) are responsive to 
therapy than other outcome measures. 
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 Determine the overall effect size of change in ultrasound in a broader population of 
patients who don’t all have swollen joints 
 To compare the responsiveness of ultrasound and other musculoskeletal variables with 
patient-reported improvement in pain 
 Patients and methods 
For the design of the USEFUL study please see 4.2.2.  For a summary of recruitment please 
see 4.4.3.  For baseline clinical and demographic characteristics, please see 4.4.1. 
 Statistical analysis 
To test whether total ultrasound scores for GS, PD and tenosynovitis were sensitive to change, 
changes in each of these variables were correlated with the responses on the Likert scale for 
improvement using Kendall’s tau-a. Median differences between each of the tau-a values 
calculated for the ultrasound variables and those calculated for the clinical variables, together 
with bootstrapped confidence intervals, were obtained.  These analyses were conducted in all 
patients in the primary analysis; a sensitivity analysis restricted the analysis to patients with 
active ultrasound present at baseline.  This correlation approach was adopted because it was 
likely that there would be variation in the extent of response to Depo-medrone. In addition, as 
a sensitivity analysis, effect sizes were calculated using the standardized test statistic Z from 
Wilcoxon signed ranks tests of differences between baseline and each post-baseline visit, 
according to the formula r=Z/sqrt(n1+n2). Effect sizes have been assessed using Cohen’s 
criteria as large (|r|>0.5), medium (|r|>0.3) or small (|r|>0.1). 
Within categories of the musculoskeletal domains of the existing instruments (SLEDAI-2K 
MSK score 0 or 4; BILAG (2004) A, B, C, D/E) descriptive summaries (mean, SD, median, 
IQR, minimum, maximum) were obtained for each of the following musculoskeletal-specific 
variables at baseline: tender joint count (68 joints), swollen joint count (66 joints), patient’s 
painful joint count, patient pain VAS, patient musculoskeletal disease activity VAS, physician 
musculoskeletal disease activity VAS, health assessment questionnaire disability index (HAQ-
 
 
 194 
DI), severity of early morning stiffness VAS, duration of early morning stiffness, total scores 
for ultrasound grey scale, power Doppler and tenosynovitis and ultrasound-detected presence 
of osteophytes in the hands and wrists. 
The following non-specific outcomes were summarised at baseline within categories of the 
musculoskeletal domains of the existing instruments (SLEDAI-2K MSK score 0 or 4; BILAG 
(2004) merged ABC vs DE), further split by the categories of any other domains found to be 
involved in at least 12 patients (a minimum usually stipulated for accurate estimation of a 
quantity in pilot studies): physician’s global VAS, patient fatigue VAS, erythrocyte 
sedimentation rate (ESR), Ig titres, complement titres. 
 Results 
8.4.1 Overall responsiveness of the clinical and ultrasound musculoskeletal variables 
The overall responsiveness in the ultrasound and clinical variables at 2 and 6 weeks is shown 
using effect sizes in Table 8-1.  In keeping with my pilot study in 20 patients, some of the 
largest effect sizes were seen for physician VAS, BILAG and ultrasound parameters.  
However, there were some differences in the USEFUL patients.  At week 2, the effect size for 
ultrasound was “medium”, but had been “large” in my pilot study.  This can be explained by 
the large number of patients in USEFUL with normal ultrasound scores at baseline. Similarly, 
the patient VAS was less responsive in USEFUL than in the pilot study, which may be because 
glucocorticoids are less effective in patients without synovitis. 
At week 6, the effect sizes for BILAG and SLEDAI were both medium in USEFUL.  In the pilot 
study BILAG had a large effect size at week 4.  This differences may also be due to the lower 
frequency of clinical synovitis in USEFUL.  Patients without swollen joints score BILAG C at 
baseline and could only improve to BILAG D if they achieved complete remission. In contrast, 
patients with severe (BILAG A) or moderate (BILAG B) synovitis at baseline can reduce their 
scores by one grade if these features are “improving” at follow up. 
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Table 8-1: Signed rank effect sizes for changes at weeks 2 and 6 
Variable All patients Baseline US active only 
Week 2 Week 6 Week 2 Week 6 
EMS VAS (mm) 0.33 (Medium) 0.29(Small) 0.37 (Medium) 0.29 (Small) 
EMS mins (min) 0.19 (Small) 0.11(Small) 0.24 (Small) 0.11 (Small) 
Tender 68 joint count 0.37 (Medium) 0.26(Small) 0.35 (Medium) 0.27 (Small) 
Swollen 66 joint count 0.32 (Medium) 0.21(Small) 0.43 (Medium) 0.30 (Medium) 
Patient painful joint count 0.33 (Medium) 0.29(Small) 0.37 (Medium) 0.40 (Medium) 
Physician MSK DA VAS (mm) 0.50(Large) 0.38(Medium) 0.51 (Large) 0.40 (Medium) 
HAQ-DI 0.19(Small) 0.16(Small) 0.23 (Small) 0.19 (Small) 
Patient MSK DA VAS (mm) 0.24(Medium) 0.20(Small) 0.27 (Small) 0.26 (Small) 
Patient MSK Pain VAS (mm) 0.28(Small) 0.16(Small) 0.32 (Medium) 0.20 (Small) 
BILAG MSK N/A 0.31(Medium) N/A 0.39 (Medium) 
SLEDAI MSK N/A 0.27(Small) N/A 0.39 (Medium) 
Total GSPD (joints) 0.33(Medium) 0.33(Medium) 0.43 (Medium) 0.41 (Medium) 
Total GSPD (tendons) 0.13(Small) 0.10(Small) 0.14 (Small) 0.13 (Small) 
EMS: early morning stiffness, HAQ: Health Assessment Questionnaire, VAS: visual analogue scale, BILAG British Isles Lupus Assessment Group. SLEDAI: 
Systemic Lupus Erythematosus Disease Activity Index.
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8.4.2 Patient-reported change in pain 
I next examined the patient-reported change in pain using the Likert scale.  Estimated 
proportions of patients within each category for change in pain are shown in (Table 8-2).  At 
week 2, 62% of the patients reported they improved, and 61% at week 6.  On the other hand, 
11% said they got worse by week 2 and 14% at week 6.  A quarter reported no change in their 
situation in both week 2 and week 6.  These results therefore also highlight that the most 
responsive variables may not necessarily be the most accurate (since some patients felt 
worse).  It is also important to note that patient reported change in pain may relate to any 
cause, while ultrasound and physicians attempt to specifically assess pain due to SLE. 
Table 8-2: Estimated proportions of patients in each category for change in pain Likert 
scale 
Change Week2 Week6 
A very great deal better 0.03 0.06 
A great deal better 0.04 0.05 
A good deal better 0.14 0.11 
Moderately better 0.06 0.05 
Somewhat better 0.11 0.07 
A little better 0.17 0.22 
Almost the same, hardly better 0.07 0.05 
About the same 0.27 0.25 
Almost the same, hardly worse - 0.04 
A little worse 0.03 0.03 
Somewhat worse 0.02 0.03 
Moderately worse 0.04 - 
A good deal worse 0.02 0.02 
A great deal worse - 0.01 
A very great deal worse - 0.01 
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8.4.3 Correlation of change in ultrasound with patient Likert responses 
The correlations between each clinical or ultrasound variable and the patient’s Likert 
responses are shown in (Table 8-3).  The values are Kendall’s Tau. The first two columns 
show the overall correlations at weeks 2 and 6.  These correlations are generally quite weak. 
The only strong correlations were seen for other patient-reported variables (EMS VAS and 
duration, and musculoskeletal pain VAS) at week 2, as expected.  The correlations between 
ultrasound variables and patient’s Likert response are very weak.  The other columns in the 
table provide a formal comparison of the strength of correlation for ultrasound parameters 
with each of the clinical variables. 
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Table 8-3: Correlation of clinical and ultrasound variables with patient's Likert response 
Variable 
Correlation with change in pain Difference (95% CI) 
Week 2 (95% CI) Week 6 (95% CI) 
cf. GSPD (joints) 
W2 
cf. GSPD (joints) 
W6 
cf. GSPD 
(tendons) W2 
cf. GSPD (tendons) W6 
EMS VAS (mm) 0.26 (0.17, 0.35) 0.16 (0.04, 0.29) -0.22 (-0.35, -0.09) -0.13 (-0.31, 0.04) -0.27 (-0.38, -0.15) -0.16 (-0.31, 0.00) 
EMS duration (mins) 0.20 (0.09, 0.31) 0.12 (0.00, 0.23) -0.16 (-0.32, 0.01) -0.08 (-0.23, 0.06) -0.20 (-0.34, -0.07) -0.11 (-0.26, 0.04) 
Tender 68 joint count 0.01 (-0.09, 0.11) 0.15 (0.04, 0.26) 0.03 (-0.12, 0.19) -0.12 (-0.27, 0.03) -0.01 (-0.14, 0.11) -0.14 (-0.28, -0.01) 
Swollen 66 joint count -0.08 (-0.18, 0.02) 0.07 (-0.03, 0.17) 0.12 (-0.03, 0.28) -0.04 (-0.17, 0.10) 0.07 (-0.03, 0.18) -0.06 (-0.19, 0.06) 
Pt painful joint count 0.16 (0.04, 0.27) 0.13 (0.01, 0.24) -0.11 (-0.24, 0.02) -0.10 (-0.24, 0.05) -0.16 (-0.28, -0.04) -0.12 (-0.26, 0.02) 
Phys MSK VAS (mm) 0.06 (-0.05, 0.17) 0.13 (0.02, 0.23) -0.01 (-0.17, 0.14) -0.09 (-0.22, 0.04) -0.06 (-0.18, 0.06) -0.12 (-0.25, 0.01) 
HAQ-DI 0.10 (-0.02, 0.22) 0.10 (0.00, 0.20) -0.05 (-0.19, 0.09) -0.07 (-0.22, 0.09) -0.10 (-0.25, 0.05) -0.09 (-0.22, 0.04) 
Patient MSK VAS (mm) 0.08 (-0.04, 0.20) 0.10 (-0.01, 0.22) -0.04 (-0.19, 0.12) -0.07 (-0.22, 0.08) -0.09 (-0.24, 0.06) -0.09 (-0.21, 0.02) 
Patient Pain VAS (mm) 0.28 (0.17, 0.39) 0.16 (0.05, 0.27) -0.24 (-0.39, -0.09) -0.13 (-0.28, 0.03) -0.28 (-0.41, -0.16) -0.15 (-0.29, -0.01) 
BILAG MSK 0.05 (-0.05, 0.14) 0.08 (-0.02, 0.18) 0.00 (-0.13, 0.13) -0.05 (-0.18, 0.09) -0.05 (-0.17, 0.08) -0.07 (-0.20, 0.06) 
SLEDAI MSK 0.05 (-0.03, 0.14) 0.13 (0.05, 0.22) -0.01 (-0.13, 0.11) -0.10 (-0.24, 0.04) -0.06 (-0.17, 0.05) -0.13 (-0.24, -0.01) 
Total GSPD (joints) 0.04 (-0.08, 0.17) 0.03 (-0.08, 0.15) - - -0.05 (-0.20, 0.10) -0.02 (-0.15, 0.11) 
Total GSPD (tendons) 0.00 (-0.09, 0.09) 0.01 (-0.08, 0.09) 0.05 (-0.10, 0.20) 0.02 (-0.11, 0.15) - - 
EMS: early morning stiffness, VAS: visual analogue scale, BILAG British Isles Lupus Assessment Group. SLEDAI: Systemic Lupus Erythematosus Disease 
Activity Index. 
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 Discussion 
In terms of clinical trials, one of the most important characteristics of an outcome measure is 
responsiveness.  Most of the validated instruments in current use have been validated as 
responsive.  For example, the BILAG was shown to be sensitive to change when compared 
to change in therapy [416]. 
However, there are far fewer studies that formally compare the different instruments with 
each other.  Also, there are fewer studies that use a formal longitudinal design where all 
patients receive the same therapy.  Lastly, there have generally been no objective measures 
of disease activity against which to compare the responsiveness of various clinical tools. 
In this study I addressed all of these needs.  My results confirmed my pilot data in 
demonstrating very different levels of responsiveness in the different outcome measures, 
and these results will be useful in choosing which variables should be analysed in clinical 
trials.  Where the results in this chapter differed from my previous study, this can be 
attributed to the greater amount of synovitis at baseline in the earlier study. 
The results were less clear when it came to comparing ultrasound responses to patient 
Likert responses. The correlation between these variables was poor.  Although this was the 
protocol-specified analysis, these results may not be unexpected given the baseline data in 
the study.  Baseline ultrasound findings showed that many patients had significant pain that 
was not due to synovitis.  This may be due to other pathologies like osteoarthritis and 
fibromyalgia that will not respond as well to glucocorticoids.  When answering the patient’s 
Likert scale, the patients would report this pain, even if it was non-inflammatory.  Hence the 
ultrasound tool that relates only to objective synovitis could differ. 
Given this interpretation, it remains possible that ultrasound response has other types of 
clinical significance apart from representing patient experience.  Ultrasound may capture only 
the response in SLE pathology, and this may have implications for longer-term outcomes.  For 
example, long term damage and quality of life outcomes may be better predicted by ultrasound 
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response to therapy.  Ultrasound responses may also be better when comparing 
immunosuppression and placebo treatment arms of a clinical trial. 
Previous data in rheumatoid arthritis are consistent with this hypothesis.  Most analyses of 
disease activity in rheumatoid arthritis are based on the DAS28, which includes the “objective” 
parameters, swollen joint count and CRP, as well as the patient-reported parameters, tender 
joint count and VAS.  The patient-reported outcomes used in RA may have the same issues 
as in my SLE study – they may reflect other types of pain, not just autoimmunity.  A recent 
study compared the DAS28 with an analysis of disease activity using only the objective 
components.  In that study, an outcome measure based only on the swollen joint count and 
CRP predicted erosions better than the DAS28 [417]. 
The results in this chapter, as well as the previous chapter, will be used in two future projects.  
First, we will use this data to design a new composite outcome measure for musculoskeletal 
SLE. Second, we will analyse these variables and the new outcome measure in a feasibility 
RCT (“ROOTS”).  Thereby we expect to be able to design more robust clinical trials in 
musculoskeletal SLE, with smaller sample sizes. 
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Chapter 9: MISTER study: Validation of ultrasound using 
MRI as the imaging gold standard in SLE (Criterion validity) 
 Objective 
1. To validate ultrasound-only synovitis using MRI 
2. To describe MRI pathology in patients with SLE arthritis in detail 
 Patients and methods 
(MISTER: Mri In Sle arThRitis) is a cross-sectional observational study was conducted in 
patients with Systemic Lupus Erythematosus.  All of the patients were ANA positive. Patients 
with positive Anti-CCP and RF positive (ever) were excluded.  Also, patients must be on a 
stable dose of immunosuppressant over the last three months.  Patients were asked to stop 
NSAIDs at least three days before the scan if possible. The maximum allowed dose of 
glucocorticoids allowed was 5 mg.  
All individuals provided informed written consent and this research was carried out in 
compliance with the Declaration of Helsinki.  The study was approved by National Research 
Ethics Committee Yorkshire and Humber–Leeds East reference 10/H1306/88.  All 
procedures were performed in accordance with relevant guidelines and regulations. The 
University of Leeds was the sponsorship. 
Although the planned total recruitment is 52 patients, an interim analysis has been presented 
here.  A total of 36 of SLE patients fulfilling SLICC 2012 criteria were recruited in this study. 
Two patients had their MRI scan done without contrast.  Patients were divided into three 
groups. The first group consisted of 11 patients with pain (arthralgia), no swelling, and 
normal ultrasound.  The second group comprised of 14 patients with arthralgia and 
ultrasound synovitis (GS≥2, PD>0) or tenosynovitis (GS≥1 and/or PD>0).  The third group 
comprised 11 with clinical synovitis (swelling) of whom 8/11 had abnormal ultrasound scans.  
All of these patients underwent MRI and ultrasound scans (hand and wrist) in the most 
symptomatic hand (the use of single hand is more comfortable for patients, reduce time and 
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cost of the scan) on the same day in addition to clinical assessments performed by trained 
rheumatologists who are blinded to the ultrasound assessment. 
 Clinical and laboratory assessments 
SLE was assessed by using BILAG-2004 [169], SLEDAI-2K 30 days[388] Joint disease was 
assessed using nine tender and swollen joint counts  (Wrist,MCP2-5,PIP2-5 to match the 
joints evaluated by the MRI scan and ultrasound), symptomatic joint count, physician 
musculoskeletal visual analogue score (VAS), patient’s pain VAS and minutes of early 
morning stiffness.   Patients were tested for routine inflammatory and serological markers.  
CRP (mg/l), ESR (mm/h), RF (IU/ml), CCP antibodies (CCP, IU/ml), complements (C3 and 
C4, g/l), ANA, extracted nuclear antibodies including anti-dsDNA, anti Ro, anti La, anti-
chromatin, anti Sm, anti-RNP and immunoglobulins (IgA, IgM, IgG,) were measured on the 
visit date in an accredited clinical diagnostic laboratory. 
 Ultrasound assessment 
Ultrasonography (grey scale (GS) and power Doppler (PD)) was performed using high 
resolution ultrasound machines; General Electric (GE Healthcare, Chicago, IL) Logiq E9 
ultrasound with multi-linear 6–15 MHz transducer.  Wrist and hand were assessed in all 
patients. Joints in the hand and wrist were examined using a standard approach of 
examining the following; radio-carpal, inter-carpal, ulnar-carpal joints and second to fifth 
MCP joints and second to fifth PIP joints.  Tendon sheaths including the first to sixth 
extensor tendons compartments of the wrist and second to fifth flexor digitorum tendon 
sheaths of the hands were assessed for tenosynovitis.  For more details, please see 4.1. 
 MRI scoring of arthritis: 
Patients have been consented to have an MRI scan of the wrists and hands.  The MRI 
machine was a 3T Siemens VERIO scanner.  The MRI protocol consisted of T1 (axial, 
coronal), T2 fat-saturated axial and STIR (short-tau inversion recovery) and T1 volumetric 
interpolate breath-hold (VIBE) 3D pre-contrast and post contrast coronal.  MRI scans were 
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obtained using standard musculoskeletal sequences with gadolinium contrast. 
Semiquantative scoring of the images used the OMERACT for assessing activity in 
Rheumatoid Arthritis, (RAMRIS) [418].  
The RAMRIS scores bone marrow oedema (23 anatomical areas, (range 0-3), synovitis (7 
anatomical areas, (range 0-3), erosions (23 anatomical areas, (range 0-10) and 
tenosynovitis was scored in 10 anatomical areas (range 0-3).  I modified the score to match 
the joint areas assessed clinically and by ultrasound.  So, there were 24 anatomical areas 
for both bone marrow oedema and erosion with total score of 51 for each variable.  For 
synovitis there were 11 areas with total score of 33 and 13 areas for tenosynovitis with total 
score of 39. The maximum total score for my modified RAMRIS is 123. 
 Statistical analysis: 
General clinical characteristics were described for each of the three groups: (1) arthralgia 
with normal ultrasound and examination; (2) arthralgia with ultrasound synovitis and normal 
examination, also called “subclinical synovitis”; (3) arthralgia with joint swelling, of whom 
most had ultrasound-confirmed synovitis. 
RAMRIS score for synovitis was the key criterion for comparing the groups and was 
compared between these groups using a Mann-Whitney U test with pairwise comparisons. 
The other RAMRIS scores (bone oedema, tenosynovitis and erosions) were also compared 
as secondary endpoints. 
The agreement between ultrasound and MRI synovitis at each site (joint or tendon sheath) 
was tested by calculating sensitivity, specificity, Kappa and PABAK statistics. Level of 
agreement between MRI and ultrasound when detecting synovitis was quantified as the 
proportion of joints in which both methods exactly agreed over the presence or absence of 
synovitis (percentage exact agreement [PEA]), proportions of category-specific negative and 
positive agreement (Sp0 and Sp1 for absence and presence of synovitis, respectively), and 
the proportions of joints where MRI and ultrasound disagreed in either direction (US>MRI, 
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US<MRI).  One common criticism is that kappa is highly dependent on the prevalence of the 
condition in the population. The kappa statistic was therefore supplemented with the 
prevalence-adjusted bias-adjusted kappa (PABAK) to give an indication of the extent to 
which differences in the overall level of synovitis identified by each assessment method 
together with imbalances in the proportions of joints with and without synovitis affected the 
calculated value of kappa. PAB AK has been employed in many previous studies for 
agreement assessment[419].  Compared with kappa, PABAK reflects the ideal situation, and 
ignores the variation of prevalence across the conditions and bias presented in the "real" 
world.  Finally, qualitative features of the imaging were described by an experienced 
radiologist. 
 Results 
A total of 36 patients were enrolled, of whom, two were males and 34 females.  The mean of 
the age for all patients was 44.3(SD 12) years.  Disease duration mean was 72(SD 79) 
months.  Most of the patients were Caucasians 25/36 (69%), 6/36 (17%) were south Asians.  
Eight patients were taking glucocorticoids and 26 patients were on hydroxychloroquine.  
Other baseline variables are detailed in (Table 9-1). 
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Table 9-1: Baseline clinical characteristics of patients in MISTER study 
    DMARD: disease modified anti rheumatic drug, NO: for number of patient, * Median (IQR), SJC: 
swollen joint count, TJC: tender joint count, EMS: early morning stiffness, BILAG: British Isles lupus 
assessment group, SLEDAI: systemic lupus erythematosus disease activity index, US: ultrasound, 
VAS: visual analogue scale. 
  
 All patients 
 
Normal US Clinical 
synovitis± 
US 
US-synovitis 
No. of patients 36 11 14 11 
Age mean(SD) 44.3(12) 42(13) 44(14) 46(12) 
Disease Duration in 
months mean(SD) 
72(79) 36(12-56)* 26(12-84)* 54(2-87)* 
TJC (0-9)* 4(1-6) 2(1-4) 5(0-9) 5(4-8) 
SJC (0-9)* 2(2-3) 0(0-0) 3(2-5) 0(0-0) 
Physician VAS* 35.5(14-54) 18(16) 41(19) 42(18) 
Patient’s pain VAS* 68(36-85) 10(2-29) 43(27-55) 43(28-58) 
Symptomatic Joint count* 17(7-27) 18(2-23) 20(16-31) 16(8-20) 
Steroid (%) 8/36(22%) 3/11(27%) 2/14(14%) 3/11(27%) 
DMARDs naïve (%) 4/36(11%) 1/11(9%) 2/14(14%) 1/11(9%) 
EMS(minutes)* 78(23-143) 30(0-120) 60(10-120) 120(53-180) 
MSKSLEDAI = 4 26/36 4/11 14/14 11/11 
MSK-BILAG 
     A 
     B 
     C 
     D 
 
3/36 
19/36 
10/36 
4/36 
 
0/11 
3/11 
5/11 
3/11 
 
1/14 
10/14 
3/14 
0/14 
 
2/11 
7/11 
2/11 
0/11 
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9.7.1 MRI scores between groups 
MRI Scores for the three groups are shown in (Figure 9-1).  RAMRIS total synovitis score 
was significantly higher in patients with subclinical synovitis compared to those with normal 
ultrasound.  There was a strong correlation between ultrasound total synovitis and MRI 
RAMRIS total synovitis scores (R=0.689, p<0.001).  The tenosynovitis and bone marrow 
oedema scores did not significantly differ between groups.  This is probably because of 
small patient numbers and low values for these scores in all groups.  The RAMRIS synovitis 
score did not significantly differ between the subclinical synovitis and clinical synovitis 
groups. 
Figure 9-1: RAMRIS Synovitis Scores according to ultrasound and clinical status 
 
Figure 9-1: The first group is patients with arthralgia and normal ultrasound and absence of clinical 
synovitis. The second group: patients with arthralgia and Ultrasound only-synovitis. The third group: 
patients with clinical synovitis +/- abnormal scan (Grey scale >1and or Power Doppler>0 for the joints 
and Grey scale>0 and or Power Doppler >0 for the tendons)  
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9.7.2 Agreement between MRI and ultrasound at each site 
Overall agreement between clinical and ultrasound assessment on joint-by-joint analysis, as 
measured by Kappa and prevalence-adjusted-bias-adjusted Kappa, was reasonably good 
and PABAK ranged between 0.37-0.90. (Table 9-2).  There were a small number of cases in 
which ultrasound detected more than MRI, or vice versa.  The best agreement was in the 
MCPs, PIPs and flexor tendons.
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Table 9-2: Agreement between ultrasound and MRI 
Joints US 
criterion 
PEA US<MRI US>MRI Sp(-ve) Sp(+ve) Kappa (95% CI) PABAK 
RCJ GS>1 ± 
PD≥1 
80.0% 
(28/35) 2.9% (1/35) 17.1% (6/35) 80.0% (28/35) 80.0% (28/35) 0.61 (0.61, 0.61) 0.60 
ICJ GS>1 ± 
PD≥1 
82.9% 
(29/35) 2.9% (1/35) 14.3% (5/35) 85.0% (34/40) 80.0% (24/30) 0.65 (0.65, 0.65) 0.66 
UCJ GS>1 ± 
PD≥1 
71.4% 
(25/35) 2.9% (1/35) 25.7% (9/35) 78.3% (36/46) 58.3% (14/24) 0.40 (0.40, 0.40) 0.43 
MCP2 GS>1 ± 
PD≥1 
77.1% 
(27/35) 
11.4% 
(4/35) 11.4% (4/35) 81.0% (34/42) 71.4% (20/28) 0.52 (0.52, 0.52) 0.54 
MCP3 GS>1 ± 
PD≥1 
68.6% 
(24/35) 
11.4% 
(4/35) 20.0% (7/35) 76.6% (36/47) 52.2% (12/23) 0.29 (0.29, 0.29) 0.37 
MCP4 GS>1 ± 
PD≥1 
85.7% 
(30/35) 5.7% (2/35) 8.6% (3/35) 91.2% (52/57) 61.5% (8/13) 0.53 (0.53, 0.53) 0.71 
MCP5 GS>1 ± 
PD≥1 
85.7% 
(30/35) 2.9% (1/35) 11.4% (4/35) 91.8% (56/61) 44.4% (4/9) 0.37 (0.37, 0.37) 0.71 
PIP2 GS>1 ± 
PD≥1 
77.1% 
(27/35) 8.6% (3/35) 14.3% (5/35) 85.7% (48/56) 42.9% (6/14) 0.29 (0.29, 0.29) 0.54 
PIP3 GS>1 ± 
PD≥1 
94.3% 
(33/35) 2.9% (1/35) 2.9% (1/35) 96.7% (58/60) 80.0% (8/10) 0.77 (0.77, 0.77) 0.89 
PIP4 GS>1 ± 
PD≥1 
85.7% 
(30/35) 5.7% (2/35) 8.6% (3/35) 92.1% (58/63) 28.6% (2/7) 0.21 (0.21, 0.21) 0.71 
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Joints US 
criterion 
PEA US<MRI US>MRI Sp(-ve) Sp(+ve) Kappa (95% CI) PABAK 
PIP5 GS>1 ± 
PD≥1 
88.6% 
(31/35) 5.7% (2/35) 5.7% (2/35) 93.1% (54/58) 66.7% (8/12) 0.60 (0.60, 0.60) 0.77 
ECU GS≥1 ± 
PD≥1 
86.1% 
(31/36) 8.3% (3/36) 5.6% (2/36) 92.3% (60/65) 28.6% (2/7) 0.21 (0.21, 0.21) 0.72 
ETS GS≥1 ± 
PD≥1 
85.7% 
(30/35) 
14.3% 
(5/35) 0.0% (0/35) 92.1% (58/63) 28.6% (2/7) 0.25 (0.25, 0.25) 0.71 
FT2 GS≥1 ± 
PD≥1 
94.4% 
(34/36) 5.6% (2/36) 0.0% (0/36) 97.1% (68/70) 0.0% (0/2) Not calculated 0.89 
FT3 GS≥1 ± 
PD≥1 
94.4% 
(34/36) 5.6% (2/36) 0.0% (0/36) 97.1% (68/70) 0.0% (0/2) Not calculated 0.89 
FT4 GS≥1 ± 
PD≥1 
97.3% 
(36/37) 2.7% (1/37) 0.0% (0/37) 98.6% (70/71) 66.7% (2/2) 0.65 (0.65, 0.65) 0.90 
FT5 GS≥1 ± 
PD≥1 
94.4% 
(34/36) 5.6% (2/36) 0.0% (0/36) 97.1% (68/70) 0.0% (0/2) Not calculated 0.89 
MRI: magnetic resonance imaging, PEA: Percentage exact agreement; Sp(+ve): proportions of category-specific positive agreement; Sp(-ve): proportions of 
category-specific negative agreement; PABAK: Prevalence-adjusted bias-adjusted kappa. US: ultrasound
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9.7.3 Qualitative features of musculoskeletal SLE appearances on MRI 
On overall review of the MRI appearances with an experienced musculoskeletal radiologist, a 
number of qualitative observations about the appearances could be made. 
V.  MRI synovitis found in wrists more than hand joints 
In common with other studies in SLE, synovitis occurred more frequently at the wrist joint (19 
patients) than in the other hand joints.  Three patients had normal ultrasound, but did have 
MRI confirmed synovitis, which is a possible explanation for inflammatory pain in the 
ultrasound-negative group. 
VI.  Extensor tendons affected more frequently than flexor tendons 
Most studies in arthritis that use RAMRIS did not report the extensor tendons.  However, in 
my study I found this was the most common site to be affected, which was also more 
commonly seen at the wrist. Only one patient had flexor tenosynovitis 
VII.  Effusions without enhancement 
We found some patients who had clinical synovitis at the MCP joints, but the RAMRIS synovitis 
scores were reported as normal for these patients.  On review of the T2 images, it was noted 
that these patients had joint effusions without synovial enhancement.  This may be non-
inflammatory, and is therefore a potential weakness of clinical examination.  However, there 
are potential artefactual explanations for this as well. The timing of the injection may be an 
issue the longer the gap, the more likely synovitis enhances.  Also, weight to dosage ratio of 
contrast injection (the dose was not matching the weight).  Six patients with normal ultrasound 
and no clinical swelling also had this type of effusion. 
VIII.  Low prevalence of bone marrow oedema and erosions 
In RA, bone marrow oedema is frequent and is a precursor to bone erosion, which is an 
important pathological process in terms of long term prognosis.  However, in the SLE patients, 
bone marrow oedema was negative for all patients in MCP and PIP joints.  Bone marrow 
oedema of the small joints of the hands appears to not to be a feature in SLE.  Bone marrow 
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oedema was seen in the wrist and carpus (intercarpal joint, in five patients) but was mild when 
it occurred.  Erosions occurred in approx. <10% of SLE cases.  In the hand and wrist, if they 
occur, this is predominantly seen in the index, middle finger MCP joints and wrist joints.  In my 
observations, the most common bone affected was the capitate (in 14 patients), followed by 
the lunate (in 10 patients) then MCP3 (in 7 patients).  Although the number of patients with 
erosions was low, it is notable since these patients are usually considered to have a non-
erosive form of arthritis. 
IX.  Avascular necrosis of the lunate as a potential explanation for pain with 
normal ultrasound 
In one patient, who had both SLE and antiphospholipid syndrome, there was bone marrow 
oedema of the entire lunate.  This is suggestive of avascular necrosis rather than being 
secondary to inflammatory arthritis.  Avascular necrosis is well described at other sites in SLE.  
Although this particular patient did also have synovitis at other sites, this finding is interesting 
since it demonstrates a potential non-inflammatory mechanism for pain related to SLE 
pathology, which would not be detected on clinical examination or on ultrasound. 
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Figure 9-2: Non-enhancing effusion in an MCP 
 
Figure 9-2: Parallel Coronal T2 fat-sat DESS (left) and Coronal T1 fat-sat VIBE post-Gadolinium 
injection images. Images acquired at the same plane and slice. The coronal T2 fat-sat DESS sequence 
a large effusion within the ring finger MCP joint. The coronal T1 fat-sat VIBE post-Gadolinium 
sequences demonstrates no appreciable enhancing synovitis within the ring finger MCP joint. 
Figure 9-3: Enhancing synovitis in hand joints 
Figure 9-3: Parallel Coronal T2 fat-sat DESS (left) and Coronal T1 fat-sat VIBE post-Gadolinium 
injection images. Images acquired at the same plane and slice. The coronal T2 fat-sat DESS sequence 
demonstrates effusions within the index, middle and ring finger MCP joints.  The coronal T1 fat-sat VIBE 
post-Gadolinium sequences demonstrates enhancing synovitis within the index, middle and ring finger 
MCP joints. 
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 Discussion: 
Although this is an interim analysis, it provides several insights into my ultrasound results. 
First, MRI was able to validate the ultrasound-only synovitis.  This is important because 
ultrasound is an operator-dependent method and it is possible for an inexperienced 
sonographer to over-score abnormalities.  The agreement with MRI re-assures that the 
ultrasound results in my other chapters were accurate.   
Three other studies have reported MRI synovitis in SLE. Ball and colleagues found synovitis 
in the MCPs in 27/34 patients and wrist synovitis in 28/34 patients, consistent with the patterns 
I found[374].  Ostendorf et al.[268, 370] used MRI to assess both hands of 14 patients with 
SLE and varied arthritis severity and duration.  They found active synovitis in 64%, 
tenosynovitis in 71%, and bone erosion in 57%.  Boutry et al. compared patients with RA, SLE, 
and systemic sclerosis.  Synovitis was identified in all SLE patients mainly at the wrists, 2nd, 
and 3rd MCP joints[371].  The pattern and distribution of joint involvement are different between 
SLE and RA.  In RA, tendon sheath inflammation is commonly seen and the extensor carpi 
ulnaris tendon appears to be most commonly affected [368, 420]. 
MRI gives some additional information that is not possible using ultrasound.  In particular it 
gives information about bone oedema and erosion.  Bone marrow oedema represents cellular 
infiltrations in the subchondral bone.  Bone marrow oedema has prognostic value in patients 
with RA [421] this may help in risk stratification and taking decision for early treatment.  It has 
high specificity and higher accuracy for joint damage progression [422].  
However, SLE is known to have less tendency for bone erosion than RA.  One previous paper 
has reported bone oedema in SLE patients in 7.5% and 35.5% at hand and wrist 
respectively[372].  This is markedly higher than I found in my study.  It is not clear whether 
this difference is due to the populations of patients recruited in the imaging protocols and 
reporting. 
In my study, I found that some patients had non-enhancing effusions. This was also shown by 
Zollers et al. They also found patients with swelling on examination with abnormal T2 images 
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but no enhancement on MRI [423].  This could explain the cause of pain in patients with normal 
clinical examination and ultrasound scan. 
The main limitation of this study was the small sample size.  However, this is a pilot study and 
could provide an important insight into larger cross-sectional and longitudinal MRI studies.   
This study did not include control groups such as RA to assess difference in pathology or 
normal volunteers to validate the frequency and importance of some of the findings.   However, 
that could be incorporated in a future extension to this study.   In this study RAMRIS scoring 
system was used, although this was actually developed to evaluate patients with RA.  Although 
MRI RAMRIS scores are known to be highly objective and reproducible, in SLE arthritis they 
have not themselves been validated against a gold standard such as synovial biopsy. 
 Conclusion 
MRI provided further validation for ultrasound assessment of SLE joint disease, it could 
potentially give additional information about the causes of pain in people with normal 
ultrasound, and demonstrates some differences in the pattern of synovitis in patients with SLE 
compared previous reports in RA.
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Chapter 10: Discussion  
 General discussion of results: 
The data presented in this thesis highlighted the importance of understanding SLE arthritis 
and its impact on the treatment and quality of life. 
To summarise the background: musculoskeletal SLE is a significant healthcare problem. 
Patients report poor quality of life despite the best current therapy and since musculoskeletal 
disease is so frequent, this has a greater impact on wellbeing at a population level than 
manifestations that are more severe, but less common.  My review of the background literature 
suggests that this problem is not only due to a lack of useful therapies.  Instead, it may be 
because physicians are not able to reliably identify the active disease that needs treatment 
and because clinical trials are not able to accurately appraise new treatments. 
I therefore developed the themes of my thesis to answer these problems. I focussed on the 
accurate measurement of musculoskeletal disease activity, particularly using imaging as an 
objective assessment. This is important because most other outcomes measures in research 
have not included an objective “gold standard”, instead of correlating instruments with overall 
physician impression and therapy decisions.  Hence, my research was designed not only to 
understand the value of imaging but, it is also used imaging as a way to understand clinical 
instruments and clinical trials. 
My key findings elucidate: (1) the prevalence of different phenotypes of musculoskeletal 
disease activity, and therefore which patients should be treated in clinical practice and trials; 
(2) the responsiveness of different instruments; (3) the pathological explanation for pain based 
on ultrasound and MRI imaging. 
These studies form part of an ongoing programme of musculoskeletal SLE research with the 
ultimate objective of designing and completing a new type of trial design. This programme is 
outlined in Figure 10-1. 
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Figure 10-1: Leeds Lupus Arthritis Programme 
Studies shown in green are completed as part of my thesis. Studies in red are still in progress (interim MRI results included in thesis, but recruitment continues). 
Studies shown in white are planned, based on my results. OM: outcome measure. ROOTS: Rituximab Objective Outcomes Study in SLE 
Lupus Arthritis Programme
USEFUL (n=133)
Definitive O.M. Study
ROOTS (n=30)
Feasibility RCT (Rituximab)
Outcome 
measure
--
Target popn
--
Trial Design
Definitive 
RCT
(Clinical
endpoint)
X-sec study (n=112)
Target population
2014           Leeds Lupus Arthritis Programme 2020
Longitudinal (n=20)
Pilot O.M. Study
MISTR (n=52)
MRI study; anatomical basis
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The ultimate product of my thesis will be to define the target population for a clinical trial as 
well as a new outcome measure (discussed further below).  The ROOTS study (Rituximab 
Objective Outcomes Study in SLE) is a feasibility RCT that has currently recruited 25/30 
planned patients.  That study will evaluate the new outcome measure in a randomised study 
using rituximab or placebo.  Once ROOTS has been completed and analysed, we will use the 
results to design a definitive multicentre RCT to test the efficacy of rituximab in 
musculoskeletal SLE.  I will use the results of the USEFUL study in further statistical analysis 
to define a new continuous outcome measure.  I anticipate that the next RCT will use that new 
clinical outcome measure as the primary endpoint, rather than ultrasound. 
10.1.1 Chapter 5: Cross-sectional study 
Previous ultrasound studies were reviewed in my literature review and also in a previous 
systematic literature review by my group.  This highlighted several key problems with these 
studies relating to the inclusion criteria, controlling for medications use and excluding rhupus.  
As a result, there was great uncertainty surrounding the prevalence of different abnormalities 
and the importance of ultrasound synovitis.  Also, the other ultrasound studies did not 
standardise which joints assessed and use did not always use OMERACT reporting of 
ultrasound findings.  I, therefore, performed a larger, more rigorously designed cross sectional 
study to define the frequency and clinical associations of ultrasound-only synovitis.  My key 
findings were that 38% of patients had swollen joints (clinical synovitis), 27% had ultrasound-
only synovitis, and 34% had no evidence of inflammation.  Ultrasound-only synovitis was 
associated with worse symptoms and serology than patients with normal scan.  These results 
therefore indicate that outcome measures, treatment decisions and trials must account for 
subclinical synovitis. 
10.1.2 Chapter 6: Pilot longitudinal study 
In my literature review, I reviewed various outcome measures used in trials.  It is apparent that 
both the BILAG and SLEDAI have limitations in responsiveness. Joint counts, VAS and EMS 
are sometimes reported but have not been well validated.  Also, most validation studies are 
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performed in patients in routine clinical care, with many different types of therapy.  In this study 
I therefore explored the responsiveness of these various instruments using patients with a 
single type of therapy (Depo-medrone) and included ultrasound as an objective standard. The 
key finding was that many clinical outcome measures underestimate responsiveness. In 
particular, patients not achieving an SRI-4 response (as used in most trials) could have a 
substantial improvement in synovitis. In summary, ultrasound demonstrates the limitations of 
existing tools, but demonstrates that a better tool could be designed. This would improve a 
clinical trial. I used the results to design the USEFUL study. 
10.1.3 Chapter 7: predictive value of ultrasound synovitis 
This study follows on from my cross-sectional findings. The results in chapter 5 showed that 
many patients without joint swelling (and therefore only scoring BILAG C/D or SLEDAI=0 for 
musculoskeletal) have objective ultrasound synovitis. I therefore asked whether patients 
should be treated according to baseline ultrasound findings. 
There were several important decisions in the design of the study that must be reviewed in 
light of the results.  First, what the outcome measure should be to compare the responses of 
ultrasound positive and negative patients.  We needed a continuous outcome measure, but 
there were very limited data on whether this should be a tender or swollen joint count, VAS or 
some other measure.  We decided to choose the most responsive outcome measure and time 
point (see below) in an interim analysis of the first 70 patients.  The study was powered based 
on this statistic. We also had to decide what therapy we would assess.  We decided to use 
glucocorticoids because it was one of the most commonly used therapies, has a fairly 
predictable efficacy, and works over a short period.  Lastly, we had to decide the best time 
points to measure the effect. In the pilot study we used two weeks and four weeks as these 
time points should match the effectiveness of glucocorticoids.  However, one problem we 
discovered with this is that it is theoretically not possible for the BILAG and SLEDAI scores to 
improve fully over this period – they capture all of the past 30 days disease activity and 
glucocorticoids don’t work instantly.  For this reason we chose two and six week time points. 
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Ultimately, our decision was to analyse the EMS VAS at two weeks between the groups of 
patients who were ultrasound positive and negative baseline. 
The primary outcome measure was not met – the groups did not differ in responsiveness 
according to ultrasound, although there was a trend to better responses with positive 
ultrasound.  However, on reviewing the baseline characteristics and responsiveness data we 
considered that there may have been some drawbacks to our choices.  The most responsive 
outcome measure may not necessarily be the best – there was more variability in outcomes 
at six weeks.  Also, an outcome measure that is largely patient-reported may be affected by 
other conditions, such as fibromyalgia.  I, therefore, performed post-hoc analyses excluding 
patients with fibromyalgia at baseline and analysing both two and six week data.  In these 
post-hoc analyses, baseline ultrasound was a statistically significant predictor of response to 
therapy. 
Another potential limitation of this study is that only glucocorticoids were assessed. 
Glucocorticoids may be effective for many different types of joint pain over a short period, such 
as osteoarthritis.  It would also be valuable to assess ultrasound and outcome measures in 
patients treated with a more specific SLE therapy.  Lastly, the USEFUL study may be affected 
by observer bias; although the clinical assessor, sonographer and patient were blinded to each 
other’s results, they were not blinded to time point.  These limitations are being addressed in 
the ROOTS study, which is randomised and compares rituximab with placebo. 
From this study we can draw several conclusions.  First, it seems clear that fibromyalgia may 
confound the assessment of SLE therapies.  Physicians should consider this in their practice, 
and in clinical trials it may be appropriate to exclude patients with fibromyalgia (without 
synovitis).  Second, although it was a post-hoc analysis, it seems reasonable to conclude that 
ultrasound can identify patients who will respond to therapy, with the exclusion of fibromyalgia 
being clinically logical.  It is worth noting at this point that I did find that synovitis could be 
present with or without fibromyalgia.  If a patient does have fibromyalgia, then it does not mean 
that they should not be considered for treatment, and indeed ultrasound may be especially 
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helpful in this scenario.  However, if a patient has fibromyalgia then it is much more difficult to 
tell whether that treatment has worked on clinical grounds alone. 
10.1.4 Chapter 8: responsiveness of ultrasound and clinical variables 
My pilot longitudinal study already showed that some variables were more responsive than 
others: ultrasound, physician VAS and BILAG were the most responsive.  SLEDAI, joint counts 
and patient-reported outcome measures were less responsive.  However, that study only 
included patients with objective synovitis – not patients with ultrasound-only synovitis, whom 
I now believe to be an important group to assess.  Also, the pilot study only included 20 
patients and collected a more limited set of clinical data. 
There were some differences from the earlier study in the responsiveness data from the 
USEFUL study.  The most responsive variables in the USEFUL study (considering only 
patients with active ultrasound at baseline) were: ultrasound, physician VAS, BILAG, SLEDAI 
and patient painful joint count, although none of these reached the same levels of 
responsiveness as in the earlier study.  This may be because of the lower degree of clinical 
synovitis in the USEFUL study, or because of the six week time point, when the effects of 
Depo-medrone may be reducing. 
The results were less clear when it came to comparing ultrasound responses to patient Likert 
responses.  The correlation between these variables was poor.  Although this was the 
protocol-specified analysis, I believe that in future research responsiveness should be 
validated against other longer term outcomes instead of patient-reported improvement.  
10.1.5 Chapter 9: MRI validation 
My MRI study is not completed yet, but I presented an interim analysis.  The key purpose of 
this study was to validate ultrasound-only synovitis.  In other words, to confirm that it is “real” 
using another method.  This was achieved: patients with ultrasound-only synovitis had higher 
MRI scores for synovitis, assessed by a radiologist who was blinded to the ultrasound results. 
There were several other interesting observations.  I was interested in why some patients 
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whose pain sounded inflammatory (e.g. they had symmetrical small joint involvement and 
morning stiffness) had surprisingly normal ultrasound.  In MISTER, a small number of patients 
had MRI synovitis which was not detected by the ultrasound, which may help explain why 
some SLE patients have pain.  Also, one patient had avascular necrosis that is another 
explanation for pain not seen on ultrasound.  Meanwhile, some MCP joints had non-enhancing 
effusions that may be reported as joint swelling but are not truly inflammatory. 
10.1.6 Recent research by other groups 
Following the completion of my full time research, another group published a new disease 
activity tool: the SLEDAS, based on the SLEDAI but with different weightings for the individual 
items.  For the musculoskeletal domain, the investigators included a term for the swollen joint 
count. I therefore assessed this instrument in my pilot longitudinal population (in press).  I 
found that it was more responsive than the SLEDAI, but not as responsive as the BILAG, 
physician VAS and ultrasound.  Therefore I remain confident that a better outcome measure 
can be designed for musculoskeletal SLE. 
 Impact of research: 
This programme of research is of importance both nationally and globally in improving 
understanding of SLE arthritis and how to monitor it.  Based on my results, physicians will be 
able to use ultrasound in their clinics to make treatment decisions and more patients with 
ultrasound-only synovitis will receive effective therapy.  The most important longer term 
outcomes will derive from the use of my results in the design of clinical trials. 
 Future prospective: 
Following my planned PhD projects I will use the results of the USEFUL and other studies to 
design a new clinical outcome measure.  Statistical analysis for this is in progress but it 
appears that a composite tool derived from variables such as the swollen joint count, physician 
VAS for musculoskeletal disease activity, patient VAS for musculoskeletal pain and ESR can 
be combined to create a tool that correlates better with ultrasound-confirmed synovitis and is 
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more responsive than existing tools.  The other advantage of this tool may be that it is easier 
to standardise between assessors with differing expertise.  Also, as a continuous variable, it 
is statistically more powerful, so that smaller numbers of patients are needed in an RCT. 
The ROOTS study will capture the data needed to calculate this tool.  Therefore at the end of 
the ROOTS study I will have the data needed to define the eligibility criteria for a study (clinical 
or ultrasound synovitis, no fibromyalgia), and the primary outcome measures, as well as a 
standard of care that does not include medium or high doses of glucocorticoids. 
I will therefore be able to design a more effective trial in SLE arthritis and provide new proven 
therapies to patients. 
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 Modified RAMRIS Score sheet 
Each of the following structures was scored, giving a maximum possible score of 123 
Characteristics Score 
BMO Total:51 0 1 2 3 
Region     
MCP2     
MCP3     
MCP4     
MCP5     
PIP2     
PIP3     
PIP4     
PIP5     
RCJ     
ICJ     
Base of Metacarpal 2     
Base of Metacarpal 3     
Base of Metacarpal 4     
Base of Metacarpal 5     
Trapizium     
Trapezoid     
Capitate     
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Characteristics Score 
Region     
Hamate     
Scaphoid     
Lunate     
Triquetrum     
Pisiform     
Distal radius     
Distal ulna     
Eosin Total:51 0 1 2 3 
MCP2     
MCP3     
MCP4     
MCP5     
PIP2     
PIP3     
PIP4     
PIP5     
RCJ     
ICJ     
Base of Metacarpal 2     
Base of Metacarpal 3     
Base of Metacarpal 4     
Base of Metacarpal 5     
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Characteristics Score 
Region     
Trapezium     
Trapezoid     
Capitate     
Hamate     
Scaphoid     
Lunate     
Triquetrum     
Pisiform     
Distal radius     
Distal ulna     
Synovitis Total: 33 0 1 2 3 
Region     
RCJ     
ICJ     
UCJ     
MCP2     
MCP3     
MCP4     
MCP5     
PIP2     
PIP3     
PIP4     
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Characteristics Score 
PIP5     
Tenosynovitis Total:39     
Region      
Flexor S/P 2nd finger     
Flexor S/P 3rd finger     
Flexor S/P 4nd finger     
Flexor S/P 5th finger     
Abductor pollicis longus/extensor pollicis 
brevis 
    
Extensor carpi radialis longus and brevis      
Extensor pollicis longus     
Extensores digitorum and indicis     
Extensor digiti minimi     
Extensor carpi ulnaris     
Flexor carpi radialis     
Flexores digitorum superficialis and 
profundus 
    
Flexor pollicis longus     
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